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I Zusammenfassung 
Die de novo Synthese von Sphingolipiden startet mit der Konjugation von L-Serin und 
Palmitoyl-CoA durch die Serin-Palmitoyltransferase (SPT). SPT kann unter gewissen 
Bedingungen auch kürzere und längere Fettsäure-CoA (C12 bis C18) sowie auch andere 
Aminosäuren verstoffwechseln, was zur Bildung einer Reihe von atypischen Sphingolipiden 
führt. Im Speziellen kann SPT auch L-Alanin oder Glycin verwenden, was zur Bildung von 1-
Deoxysphingolipiden respektive 1-Deoxymethylsphingolipiden führt. Mehrere Mutationen in 
der SPT sind mit der hereditären sensorischen und autonomen Neuropathie Typ 1 (HSAN1) 
assoziiert, welche zu einer permanenten Verschiebung der Substratspezifität von L-Serin zu 
L-Alanin und Glycin führt, was in einer erhöhten Produktion von 1-Deoxysphingolipiden und 
1-Deoxymethylsphingolipiden resultiert. 1-Deoxysphingolipiden und 1-
Deoxymethylsphingolipiden fehlt die C1-Hydroxylgruppe der Sphingolipide und sie können 
darum weder im kanonischen Stoffwechselweg weiter verstoffwechselt noch abgebaut 
werden. Darum werden 1-Deoxysphingolipide und 1-Deoxymethylsphingolipide 
typischerweise als metabolische Sackgasse angesehen, wobei sonst wenig über deren 
Metabolismus bekannt ist.  
Während dieser Promotionsarbeit haben wir uns auf zwei Aspekte der Sphingolipidbiologie 
fokussiert. Auf der einen Seite haben wir die Struktur von atypischen 1-Deoxysphingosine 
charakterisiert und den Metabolismus von 1-Deoxymethylsphingolipiden studiert. Auf der 
anderen Seite haben wir eine Flüssig-Chromatographie-Methode gekoppelt mit 
Massenspektrometrie (LC-MS) für die Detektion und Quantifizierung von typischen und 
atypischen Sphingolipiden entwickelt und validiert sowie die Möglichkeit für die Nutzung 
einer online-Probenextraktion von Sphingolipiden mit turbulenter Flüssigchromatographie 
ausprobiert.  
In Kapitel eins haben wir gezeigt, dass die Position der Doppelbindung im nativen 1-
Deoxysphingosine bei (14Z) ist und nicht wie beim kanonischen Sphingosine bei (4E), was 
zu einer anderen Struktur im Grundgerüst von 1-Deoxysphingosine führt. Darum haben wir 
über die Existenz einer weiteren Sphingolipid Desaturase spekuliert, die im Stoffwechsel von 
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Sphingolipiden involviert ist. Im Kapitel zwei haben wir den Stoffwechsel von 1-
Deoxymethylsphingolipiden genauer untersucht. Neben den schon bekannten 1-
Deoxymethylsphinganine und 1-Deoxymethylsphingosine, haben wir fünf weiter 
Abbauprodukte von 1-Deoxymethylsphinganine identifiziert. Mehrere Enzyme des 
kanonischen Sphingolipid-Stoffwechsels sind in der Bildung von ungesättigten (DES 1/2) 
oder mono-hydroxylierten (DES 2) Spezies involviert. Zudem werden 1-
Deoxymethylsphingolipide über einen bis jetzt unbekannten Weg di-hydroxyliert, eine wohl 
für 1-Deoxymethylsphingolipide spezifische Reaktion.  
Im Kapitel drei haben wir angeschaut, ob eine online-Extraktion mit turbulentem Fluss für 
eine effiziente Extraktion von Lipiden genutzt werden kann. Unsere Resultate legten nahe, 
dass eine online-Extraktion mit turbulentem Fluss für Lipide aus biologischen Proben nur von 
begrenztem Nutzen ist. Die online Extraktion zeigte eine tiefe Wiederfindungsrate zwischen 
12 % (1-Deoxyceramide) und 93 % (S1P) für die verschiedenen Sphingolipidklassen im 
Vergleich zu den Standard flüssig-flüssig-Extraktionen für Lipide. Im vierten Kapitel zeigen 
wir eine LC-MS2 Methode für die umfassende Analyse von Sphingolipiden (inkl. freie 
sphingoid Base, Ceramid, Sphingomyelin, Hexosylceramid und Sphingosin-1-Phosphat, aber 
auch die atypischen 1-Deoxysphingolipide) in verschiedenen Matrizen. Die Methode erlaubt 
auch eine Analyse von anderen Lipidklassen in der gleichen Messung, wie 
Glycerphospholipide oder Sterole. 
Im fünften Kapitel haben wir die neu entwickelte Methode bei verschiedenen 
biomedizinischen Fragestellungen angewandt, was eine Validierung der Methode im 
biologischen Kontext ermöglichte. Als Erstes haben wir das Sphingolipidprofil in Plasmen 
von Patienten mit einer Mutation in der Sphingosin-1-Phosphat Lyase (SGPL1) analysiert. 
Diese Mutationen im SGPL1-Gen verursachen eine hereditäre sensorische Neuropathie, 
was eine bis jetzt unbekannte Verbindung zwischen dem gestörten Abbau von S1P und 
einer Neuropathie aufzeigt. Zweitens haben wir die Änderungen im Sphingolipidom in 
Plasmen von Mäusen nach einer Magen-Bypass-Operation untersucht. Weiter haben wir die 
Sphingolipide in ORMDL3 KO Mäusen untersucht. ORMDL3 fungiert als Aktivitätsregulator 
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des eukariotischen SPT-Komplexes und zeigt in genomweiten Assoziierungsstudien eine 
Korrelation mit Asthma. Als Letztes haben wir eine allgemeine Lipidanalyse in einem 
Mausmodell für altersbedingte Macula Degeneration (ADM) angewendet, um den Effekt der 
Lipidtransporter ABCA1 und ABCG1 und die damit verbundene Akkumulation von Lipiden im 
Augengewebe im Kontext der ADM zu betrachten.  
Zusammenfassend haben wir Techniken der Flüssigchromatographie in Kombination mit 
Massenspektrometrie angewendet, um die Struktur von 1-Deoxysphingosine aufzuklären, 
den Stoffwechselweg von 1-Deoxymethlsphinganine zu bestimmen und eine LC-MS2 
Analysemethode entwickelt, mit welcher ein exaktes Sphingolipidprofil nicht nur für typische 
und relativ häufige Sphingolipide, sondern auch für atypische und seltene Sphingolipid-
Spezies ermittelt werden kann.  
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II Abstract 
Sphingolipid de novo synthesis is initiated by the conjugation of L-serine and palmitoyl-CoA, 
a reaction catalysed by serine-palmitoyltransferase (SPT). Under certain conditions, SPT 
also metabolises other acyl-CoA (C12 to C18) and other amino acids, leading to the formation 
of a diverse group of atypical sphingolipids. Especially, SPT can use L-alanine but also 
glycine as alternative substrates, leading to atypical 1-deoxysphingolipids and 1-
deoxymethylsphingolipids respectively. Several mutations in SPT are associated with 
hereditary sensory and autonomic neuropathy type 1 (HSAN1) that lead to a permanent shift 
in the substrate preference from L‐serine to L‐alanine and glycine resulting in increased 
production of 1‐deoxysphingolipids and 1-deoxymethylsphingolipids. 1-Deoxysphingolipids 
lack the C1 hydroxyl group and as such are not metabolized or degraded over the canonical 
sphingolipid pathway. Thus, 1‐deoxysphingolipids and 1-deoxymethylsphingolipids have 
typically been regarded as “dead‐end” metabolites with little else known about their 
metabolism.  
During the course of my PhD thesis, we focused on two aspects of the sphingolipid biology. 
On one hand, we characterized the structure of the atypical 1-deoxysphingosine, as well as 
the metabolism of 1-deoxymethylsphingolipids. On the other hand, we developed and 
validated a liquid-chromatography and mass spectrometry (LC-MS) method to detect and 
quantify typical and atypical sphingolipids and elaborated the possibility of online sample 
extraction of sphingolipids using online turbulent flow chromatography.  
In chapter one, we showed, that the double bond position of native 1-deoxysphingosine is at 
the (14Z) position, compared to the (4E) double bond of the canonical sphingosine, which 
results in a different backbone structure for 1-deoxysphingosine. Therefore, we speculated 
about the existence of another sphingoid base desaturase, involved in the metabolism of 1-
deoxysphingolipids. In chapter two, we investigated the metabolism of 1-
deoxymethylsphingolipids. Besides the already known 1-deoxymethylsphinganine and 1-
deoxymethylsphingosine, we identified five novel downstream metabolites of 1-
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deoxymethylsphinganine. Several enzymes of the canonical sphingolipid metabolism are 
involved in the formation of desaturated (DES 1/2) or mono-hydroxylated (DES 2) 1-
deoxymethylsphingolipid species. Additionally, they are di-hydroxylated over a yet unknown 
pathway, which seems to be specific for 1-deoxymethylsphingolipid. 
In chapter three, we investigated whether a turbulent flow online extraction system can be 
efficiently used for lipid extraction. Our results indicated that turbulent flow online extraction 
of lipids from biological samples is of limited use. The online extraction showed poor 
recovery, ranging from 12 % (1-deoxyceramides) to 93 % (S1P) for different sphingolipid 
classes compared to standard liquid-liquid extraction procedures. In chapter four, we report 
an LC-MS2 method for a comprehensive analysis of sphingolipids (including free sphingoid 
base, ceramide, sphingomyelin, hexsosylceramide and sphingosine-1-phosphate, but also 
the atypical 1-deoxysphingolipids) in different matrices. The method also allows the analysis 
of other lipid classes such as glycerophospholipids or sterols within the same run.  
In chapter five, we applied the newly developed method to several biomedical questions, 
which allowed validating the method in a biological context. First, we analysed the 
sphingolipid profile in plasma of patients with mutations in sphingosine-1-phosphate lyase 
(SGPL1). The mutations in the SGPL1 gene cause a hereditary sensory neuropathy, which 
showed a hitherto unknown connection between the degradation of S1P and neuropathy. 
Second, we studied the sphingolipidome in plasma of mice undergoing gastric bypass 
surgery. Further, we evaluated the sphingolipidome of ORMDL3 KO mice. ORMDL3 is an 
activity regulator of the eukaryotic SPT complex, which was linked to asthma in genome wide 
association studies. Finally, we applied an unbiased lipidomics approach to a mouse model 
for age-related macula degeneration (AMD) to study the effect of the lacking lipid 
transporters ABCA1 and ABCG1 on the accumulation of lipids in eye tissue of these mice. 
In summary, we used liquid chromatography coupled to mass spectrometry techniques to 
elucidate the structure of 1-deoxysphingosine, unravel the metabolism of 1-
deoxymethylsphinganine, and developed a LC-MS2 for the comprehensive quantification of 
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sphingolipidome for not only typical and relatively abundant sphingolipids as well as the 
minor and atypical sphingolipid species. 
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III Introduction 
Derived from the Greek word ‘lipos’, which essentially means Fat, lipids are described as 
molecules of biological origin that are soluble in organic solvents, with only little to no 
solubility in water. The international lipid classification and nomenclature committee 
describes lipids as hydrophobic or amphiphilic molecules that may originate, entirely or in 
part by carbanion-based condensation of thio-ester and or by carbocation-based 
condensation of isoprene units 1, 2. In reality, the lipids are a very diverse class of metabolites 
consisting of many sub-types, which are distinguished by physical and chemical properties 
as well as their source of synthesis and underlying chemical units. Evolutionary, delimiting 
lipid membranes ensured the integrity of cells as exchangeable functional units but also 
allowing the co-evolution of genetic material and the metabolic systems 3. Lipids constitute 
one of the most abundant and diverse molecules in living organisms across all kingdoms of 
life. Lipids constitute about 50% of animal cell membranes, and are the most abundant small 
molecules found in human plasma 4. Given their diverse physiological functions, this 
structural diversity of lipids is not surprising. As storage lipids, mainly in the form of 
triacylglycerol’s, they form the most strongly concentrated source of energy. Phospholipids 
(PL), such as phosphatidylcholine and phosphoethanolamine are the major structural lipid 
components of eukaryotic membranes. These PL maintain the quasi-fluid state of the 
membranes and regulate protein functions 5. Distinct sterols are the major non-polar lipid 
constituents of the cellular membranes in yeast, plants, and mammals, which mainly differ in 
desaturation and the position of methylation within the sterol nucleus 6. Sphingolipids, on the 
other hand, contain a specific amino –alcohol backbone, which is amide linked to a fatty acid 
to form a ceramide. This ceramide can be modified, such as with phosphocholine to form 
sphingomyelin, or glycans to form glycosphingolipids 7. Sphingomyelins associate with 
sterols to form ordered lipid domains within the plasma-membrane which are termed lipid 
rafts, which are essential for signal transduction, protein sorting and trafficking 8. In addition 
to this, phosphorylated forms of sphingosine, (sphingosine-1-phosphate) and ceramide 
(ceramide-1-phosphate) are essential lipid signalling molecules which aid in cell survival and 
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apoptosis 9. Although the combinatorial permutations of substrates allow the generations of 
tens of thousands of different lipid molecules, just close to a thousand have been identified in 
cells and membranes so far. The number of identified and characterized lipids is increasing 
by the time, due to the availability of better standards and the development of more sensitive 
detection methods 10. There is still a need for further development. 
III.1 Lipid classification 
The diverse group of lipids can be classified as hydrophobic or amphipathic small molecules 
that originate entirely or in part by carbanion-based condensations of ketoacyl subunits (as 
fatty acids, glycerolipids, glycerophospholipids, sphingolipids, saccharolipids and 
polyketides) and/or by carbocation-based condensations of isoprene subunits (sterol and 
prenol lipids) 1, 11. The Lipid maps consortium published a classification system, where lipids 
can be classified as fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol 
lipids, prenol lipids, and saccharolipids 1, 11 (Figure I-1). 
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Figure I-1: Representative structures for each lipid category. 
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III.1.1. Fatty Acids 
The simplest lipids are free fatty acids. Commonly they are monocarboxylic acids with a long 
and unbranched hydrocarbon chains with a single carboxyl group at the end. Most of the 
fatty acids have an even number of carbon atoms between 14 and 22. This carbon chain can 
be saturated or desaturated, containing one or multiple double bonds, typically in a cis 
configuration. In polyunsaturated species, these double bonds are always separated by three 
carbons 12-15. Fatty acids are significant sources of energy and essential building components 
of membrane lipids. They are either derived from food or are synthesized from acetyl-
coenzyme A (acetyl-CoA) through complex sets of reactions. Intermediary products of 
glycolysis and citric acid cycle contribute to the formation of the backbone carbons of fatty 
acids and glycerols for the synthesis of lipids 16, 17. 
Fatty acids represent the primary building block of complex lipids. For most of the complex 
lipids, one or multiple fatty acids are connected to a glycerol backbone by ester bounds. 
Because of the repetition of methylene groups, fatty acids are hydrophobic, and these 
hydrophobic properties are responsible for most of the characteristics of the more complex 
lipids 18, 19. 
III.1.2. Glycerolipids 
The group of glycerolipids composes of all glycerol-linked lipids. Three different functional 
groups can be attached to the glycerol backbone, differentiating between neutral 
glycerolipids and glycerophospholipids 1. 
Neutral glycerolipids are mostly acylglycerols, where fatty acids are esterified with a glycerol 
backbone, forming mono-, di- or triacylglycerol. These lipids are mainly used for energy 
storage 20-22. Next to fatty acid linkage, also sugar residues can be conjugated over glycosidic 
linkage on the sn-3 position 23. 
Glycerophospholipids consist of two fatty acids bound to a glycerol backbone (at the sn-1 
and sn-2 position) and to a polar phosphate-containing head group attached to the third 
carbon of the glycerol backbone (sn-3 position). With the phosphate group, other small 
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molecules such as choline, serine, ethanolamine or inositol can be conjugated leading to 
different subclasses of phospholipids, dependent on the head group attached. Phospholipids, 
therefore, have a hydrophobic tail and a hydrophilic head, which is an essential property for 
the formation of membranes 4, 24.  
III.1.3. Prenol lipids 
The prenol lipids are subdivided primarily by biological function. Sterols, with cholesterol as 
the most studied species, are composed of four carbon rings instead of a linear carbon 
chain. Sterols are essential parts of biological membranes 25-27, whereas steroids (which also 
contain the same fused four-ring core structure) play a role as hormones and signalling 
molecules 28.  
III.1.4. Sphingolipids 
Sphingolipids are not based on a glycerol backbone but a sphingoid base formed by the 
condensation of L-serine with a fatty acid 29. The sphingoid base can be N-acetylated, and 
head groups like carbohydrates (glycosphingolipids) or phosphocholine (as in sphingomyelin) 
can be attached 30, 31.  
Sphingolipids form the most heterogeneous lipid class with the largest number of different 
species 32. Sphingolipids have been reported to play a role in senescence, inflammation, and 
apoptosis and are relevant for diseases like Alzheimer's, diabetes and atherosclerosis 33-37.  
III.2 Lipids in human plasma 
The plasma lipidome consist of more than 500 lipid species distributed among six classes of 
lipids, including fatty acids, glycerolipids, glycerophospholipids, sphingolipids, and prenol 
lipids 32. The number of identified species is so far limited by the sensitivity of available 
analytical technologies and will probably grow in the future with the advance of mass 
spectrometry. After sterol lipids, glycerophospholipids represent the second major 
component of the plasma lipidome, counting for ~32% of plasma lipids (Figure I-2A). Plasma 
glycerophospholipids comprise of more than 160 individual molecular species with the PCs 
and PEs being the most abundant lipids (Figure I-2B). In addition, plasma contains 
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considerable amounts of LPCs, LPEs and PIs as well as minor amounts of PC-derived and 
PE-derived plasmalogens 32. Plasma sphingolipids comprise more than 200 molecular 
species. Total sphingolipids were determined about ~4% of total lipids in the plasma (Figure 
I-2A). This diversity results from the attachment of different sphingoid base backbones to 
different fatty acids to form diverse ceramides, which can be further combined with different 
head groups to form complex sphingolipids. Sphingomyelins (SM) are the major 
sphingolipids, representing ~95% of total sphingolipids, followed by Ceramides (Cer) (~3.5%) 
and monohexosylCeramides (hexCer) (<1%) (Figure I-2C) 32, 38. Among the sphingoid bases, 
C18 sphingosine is the most abundant backbone, representing ~60% of total sphingoid 
bases. C18 Sphingadiene, C18 Sphinganine and C16 Sphingosine represent 20%, 10% and 
10% respectively. Other sphingoid bases are present to a minor amount (< 5%) 4, 32. 1-
deoxysphingolipids (1-deoxySL) are present in the plasma of healthy individual but account 
for less than 1% of the total plasma sphingolipids 39, 40. 
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Figure I-2: A: Distribution of plasma lipids, B: glycerophospholipids and C: sphingolipids. The figure is reproduced 
from the data reported by Quehenberger and colleagues 32. Cer stands for ceramide; MHCer, monohexosyl 
ceramide; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PA, phosphatidic acid; PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, 
phosphatidylserine; SB, sphingoid base; SM, sphingomyelin. 
Plasma glycerophospholipids, triacylglycerol, sterols and sphingolipids are associated with 
lipoproteins 41-43. Glycerophospholipids and sphingolipids are not equally distributed among 
different plasma lipoproteins. Specifically, high-density lipoproteins (HDL) carry larger 
proportions of PC, PE and PE-based plasmalogens 41, 43. VLDL and LDL contain higher 
amounts of the plasma sphingomyelin and ceramides compared to HDL 38. Interestingly, 
plasma 1-deoxySLs are found only in the VLDL and LDL but not in the HDL fraction of 
plasma of healthy subjects 39. 
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III.3 Sphingolipid metabolism 
III.3.1. Canonical sphingolipids 
De novo sphingolipid synthesis is initiated in the ER by the condensation of palmitoyl-CoA 
and L-serine, a reaction that is catalysed by Serine-Palmitoyltransferase (SPT) 44-46 (Figure 
I-3). This first reaction by SPT is the rate-limiting step in the biosynthesis of sphingolipids. 
SPT is a pyridoxal 5'-phosphate (PLP)-dependant enzymes in the subfamily of α-oxolamine 
synthases. SPT is a multimeric protein complex, consisting of three subunits, SPTLC1, 
SPTLC2 and SPTLC3 44-48. Besides the canonical substrates (L-serine and palmitoyl-CoA), 
SPT can also metabolize different acyl-CoA with chain lengths of C12-C18, as well as other 
amino acids like L-alanine or glycine, thereby forming a variety of atypical sphingolipid 
metabolites 34. The reaction of L-serine with palmitoyl-CoA generates C18 based 
sphingolipids, whereas the reaction with other acyl-CoA results in the formation of different 
chain length sphingolipids. With the use of L-alanine or glycine, atypical 1-deoxysphingolipids 
and 1-deoxymethylsphingolipids respectively are formed, which lack the C1-hydroxyl group 40, 
49, 50. 
The condensation of L-serine with palmitoyl-CoA by SPT generates 3-ketosphinganine, 
which is rapidly reduced to sphinganine (SA) by the NADPH-dependant 3-keto-sphinganine 
reductase enzyme (KDHR) 51. SA is N-acetylated by Ceramide synthase (CerS) to form 
dihydro-ceramides 52. CerS is a family of six enzymes (CerS1-6) with different tissue 
distribution and specificities for certain fatty acid chain length as substrates 53. The formed 
dihydro-ceramides are converted to ceramides by the introduction of a double bond at (4E) 
by the dihydroceramide Δ4-desaturase 54. Dihydroceramide Δ4-desaturase is present in two 
isoforms, DES1 and DES2. DES1 primarily introduces the (4E) double bond. DES2 reacts in 
a two-step reaction forming phyto-sphingosine intermediate, a hydroxylated product at ∆4, 
and then, introduces a (4E) double bond as second step 55, 56. All of these reactions in the de 
novo formation of sphingolipids take place in the ER. For further metabolism, ceramides 
have now to be transported from the ER to the Golgi compartment through vesicular or non-
vesicular transport 57. 
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By the attachment of a phosphocholine group to the C1 hydroxyl group of (dihydro-) 
ceramides, sphingomyelin synthase produces sphingomyelin 58, 59. By the attachment of 
glucose and galactose to the C1-hydroxy group, glycosphingolipids are formed by the 
ceramide-glucosyltransferase or ceramide-galactosyltransferase respectively. With the 
addition of further glucose or galactose molecules, more complex glycosphingolipids are built 
60-64. In the Golgi, but also in the ER, plasma membrane ceramides are converted into 
membrane sphingolipids, by the formation of complex phosphosphingolipids or catabolized in 
salvage pathways 57. 
Catabolism of sphingolipids starts by the degradation of sphingomyelins and 
glycosphingolipids to ceramides. This process involves dedicated catabolic enzymes, such 
as glycohydrolases and sphingomyelinases that reside in the Nucleus, the ER, Golgi, and 
lysosomes. Sphingomyelins are degraded by the sphingomyelinases (SMase). Isoforms of 
SMase act in acidic, alkaline or neutral pH environment depending on their localization, pH 
optimum, and the microenvironment in the cell 31, 65-68. Glycosphingolipids are degraded by 
the sequential removal of sugar molecules and are finally degraded to ceramides by 
glucosylceramidase 69. Ceramides are deacylated by ceramidase to release a second 
sphingoid backbone, sphingosine (SO), which bears a double bond at (4E) compared to 
sphinganine 70-72. Sphingosine is either recycled to ceramides by ceramide -synthase or 
phosphorylated at C1 hydroxyl group by sphingosine kinase (SK1/SK2) 73-76. S1P, once 
formed, can again be converted back to SO through the action of S1P phosphatases, 
(S1PPase 1/2), or hydrolyzed to trans-2-hexadecenal and ethanolamine phosphate in the ER 
by Sphingosine-1-Phosphate Lyase (SGPL1) 77, 78. This last reaction is irreversible and the 
only exit point of the pathway. 
Next, to the most abundant backbone structures, sphinganine (SA) and sphingosine (SO) 
and the low abundant backbone structure phyto-sphingosine, another backbone called 
sphingadiene, bearing two double bonds, is known for sphingolipids. Sphingadiene bears the 
sphingosine (4E) double bond and an additional double bond, which was reported to be at 
(14Z) in human plasma. This sphingadiene is the second most abundant backbone structure 
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found in human plasma. Although the structure of plasma sphingadiene was published in 
1969 by Renkonen et al. the responsible enzyme for second double bond insertion at (14Z) 
is still unknown 79. The complete metabolic pathway of sphingolipids can be seen in Figure 
I-3.  
  
Figure I-3: Overview of sphingolipid metabolism with the essential enzymes and reactions in normal sphingolipid 
metabolism using the canonical substrates (L-serine and palmitoyl-CoA ). SPT: L-serine palmitoyltransferase, 
KDHR: 3-Ketodihydrosphingosine Reductase, CerS: ceramide synthase, DES: Dihydroceramide Δ4-desaturase, 
SK: sphingosine kinase, SPP: sphingosine phosphate phosphatase. 
III.3.2. Atypical chain length sphingolipids 
Although palmitoyl-CoA is the preferred acyl-CoA for SPT, it can also use other acyl-CoAs in 
the condensation reaction. The use of myristoyl and stearoyl-CoA results in the formation of 
sphingolipids with C16 and C20 backbones, respectively, while the use of pentadecanoyl and 
heptadecanoyl-CoA gives rise to C17 and C19-based sphingolipids 49, 80, 81. 
SPT is composed of the three subunits: SPTLC1 (53-kDa), SPTLC2 (63-kDa) and SPTLC3 
(62-kDa). While SPTLC1 and SPTLC2 are ubiquitously expressed, SPTLC3 is restricted to 
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certain tissues primarily placenta, liver, heart, kidney and skin 48. SPT it is believed to be an 
octameric complex with four SPTLC1/SPTLC2 or SPTLC1/SPTLC3 dimers forming a 
dynamic complex 47, 82. Moreover, while SPTLC2 prefers palmitoyl-CoA, SPTLC3 can use 
C14-C18 acyl-CoAs 83. Overexpression of SPTLC3 in HEK293 cells resulted in the generation 
of short-chain (C16) and long chain (C19, C20) sphingoid bases 83.  
III.3.3. Atypical 1-deoxy-sphingolipids 
In 2000, an atypical sphingoid base which lacked the C1-hydroxyl group of canonical 
sphingolipids was isolated from the marine organism, Spisula	polynyma, and was therefore 
named spisulosine 84. This compound was found to be cytotoxic through inducing a 
characteristic loss of actin stress fibres 84 and was therefore tested as ES-285 in an 
experimental anticancer drug trial 85-87. Interestingly, almost a decade letter, the same 
compound was identified in mammals, including humans, by two independent lines of study 
and was renamed as 1-deoxysphinganine (1-deoxySA) 40, 50.  
Besides the canonical substrate L-serine and palmitoyl-CoA, SPT can use other acyl-CoA’s 
as well as L-alanine or glycine as the substrates. The use of alternative amino acids 
generates a category of atypical 1-deoxysphingolipids (1-deoxySL) and 1-
deoxymethylsphingolipids (1-deoxymethylSL) which lack the C1-OH group of canonical 
sphingolipids 7, 50. 
Several missense mutations in SPT that are associated with the rare inherited neuropathy 
HSAN1 (Hereditary sensory and autonomic neuropathy type 1) induce a permanent shift in 
the substrate specificity of the enzyme resulting in increased 1-deoxySL formation 40, 88. 
Penno et al. 40 was the first who discovered 1-deoxySA and its downstream metabolites in 
the context of HSAN1. Since then, a number of mutations in the SPTLC1 and SPTLC2 
subunits have been found to shift the substrate preference of SPT from L-serine to L-alanine 
and to cause the disease 40, 89-91. 
HSAN1 is a rare autosomal and dominantly inherited axonopathy and clinically characterized 
by a progressive loss of pain and temperature sensation. It is often accompanied by 
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neuropathic pain attacks and skin ulcers 40. Clinical symptoms start typically in the 2nd to 3rd 
decade of life with the loss of sensations for pain, temperature and vibration in the feet and 
hands. The disease is slowly progressing in a stocking-and-glove distribution. Sensory loss 
leads to ulcers and mutilations, which might require amputations. Positive sensory symptoms 
such as parasthesias or lancinating pain, motor or autonomic symptoms are also frequently 
present 92, 93 . 
1-DeoxySL are toxic to primary sensory neurons in culture and lead to neurite retraction and 
the disruption of the neuronal cytoskeleton structure in a dose-dependent manner 40, 94. They 
also interfere with the survival and insulin secretory capacity of pancreatic beta cells, and 1-
deoxySL plasma levels have been found to be prospective biomarkers for the risk to develop 
type 2 diabetes mellitus (T2DM) 95-97. Zitomer et al. 50 found that 1-deoxySA accumulates 
when cells in culture or animals are treated with the ceramide synthase inhibitor Fumonisin 
B1 (FB1). This lipid was shown to be produced by wild-type SPT, as the production of 
1-deoxySA was not present in CHO-LYB cells which are lacking a functional SPT, but 
reappeared when the normal SPTLC1 subunit was restored 50. Wild-type SPT can in fact 
produce considerable amounts of 1-deoxySA. After four days in culture, RAW264.7 cells had 
approximately equal levels of 1-deoxydihydroceramides (1-deoxyDHCer) and ceramides 98. 
These cells are known to deplete L-serine in the medium while accumulating L-alanine 99. 
So far, no explanation exists as to why SPT is not faithful to one amino acid. The side chain 
of L-alanine is smaller than the hydroxymethyl-group of L-serine, and could therefore fit into 
the same binding pocket. The side chain hydroxyl of L-serine interacts with the 5’- phosphate 
of the PLP domain, which appears to be optimal for both substrate binding and catalytic 
efficiency 100. Interestingly, the SPT reaction interconnects lipid and amino acid metabolism, 
which is further upstream connected to carbohydrate metabolism. This connection suggests 
that metabolic changes in carbohydrate or fatty acid metabolism also influence sphingolipid 
formation 34.  
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1-Deoxysphinganine (1-deoxySA) can be converted to 1-deoxy-dihydroceramides (1-deoxy-
DHCer). These 1-deoxy-dihydroceramides are desaturated to 1-deoxyceramides (1-
deoxyCer) by the introduction of a double bond but not further converted to complex 
sphingolipids because of the missing C1-OH group. During catabolism, 1-deoxyCer are 
degraded by ceramidase to form 1-deoxysphingosine (1-deoxySO) but cannot be 
phosphorylated to form the catabolic intermediate sphingosine-1-P (S1P). This prevents its 
cleavage to hexadecenal by S1P-lyase implying that 1-deoxySL cannot be degraded by the 
canonical catabolic pathway 50. Apart from this, it was assumed that 1-deoxySA is 
metabolized by the same set of enzymes as canonical sphingoid bases 7.  
III.4 Principles of lipidomics 
The term “omics” derives from Latin “ome” which means some or many. It refers to 
analytical methods which record a large number of analytes within one sample and 
within one process 101. Lipidomics describes techniques to study the structure and function 
of the entire set of lipids (the lipidome) formed in a cell or organism. With lipidomics, 
interactions of lipids with other lipids, proteins, and metabolites are investigated. Lipidomics 
focuses specifically on the profiling of lipids, whereas metabolomics is typically an unbiased 
approach to measure metabolites and metabolic changes in biological systems 102. 
III.4.1. Lipidomics Workflow 
 
Figure I-4: A workflow for lipidomics analysis.  
A lipidomics experiment consists of several steps, which are depicted in Figure I-4. The 
experimental design includes protocols for each step in the process, that is sample collection 
and storage, sample preparation and the data acquisition techniques (the actual 
measurement). After sample collection and storage, the sample needs to be processed for 
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the exact measurement. Lipids can be measured with mass spectrometry detectors either 
directly or after separation with different techniques such as thin-layer, gas- or liquid-
chromatography 2. Mass spectrometry-based tools are nowadays the most widely used 
technique for lipid profiling and quantification 103, as new developments like electrospray 
ionization and high-resolution accurate mass spectrometry allow the analysis of a broad set 
of lipids. Additionally, new bio-informatics tools have been developed and implemented for 
the analysis of the big datasets from mass spectrometry-based lipidomics 2.  
III.4.2. Sample preparation 
The selection of the right preparation method is a critical step, as it can influence the 
observed lipid profile 104. The goal of pre-treatment is to extract the analytes of interest 
without bias due to degradation or the introduction of contamination 105. Sample pre-
treatment targets the enrichment of analytes of interest and the removal of impurities, like 
proteins, salts, sugars, or amino acids, which interfere with the analysis. The solvent system 
should be capable of effectively extracting lipids representative of the sample under study 
without the mentioned biases. The performance of the lipid extraction for a given sample 
(tissue, cell, or fluid) with a particular solvent system depends on the partitioning of the 
different lipids between the polar and apolar phases of the extraction system used and 
consequently on the sample lipid composition 105. For lipidomics studies, sample preparation 
techniques are required, which are reproducible, fast and therefore suitable for high 
throughput approaches, which cover a broad range of lipids with different polarities. At the 
same time, preparation methods need to be compatible with the instrument techniques used 
for the analysis 106. Lipids in native samples are usually not in their free form but bound to 
proteins. Chromatographic separation techniques, which are commonly coupled to mass 
spectrometry analysis, do not tolerate proteins during the (lipid) analysis as they interact with 
the stationary phase, interfere with the retention of analytes, form precipitates blocking or 
binding analytes, and interfere with most of the detectors. Therefore, proteins have to be 
efficiently removed from the sample prior to the analysis with mass spectrometry 107. 
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Currently, several strategies are used, like simple protein precipitation, liquid-liquid extraction 
or solid phase extraction before LC-MS analysis 106, 108. So far, all of these traditional 
extraction methods result in optimal extraction for some but not all lipid classes. According to 
literature, it appears that it would be best to use a specific and optimal extraction method for 
each lipid class 32, 109. The most commonly used methods for liquid-liquid extraction where 
introduced by Folch 110 in 1957 or Bligh and Dyer 111 in 1959 and modified and improved over 
time. The two methods are based on a two-phase liquid-liquid extraction, which uses 
methanol (MeOH) and chloroform. Over the years, protocols containing other organic 
solvents, such as methyl-tert-butyl-ether (MTBE) 112 or butanol 113 were tested, trying to get 
rid of the toxic chloroform.  
Iverson et al. 114 compared the Folch method and the Bligh and Dyer method and showed 
similar recoveries in the extraction of the predominant phospholipid classes 114, and similar 
conclusions were reported in other studies comparing the Folch method with alternative 
extraction solvent systems, such as MTBE 112 or butanol 113. MTBE has become particularly 
popular for sphingolipidomics studies and the extraction of lipids from fluids 38, 41. Generally, 
the alternative solvent systems were not reported to present significant differences in the 
extraction of most abundant lipid classes when compared with the traditional solvent 
systems. Rather, the advantage of these extraction systems lies in the avoidance of 
chlorinated solvents, which are environmental hazards 105. Reis et al. 105 compared the 
efficiency of several methods of liquid extraction  for the efficiency to extract major as well as 
minor species (phosphatidylinositols, lyso-lipids, ceramides, and cholesterol sulfates) from 
LDL. They found, that extraction of less abundant lipids was greatly influenced by the solvent 
system used, whereas solvent composition had a small effect on the extraction of 
predominant lipid classes (triacylglycerides, cholesterol esters, and phosphatidylcholines). 
Overall, the Folch method was most effective for the extraction of a broad range of lipid 
classes from LDL, although the hexane-isopropanol method was best for apolar lipids and 
the MeOH-MTBE method was suitable for hexosylceramides 105. 
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Further, a sample can also be prepared by precipitating the proteins and extract the 
containing lipid with a one-phase extraction method. Different organic solvents, like 
methanol, acetonitrile or isopropanol or a combination of methanol / chloroform / methyl-tert-
butyl-ether were tested and compared towards their utility in lipidomics 109. These solvents 
will lead to the denaturation of proteins to which lipids are bound. The denatured proteins can 
be easily removed by centrifugation after lipids had been released from protein binding and 
solubilized in the extraction solvent. Single phase protein precipitation is more comfortable in 
handling and less time consuming, compared to two-phase extraction protocols, making 
them applicable for the handling of larger numbers of samples 109, 115. 
Turbulent flow chromatography is another technique for sample preparation, which was 
established for the analysis of small molecule 116 including metabolites 117. It allows 
automation, as the sample can be directly injected into the chromatographic system. This 
reduces the manual sample preparation steps but also allows high throughput approaches 
118-122. 
III.4.3. Separation based techniques for lipidomics 
For data acquisition, two strategies are currently used. Samples are either 
chromatographically separated before detection or directly infused to the detector without 
prior separation in a so-called shotgun approach. Both procedures have their advantages 
and disadvantages 2.  
In a shotgun analysis, lipid extracts are directly infused to the detector. As there is no 
separation before detection, the shotgun analysis is rather fast and reproducible, but it does 
not allow differentiation between isobaric / isomeric compounds. Furthermore, ion 
suppression by matrix components during detection happens to all analytes, in the same 
manner, and thereby interferes with the quantification of low abundant compounds. Ion 
suppression can be seen as a competition for ionization between molecules introduced into 
the MS source at the same time. However, quantification is more accurate with shotgun 
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approaches, as ion suppression applies in the same manner to the analyte and the 
corresponding internal standard 2, 123-125.  
Thin-layer chromatography 
Thin-layer chromatography (TLC) was the earliest chromatographic method used to separate 
lipids. Separation is achieved on a solid stationary phase, typically a silica gel plate, due to 
the polarity of the analytes. Analytes are loaded onto the TLC plate and eluted over the plate 
with a liquid mobile phase. TLC is a rather inexpensive and fast technique, delivering useful 
information with little effort and allows separation of a mixture of lipids with different polarities 
in a single run. The use of variations of mobile phase and stationary phases, even enables 
the separation of complex lipid mixtures. As a new TLC plate is used for every analysis, carry 
over from previous samples can be avoided and also suspicious samples can be analysed 
without risk of destroying the stationary phase. However, oxidation of lipids might occur 
during storage of the examined plates, and preparative applications are quite limited. Further, 
TLC shows low resolution and low sensitivity 101, 124, 126, 127.  
Gas chromatography 
Gas chromatography (GC) uses a solid stationary phase and a gas mobile phase. Hydrogen 
is preferred as the carrier gas as it has a lower elution temperature that allows for shorter 
times of analysis and less risk of thermal degradation of samples 127. GC is widely applied in 
the study of fatty acids, where it provides a simple, fast and reliable tool for isobaric 
separation and quantification. For the analysis of fatty acids with GC, fatty acids need to be 
derivatized to fatty acid methyl esters, which makes the sample preparation process 
somewhat time-consuming. GC has limited applications because compounds must be 
thermally stable compounds, as separation occurs in the gas phase at high temperature and 
pressure. Although derivatization can solve the volatility problems, this is usually just 
applicable for simple molecules.  As for complex biomolecules, derivatization might involve 
several reaction steps or eliminate crucial structural information 101, 124.  
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High-performance liquid chromatography 
In high-performance liquid chromatography (HPLC) analytes are separated on a solid 
stationary phase and eluted with liquid mobile phase. For HPLC separation, two strategies 
are used to separate lipid on a stationary phase. In reversed-phase liquid chromatography 
(RPLC), the lipid species are separated on a C18 or lately also C30 column. The separation 
of lipids by RPLC is based on lipophilicity, where the lipids elute according to their carbon-
chain length and the number of double bonds (in the fatty acid). Thus, lipid species 
containing longer acyl chains are eluted from the LC column later than shorter chain lipids, 
and saturated acyl structures are eluted after polyunsaturated species. Normal phase 
(NPLC) or hydrophilic interaction liquid chromatography (HILIC) separates lipids according to 
hydrophilic functionalities, such as the polar head groups 128-130. 
HPLC is somewhat time-consuming, moreover internal standards are frequently not eluted at 
the same time as the corresponding analytes, so that it is difficult to control for ion 
suppression and thereby guarantee accurate quantification 101, 124. 
III.4.4. Mass spectrometry techniques for lipidomics 
Lipids can be analysed by mass spectrometry either with direct infusion of the sample to the 
mass spectrometer or by pre-separation for example with liquid chromatography. With the 
combination of separation and mass spectrometry, it is possible to annotate not only the 
different lipid classes but also the individual lipid species 101, 131. 
Nowadays, there are three different mass filter techniques used in lipidomics with mass 
spectrometry, namely triple quadrupole, time-of-flight, (TOF), and orbitraps. Triple 
quadrupoles are usually used for targeted quantification of lipids, whereas TOF and orbitrap 
instruments also allow untargeted analysis by their higher resolution of masses (Table I-1)132, 
133. 
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Table I-1: Several mass spectrometry analytical methods used in lipidomics, adopted from Taguchi et al. 132 
Analytical method Sensitivity Advantages 
Untargeted 
• Data dependant 
product ion scan 
• Data independent 
product ion scan 
For high content molecules 
with low sensitivity 
Possible to find unexpected 
molecules, re-analysis possible 
Focused 
• Neutral loss scan 
• Precursor ion scan 
For medium content molecules 
with medium sensitivity 
Possible to find small amounts 
of molecules within focused 
classes 
Targeted 
• Multiple reaction 
monitoring 
For low content molecules with 
high sensitivity 
Possible to find new low 
abundant structural isomers, 
but just within predefined 
species 
 
By the use of high-resolution accurate mass spectrometry, it is possible to determine the 
exact mass of lipid molecules and to resolve isobars with different atomic composition or 
isotopic interferences.  
For all of the mentioned techniques, it is possible to acquire full m/z (mass over charge ratio) 
but also measure on the tandem-MS (MS2) level. The fundamental principle of MS2 is to 
select a precursor ion, fragment it and measure the m/z ratio of the formed product ions. With 
MS2, any selected lipid ion can be further fragmented and characterized giving information 
about building its blocks, like the fatty acid chain length of isomeric compounds 2, 134. Isobaric 
lipids might be separated by elution time upon liquid chromatography, high-resolution 
accurate mass spectrometry and because of specific fragmentation pattern of different 
building blocks, also by the use of MS2 technique 134. 
Triple quadrupoles 
 
Figure I-5: Principle of triple quadrupole mass spectrometer 
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A triple quadrupole consists of two quadrupole mass analysers (Q1 and Q3) and a 
quadrupole collision cell (q2), as shown in Figure I-5. By coupling two quadrupoles with a 
collision cell, it is possible to perform different types of scans on the MS2 level. They are 
typically operated in single-reaction monitoring (SRM) mode (also called multiple-reaction 
monitoring (MRM)). In SRM mode, the precursor ion is monitored in Q1, fragmented in q2 
and the transitions of the precursor ion to multiple fragments are monitored in Q3. This 
provides a significant gain in sensitivity compared with the acquisition of full spectral data. 
Other operating modes with triple quadrupole analyzers, are product-ion, precursor-ion and 
neutral-loss scan 135, 136. The different types of MS2 experiments are shown in Figure I-6.  
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Figure I-6: Schematic representation of various types of tandem mass spectrometry experiments. (A) Product ion 
scanning is the most common MS2 experiment. In this experiment, the first analyser (MS1) is set to a value that 
selects one specific precursor ion at a time. The selected ion undergoes CID in the collision cell, and the all 
resulting fragments are analysed by the second analyser (MS2). This process is repeated for different precursors. 
(B) Precursor ion scanning sets the second analyser (MS2) to transmit only one specific fragment ion to the 
detector. MS1 is scanned to detect all the precursor ions that generate this fragment. (C) Neutral loss scanning 
scans both analysers in a synchronized manner, so that the mass difference of ions passing through MS1 and 
MS2 remains constant. The mass difference corresponds to a neutral fragment that is lost from the ion in the 
collision cell. (D) MRM consists of a series of short experiments in which one precursor ion and one specific 
fragment characteristic for that precursor are selected by MS1 and MS2, respectively. Typically, the instrument 
cycles through a series of transitions (precursor-fragment pair) and records the signal as a function of time 
(chromatographic elution). MRM is used for the detection of a specific analyte with known fragmentation 
properties in complex samples. Figure taken from Domon et al. 137 
Further, rapid polarity switching and moving from detection of positive and negative ions 
allows a wide range of compounds to be incorporated into one method 135.  
Triple quadrupole MS is the preferred technique for targeted sensitive and quantitative 
analysis of a limited amount of lipids. However, triple quadrupoles have certain limitations. 
Because of limited resolution, they are less suitable for untargeted discovery, but a good 
option for targeted sensitive and quantitative analysis of a limited amount of lipids. Also, 
because of pre-defined transition monitoring in SRM mode, the reprocessing of data to 
search for unknown compounds is not possible 125, 135, 138, 139. 
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Time-of-flight 
A time-of-flight mass analyzer uses the differences in transit time through a drift region of 
ions with different masses to separate them. In a time-of-flight analyzer, a group of ions is 
accelerated in a flight tube and sent to the detector. The ions are accelerated by getting an 
identical high-voltage pulse. Because equally charged ions have the same kinetic energy, 
molecules with lower masses achieve higher velocity and reach the detector first 135 (Figure 
I-7.  
 
Figure I-7: Principle of Time-of-flight mass spectrometer 
Time-of-flight mass spectrometry offers high resolution and mass accuracy and provides the 
possibility to analyse elemental composition and whit this, high specificity in the analysis 125, 
138, 139. 
Orbitrap 
In the Orbitrap analyser, a group of ions is injected into a small electrostatic device. Their 
ions circle around a central, spindle-shaped electrode at high energies. The axial motion of 
the ions is followed and picked up by the detector, and this signal is Fourier transformed (FT) 
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for high-resolution mass spectra. Ions can be sent out to a collision cell for fragmentation and 
fragments are sent back to the orbitrap for mass analysis (Figure I-8).  
 
Figure I-8: Principle of Orbitrap mass spectrometer. Figure adopted from Thermo scientific (planetorbitrap.com) 
Orbitrap analysers operate at a different mass resolution that is proportional to acquisition 
time and inversely proportional to the square root of the m/z ratio. Thus, we expect resolution 
values for the orbitrap to be highest at low masses. This is different to time-of-flight 
analysers, where resolution is consistent across the mass range. Orbitraps offer scan filters 
with a very high resolution, which allows determining the exact mass of a molecule and to 
couple this information with fragmentation data 123, 135, 140. 
III.4.5. Data analysis 
Lipidomics generates large amounts of data, which are processed by various bioinformatics 
methods to detect and quantify metabolite peaks and annotate compound names 2. Although 
liquid chromatography and mass spectrometry techniques have been evolved rapidly to allow 
high-throughput lipidomics, the processing of the generated data and elucidation of lipid 
structures is not as trivial. There are combinatorial challenges when it comes identification, 
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quantification, and interpretation of the diversity of lipid structures. Detailed structural 
annotation requires a sophisticated MS2 approach, which combines information from 
retention time, high-resolution accurate mass data, and fragmentation pattern in different 
analysis polarities. The analytical progress in the structural elucidation of lipid led to novel 
challenges for bioinformatics 141, 142. 
The first step in data processing is to collect as many valid compound signals from a data set 
as possible, while at the same time, minimizing the number of detected artefact peaks and 
noise. High abundant species usually give strong and distinct signals, but as the metabolite 
concentrations are close at the detection limit, it becomes difficult to identify and quantify the 
peaks automatically. Software solutions need to be developed for the automatic identification 
and quantification of lipids in high-throughput lipidomics experiments, which also cover the 
low abundant compounds 2, 142. 
The second step is to incorporate this analysed and quantified data into a biological context 
and combine it with other data for example from different "omics" techniques. Therefore, 
further downstream analysis such as statistics, biological pathway or metabolic flux analysis 
can be performed 2, 142. 
III.5 Aim of the study 
With our previous analytical workflows for lipid analysis, the individual lipid classes like 
phosphoglycerates, sphingosine-1-phosphates, and sphingolipids were each analysed by 
separate methods for sample preparation and extraction, but also for LC-MS analysis. One 
aim of this project was to unify and further expand our existing LC-MS2 based methods into a 
more comprehensive lipidomics analysis, which includes a single and fast sample 
preparation protocol and a unique LC-MS analysis.  
Moreover, the atypical 1-deoxysphingosine was structurally characterized, and the metabolic 
pathway of atypical 1-deoxymethylsphingolipids was further investigated. 
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1.1 Abstract 
1-Deoxysphingolipids (1-deoxySL) are formed by an alternate substrate usage of the enzyme 
serine-palmitoyltransferase and devoid of the C1-OH-group present in canonical sphingolipids 
(SL). Pathologically elevated 1-deoxySL levels are associated with the rare inherited 
neuropathy HSAN1 and diabetes type 2 (T2DM) and might contribute to beta cell failure and the 
diabetic sensory neuropathy. In analogy to canonical SL it was assumed that also 1-deoxySL 
bear a (4E) double bond which is normally introduced by sphingolipid delta(4)-desaturase 1 
(DES1). This, however, was never confirmed. We therefore supplemented HEK293 cells with 
isotope labeled D3-1-deoxy-sphinganine (1-deoxySA) and compared the downstream formed 
D3-1-deoxy-sphingosine (1-deoxySO) to a commercial synthetic SPH m18:1(4E)(3OH) 
standard. Both compounds showed the same mass-to-charge ratio (m/z) but differed in their 
RPLC retention time and APCI in-source fragmentation, suggesting that the two compounds are 
structural isomers. Using dimethyl disulfide (DMDS) derivatization followed by MS2 as well as 
differential mobility spectrometry combined with ozon-induced dissociation mass spectrometry, 
we identified the carbon-carbon DB in native 1-deoxySO to be located at (Δ14) position. 
Comparing the chromatographic behavior of native 1-deoxySO to chemically synthesized 
SPH m18:1(14Z) and (14E) stereoisomers assigned the native compound to be 
SPH m18:1(14Z). This indicates that 1-deoxySL are metabolized differently than canonical 
sphingolipids. 
Keywords 
deoxysphingolipids, 1-deoxysphingosine, double bond position, dimethyl disulfide adducts, 
mass spectrometry, differential mobility spectrometry, ozone-induced dissociation, structural 
isomers 
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1.2 Introduction 
Sphingolipids are typically formed by the condensation of L-serine and palmitoyl-CoA, a 
reaction catalyzed by the serine-palmitoyltransferase (SPT) enzyme. Besides these canonical 
substrates SPT can use other acyl-CoA’s but also L-alanine or glycine as substrate which then 
forms a category of atypical 1-deoxysphingolipids (1-deoxySL) which lack the C1-OH group of 
canonical sphingolipids 1, 2. 
Several missense mutations in SPT, which are associated with the rare inherited neuropathy 
HSAN1, induce a permanent shift in the substrate specificity of the enzyme resulting in a 
increased 1-deoxySL formation. HSAN1 is a rare autosomal and dominantly inherited 
axonopathy and clinically characterized by a progressive loss of pain and temperature 
sensation often accompanied by neuropathic pain attacks and skin ulcers 3. 1-DeoxySL are 
toxic to primary sensory neurons in culture and lead to neurite retraction and the disruption of 
the neuronal cytoskeleton structure in a dose dependent manner 3, 4. They also interfere with the 
survival and insulin secretory capacity of pancreatic beta cells and 1-deoxySL plasma levels 
have been found to be prospective biomarkers for the risk to develop T2DM 5-7. 
The 1-deoxy-sphinganine (1-deoxySA) that is formed by SPT can be converted to 1-deoxy-
ceramides (1-deoxyCer) but not to complex sphingolipids because of the missing C1-OH group. 
During catabolism 1-deoxyCer is degraded by ceramidase to form 1-deoxysphingosine (1-
deoxySO) but not phosphorylated to form the catabolic intermediate sphingosine-1-P (S1P). 
This prevents its cleavage to hexadecenal by S1P-lyase meaning that 1-deoxySL cannot be 
degraded by the canonical catabolic pathway 2. Apart from that, it was assumed that 1-deoxySA 
is metabolized by the same set of enzymes as canonical sphingoid bases and that 1-deoxySO 
like SO bears a (4E) double bond which is introduced by the sphingolipid delta(4)-desaturase 1 
(DES1).  
However, we observed that natively formed 1-deoxySO showed a different RPLC retention time 
than a synthetic SPH m18:1(4E)(3OH) standard, though the m/z was identical for both 
compounds. This suggested that native 1-deoxySO and the synthetic SPH m18:1(4E)(3OH) are 
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structural isomers probably differing in position and / or configuration of the carbon-carbon 
double bond. To further elucidate this difference we used a set of tandem mass spectrometry 
methods in combination with total synthesis to elucidate the real double bond position and 
configuration of native 1-deoxySO. 
1.3 Materials and Methods 
Unless stated differently all solvents and reagents were purchased from Sigma-Aldrich Chemie 
GmbH (Buchs, Switzerland) excluding methanol, which was purchased from Honeywell 
specialty chemicals Seelze GmBH, Germany. 
1.3.1 Cell extract 
HEK293 cells were fed with 1 µM deuterium labelled D3-1-deoxysphinganine (Avanti Polar 
Lipids, Alabaster, AL) or with the unlabeled 1-deoxysphinganine (Avanti Polar Lipids, Alabaster, 
AL). Cells were harvested after 24 h and the whole sphingolipid extract was hydrolyzed to get 
the free sphingoid bases as described previously with some modifications 7, 8. The cell pellet 
was dissolved in 100 µL of PBS. 500 µL methanol including D7-sphingosine and D7-sphinganine 
(Avanti Polar Lipids, Alabaster, AL) as the internal standards were added. Lipids were extracted 
for one hour under constant agitation at 37°C. Samples were centrifuged to pellet precipitated 
proteins and the supernatant transferred into a new tube. Lipids were hydrolyzed by adding 75 
µL of methanolic HCl (1 N HCl and 10 M H2O in methanol) and incubated for 16 h at 65°C. HCl 
was neutralized by adding 100 µL of KOH (10M). Then 625µL chloroform was added followed 
by 100 µL 2N ammonium hydroxide and 0.5 mL alkaline water to complete phase separation. 
The sample was vortexed, centrifuged at 16,000 g for 5 min, the upper phase discarded and the 
lower (organic) phase washed 3 times with alkaline water. The organic phase was finally dried 
under N2 and stored at −20oC until analysis. 
Throughout this paper we refer to the extracted 1-deoxySO as native. 
1.3.2 LC-MS Method 
A commercial 1-deoxySO standard (SPH m18:1(4E)(3OH)) was purchased from Avanti Polar 
Lipids Inc. (Alabaster, AL). SPH m18:1(14Z)(3OH) was synthesized according to the method 
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described below. The SPH m18:1(E)(3OH) standards (5E, 8E, 12E, 13E, 14E) were 
synthesized based on an unpublished method that will be issued elsewhere *. An LC-MS 
method described previously 8, was used to compare retention times and in source 
fragmentation. Sphingoid bases were separated by RPLC on a C18-column (Uptispere 120 Å, 5 
µm, 125 × 2 mm; Interchim, Montluçon, France) and analyzed on a TSQ Quantum Ultra or a Q 
Exactive (Thermo, Reinach, BL, Switzerland) using an atmospheric pressure chemical 
ionization (APCI) interface. Mobile phases consisted of A: ultra-pure H2O / MeOH 1/1 v/v with 
2.6 mM ammonium acetate and B: MeOH. Gradient was set from 50 % B to 100 % B within 25 
min followed by 5 min 100 % B and 5 min of equilibration with a flow rate of 0.3 mL/min. For 
mass spectral detection, the following parameters were set on the APCI source: discharge 
current of 4 µA, vaporizer temperature of 450 °C, sheath gas pressure 20 AU, aux gas 5 AU 
and capillary temperature of 200 °C. 
1.3.3 DMDS adduct analysis 
Dimethyl disulfide (DMDS, 100 µL) and 20 µL of I2 (in diethyl ether, 60 mg/mL) was added to 
whole cell extracts or 15 nmol SPH m18:1(4E)(3OH) standard. Samples were agitated for 16 h 
in an Eppendorf Thermo Shaker at 1400 rpm and 35°C. The reaction was quenched with 100 
µL of 5% aqueous Na2S2O3, extracted with 200 µL of hexane and dried under N2. Samples were 
dissolved in 200 µL isopropanol for further analysis according to the method of Dunkelblum et al 
9. The sample was directly injected into the MS at a flowrate of 10 µL/min. The [M + H]+ ion of 
the DMDS adduct of 1-deoxySO was generated by electrospray ionization (ESI) on a Thermo 
Fisher Scientific Q-Exactive and both collision-induced dissociation and high-resolution accurate 
mass analysis were performed. For detection, the following parameters were set on the ESI 
source: spray voltage of 4.2 kV, vaporizer temperature of 30°C, sheath gas pressure 5 AU, aux 
gas 0 AU, capillary temperature of 320°C and for fragmentation in-source collision-induced 
dissociation (CID) was performed at 30 eV and higher-energy collision induced dissociation 
(HCD) of the ion at m/z 378.3 was performed with setting of 25. 
                                                
* Manuscript in preparation 
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1.3.4 Differential Mobility Spectrometry combined with Ozone-Induced 
Dissociation 
A SelexIONTM differential mobility spectrometer (DMS) was employed with a QTRAP®5500 triple 
quadrupole ion-trap mass spectrometer (SCIEX, Ontario, Canada). The instrument has been 
modified for ozone-induced dissociation (OzID) as previously described 10. Solutions for analysis 
were prepared in LC-grade methanol (VWR Scientific, Murrarie, QLD, Australia) with 5 mM 
UPLC-grade ammonium acetate (Sigma Aldrich, St. Louis, MO); SPH standard concentrations 
were 0.05 µM. Sample solutions were subjected to ESI in a TurboVTM (SCIEX) and passed 
through the mobility spectrometer. Compensation voltage (CV) applied across the electrodes 
was scanned while the separation voltage (SV) was held constant at 4100 V. Ionograms were 
obtained from scanning CV and represent the sum of five mass spectra at each voltage point 
and have been smoothed using PeakView® (SCIEX). The ESI source and DMS cell 
temperatures were 100 and 150°C, respectively; the ESI voltage was set to 5500 V. Nitrogen 
was set to 20 psi for each of the following: resolving gas in the DMS cell, the nebulizing ESI 
gas, and the MS curtain gas. Ions exiting the DMS cell into the mass spectrometer were mass 
selected in first quadrupole prior to isolation in the collision cell with ozone present. Ozone was 
produced by an external generator (Titan, Absolute Ozone, Alberta, Canada) operating at 220 
g/Nm3 (10.3% v/v ozone in oxygen) from which a small portion was mixed into the nitrogen 
collision gas input to the mass spectrometer through a variable leak valve (Nenion, Lustenau, 
Austria). The isolation time for ionized lipids in the collision cell was optimized between 100 ms 
and 15 s depending on the ozone-reactivity of a given ionized lipid 11, 12. Following ozonolysis, 
ions were transferred to the third quadrupole region where mass analysis was performed using 
a trap-scan at 1000 Th/s. OzID spectra obtained at discrete CV values were averaged between 
2 to 5 mins. 
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1.3.5 Synthesis of 1-deoxysphingosine (SPH m18:1(14Z)(3OH) or (2S,3R,14Z)-2-
aminooctadec-14-en-3-ol) 
Eleven intermediate compounds en route to the target SPH m18:1 (14Z)(3OH) were 
synthesized as described in the supplementary info. A stirred solution of compound 11 (57 mg, 
3 mmol) in 1,4- dioxane (1 mL) at 0°C was treated with a solution of 4M HCl-dioxane (2 mL) 
over a period of 10 min. The resulting reaction mixture was allowed to stir for 1 h at the same 
conditions, gradually warmed to ambient temperature, and followed by TLC analysis. After 
being stirred for additional 2 h (as monitored by TLC, Pet. ether/EtOAc 4:1; Rf(adduct)= 0.5; 
Rf(product)=0.0; visualized with KMnO4 solution), the reaction mixture was concentrated under 
reduced pressure. The resultant residue was dissolved in with CH2Cl2 (50 mL) and sequentially 
washed with saturated NaHCO3 solution (40 mL), water (30 mL), and brine solution (40 mL). 
The organic layer was subsequently dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo to afford a pale yellow oily residue. Flash column chromatography of the obtained crude 
amine over silica gel using ethylacetate and isopropanol as eluents (from 0-10% isopropanol in 
ethylacetate) provided the final compound 12 as colorless oil. Yield: 32 mg (71%). Rf: 0.32 
(EtOAc/iso-propanol 4:1, visualized with 1.3% ninhydrine). 1H NMR (500 MHz, MeOD) δ 5.35 
(ddd, J = 5.9, 3.6, 2.8 Hz, 2H), 3.70 (ddd, J = 8.1, 5.3, 3.0 Hz, 1H), 3.26 (qd, J = 6.7, 3.1 Hz, 
1H), 2.07 – 1.98 (m, 4H), 1.52 (dt, J = 10.3, 8.2 Hz, 1H), 1.47 – 1.41 (m, 2H), 1.41 – 1.28 (m, 
18H), 1.21 (d, J = 6.8 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).13C NMR (126 MHz, MeOD) δ 131.05, 
130.65, 71.71, 52.61, 34.02, 30.86, 30.75, 30.73, 30.69, 30.65, 30.35, 30.31, 28.15, 27.00, 
23.98, 14.16, 12.08. HRMS (ESI+) m/z calcd for C18H38NO [M + H]+ 284.2953; found 284.2959. 
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1.4 Results 
1.4.1 1-deoxySO is a downstream metabolite of 1-deoxySA 
 
Figure 1-1: (A) Difference RPLC retention time of synthetic SPH m18:1(4E)(3OH) and native 1-deoxySO extracted 
from HEK293 cells treated with 1-deoxySA or D3-1-deoxySA. (B) APCI in-source fragmentation of a synthetic 
SPH m18:1(4E)(3OH) standard, native 1-deoxySO and D3-1-deoxySO: the precursor [M + H]+ ion (m/z of 284) is 
identical for SPH m18:1(4E)(3OH) and native 1-deoxySO. However, synthetic SPH m18:1(4E)(3OH) formed an 
abundant [M + H - H2O]+ product ion (m/z 266) which was formed much less from native 1-deoxySO and D3-1-
deoxySO at identical conditions. MS spectra were recorded on a triple quad MS (TSQ Quantum Ultra) with APCI 
ionization. 
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HEK293 cells were cultured in the presence of deuterium labeled D3-1-deoxySA or unlabeled 1-
deoxySA. Cells were harvested after 24 h and the profile of the extracted sphingoid bases 
analyzed by RPLC-MS. We observed the appearance of [M + H]+ ions with m/z 284.3 
(unlabeled 1-deoxySO) and of m/z 287.3 (labeled D3-1-deoxySO) which both eluted at the same 
time from the LC column (Figure 1-1A), indicating that 1-deoxySO is a product formed 
downstream of 1-deoxySA (labeled and unlabeled).  
1.4.2 Comparison of synthetic SPH m18:1(4E) and native 1-deoxySO 
Retention time and APCI in-source fragmentation was compared between native 1-deoxySO 
and a commercially available synthetic SPH m18:1(4E)(3OH) standard. The native 1-deoxySO 
eluted from the C18 column after 12.70 min whereas the synthetic SPH m18:1(4E)(3OH) eluted 
after 14.77 min (Figure 1-1A). [M + H]+ ions formed by APCI showed in-source fragmentation 
and a significant water loss for the SPH m18:1(4E)(3OH) standard which was considerably less 
pronounced for the native 1-deoxySO (B). As both molecules showed identical m/z using high-
resolution accurate mass spectrometry (HRAMS, < 2ppm for [M + H]+ and [M + H - H2O]+ ) the 
observed deviations in retention time and in-source fragmentation suggested that native 1-
deoxySO and the synthetic SPH m18:1(4E)(3OH) were structural isomers. 
1.4.3 Dimethyl disulfide (DMDS) derivatization 
As the synthetic SPH m18:1(4E)(3OH) and the native 1-deoxySO showed different RPLC 
properties we aimed to elucidate the carbon-carbon double bond position of native 1-deoxySO 
by derivatization with dimethyl disulfide (DMDS). The DMDS adducts of 1-deoxySO were 
analyzed by HRAMS using direct injection and ESI ionization. The [M + H]+ ions from the DMDS 
adducts of 1-deoxySO were selected at m/z 378.3 and subjected to collision-induced 
dissociation. The CID spectrum showed four abundant but non-specific product ions at m/z 
330.3 [M + H - CH3SH]+, 312.3 [M+H - CH3SH - H2O]+, 282.3 [M + H -2CH3SH]+ and 264.3 [M + 
H - 2CH3SH - 2H2O]+ corresponding to the neutral loss of methane thiols and water as indicated 
(Figure 1-2). 
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Figure 1-2: (A) Hydrolyzed lipid 
extract from HEK293 cells was 
subjected to DMDS derivatization 
and analyzed on a high-resolution 
accurate mass spectrometer using 
ESI ionization and direct injection. 
The [M + H]+ ion formed from 
DMDS adduct of native 1-deoxySO 
(m/z of 378.2857) was in excellent 
agreement (< 1 ppm) with the 
calculated mass of 378.2859 
(C20H44NOS2+). The precursor ion 
was selected for collision-induced 
dissociation yielding to the 
spectrum shown. Product ions A 
(m/z 274) and B (m/z 103) are 
indicated in the spectrum and are 
diagnostic for a fragmentation at 
(Δ14) position. (B) Spectrum from 
SPH m18:1(4E)(3OH) showing 
product ion B (m/z 243). (C) 
Spectrum from SPH 
m18:1(14Z)(3OH) showing product 
ions A (m/z 274) and B (m/z 103). 
Putative structures for the 
diagnostic product ions are shown 
as insets in the spectra.  
 
  
Chapter 1: Elucidating the chemical structure of native 1-deoxysphingosine 
49 
Importantly, two less abundant but structurally diagnostic product ions were observed at m/z 
274.2 (A) and 103.1 (B). These product ions were formed by a cleavage of the carbon-carbon 
bond between the two methyl sulfide moieties. The mass distribution of the two fragments 
indicated a double bond in (Δ14)-position for native 1-deoxySO. Product ions indicating a 
fragmentation at the (Δ4)-position (m/z 243.2 and 134.1) were not detected.  
Differential-mobility spectrometry (DMS) combined with Ozone-Induced Dissociation 
DMS has previously been deployed successfully for lipid isomer separation prior to mass 
spectrometric analysis 10, 13. Here it was combined with OzID which exploits the reaction 
between mass-selected lipid ions and gaseous ozone inside a mass spectrometer to drive 
fragmentation diagnostic of the position(s) of carbon-carbon double bonds 12, 14. In these 
experiments the D3-labeled hydrolyzed extract from HEK293 cells was spiked with a 1:1 mixture 
of the unlabeled commercial SPH m18:1(4E)(3OH) and synthesized SPH m18:1(14E)(3OH) 
structural isomers and the mixture subjected to electrospray ionization. Figure 1-3A shows 
DMDS ionograms obtained for m/z 284 (black trace) and 287 (red trace) corresponding in mass 
to the [M + H]+ ions expected from unlabeled and labeled 1-deoxySO, receptively. The black 
trace shows peaks corresponding to at least two chemically distinct ion populations of m/z 284 
(i.e., isobars): one with a maximum CV at around 17 V and another peaking at 20 V. Isobars 
carrying m/z 284 in this mixture should be dominated by the protonated forms of the synthetic 
SPH m18:1(4E)(3OH) and SPH m18:1(14E)(3OH) isomers. The red trace, corresponding to 
isobars of m/z 287 (Figure 1-3A), showed an analogous pair of peaks at CV 17 and 20 V. These 
signals could be assigned to [M + H]+ ions arising from native forms of 1-deoxySO present in 
the cell extract. To interrogate the structure of the ions responsible for each of the two peaks in 
the ionogram, OzID spectra were acquired for m/z 284 and 287 ions using fixed CV settings of 
17 V and 20 V. Figure 1-3B shows product ions arising from the synthetic lipids (at m/z 284) in 
black and the corresponding D3-labeled native lipid (at m/z 287) in red. Both spectra revealed 
product ions arising from neutral loss of 40 and 24 Da characteristic of ozonolysis of a carbon-
carbon double bond at the (Δ14)-position on the sphingoid backbone 15 (see Supplementary 
Figure 1A and Supplementary Table 1). Conversely, in the OzID spectra obtained at a CV of 20 
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V (Figure 1-3C) these product ions were absent, while fragments arising from oxidative 
cleavage of a (Δ4)-double bond (neutral losses of 180 and 164) were observed at m/z 104 and 
120 for the unlabeled standard (see Supplementary Figure 1B and supplementary Table 1). Of 
this pair of ions, the aldehyde is mass-shifted and appears as expected at m/z 107 for the D3-
isotopologue while the m/z 123 is absent in this spectrum: possibly due to the lower abundance 
of the CV = 20 V feature in the native extract. Interestingly, an abundant water loss was 
observed in the spectra in Figure 1-3C, which is much diminished in the spectra in Figure 1-3B 
providing further evidence of the structural difference between the two lipids.  
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Figure 1-3: ESI(+) was undertaken on a mixture of D3-labeled hydrolyzed HEK293 cell lipid extracts spiked with 
unlabeled synthetic standards SPH m18:1(4E)(3OH) and SPH m18:1(14E)(3OH). (A) Ionograms showing separation 
in voltage space of the [M + H]+ ions formed from the two lipid isomers. Each of the synthetic lipids spiked into the 
extract produced a peak in the black trace (m/z 284) and similar features were observed for the labeled HEK293 
extract shown in the red trace (m/z 287). (B) OzID spectra obtained for synthetic standard (black spectrum) and the 
D3-labelled extract (red spectrum) corresponding to the first feature in the ionogram (i.e., CV = 17 V ozone reaction 
time of 100 ms). (C) OzID spectra obtained for synthetic standard (black spectrum) and the D3-labelled extract (red 
spectrum) corresponding to the second feature in the ionogram (i.e., CV = 20 V ozone reaction time of 15 s). OzID 
product ions characteristic of the locations of the carbon-carbon double bonds are indicated by closed circles and 
enable assignment of the position of desaturation to (B) (Δ 14) - position and (C) (Δ4) - position. 
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DMS-OzID analysis was also performed on non-hydrolyzed lipid extract from HEK293 cells. 
Four 1-deoxyceramide species could be detected as [M + H]+ ions consistent with the 
assignments: Cer m18:1/16:0, Cer m18:1/18:0, Cer m18:1/22:0 and Cer m18:1/24:1. As before, 
the OzID spectra showed a neutral loss of 40 Da as a characteristic signature for 1-deoxySO 
with a carbon-carbon double bond at the (Δ14)-position (Figure 1-4). These data support the 
presence of the (Δ14) carbon-carbon double bond in both 1-deoxyceramide and the 1-deoxySO 
and exclude the possibility that the observed (Δ14) desaturation is formed as an artifact of the 
hydrolysis reaction. 
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Figure 1-4: ESI(+)-OzID spectra obtained for m/z values corresponding to deoxyceramides present in an non-
hydrolyzed HEK293 cell lipid extract. All spectra show a product ion at m/z 266, which is consistent with the collision-
induced dehydration of the backbone followed by cleavage of the amide bond to liberate the acyl chain. Product ions 
arising from a characteristic neutral loss of 40 Da from the [M+H]+ or [M+H-H2O]+ are marked with circles and are 
consistent with an n-4 double bond (i.e., a Δ14 double bond in the SPH m18:1 backbone). Product ions arising from a 
characteristic neutral loss of 110 Da from the [M+H]+ or [M+H-H2O]+ are marked with squares and are consistent 
with the presence of an n-9 double bond (e.g., 24:1 Δ15 acyl chain). These spectra are consistent with the 
deoxyceramides (a) Cer m18:1(Δ14)/16:0, (b) Cer m18:1(Δ14)/18:0, (c) Cer m18:1(Δ14)/22:0, (d) Cer 
m18:1(Δ14)/24:1(Δ15). (See also supplementary Figure 2 and supplementary table 1). Product ions marked with an 
asterisk (*) showed different mobility characteristics to the OzID peaks and likely arise from isobaric interference.  
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1.4.4 Synthesis of deoxy-Sphingosine standards 
Although the previous analysis confirmed the (Δ14) carbon-carbon double bond in native 1-
deoxySO they did not unambiguously assign the stereochemistry of the bond. To further confirm 
the position and configuration of the double bond a number of 1-deoxySO analogues with 
different double bond positions and confirmations (5E, 8E, 12E, 13E, 14E and 14Z) were 
synthesized. Here we focus on the synthesis of the SPH m18:1(14Z)(3OH) as details on the 
synthesis of the other derivatives will be published elsewhere†. The synthesis of 
SPH m18:1(14Z)(3OH) 12 commenced from commercially available 1,10-decandilol (Figure 
1-5). Treatment of 1,10-decanediol with dihydropyran in the presence of a catalytic amount of p-
toluenesulfonic acid (PTSA) afforded the mono-THP ether 3 in moderate yield. Subsequent 
conversion of mono-hydroxyl compound 3 to the corresponding bromo derivative 4 was 
accomplished through treatment of 3 with tetrabromomethane (CBr4) and triphenyl phosphine 
(PPh3) to provide compound 4. With intermediate 4 in hand, the coupling with lithiated 1-
pentyne was performed following a previously described protocol 16 with some modifications 
(see supporting information Table 1 for details). Thus, tert-butyllithium was added to 1-pentyne 
at -78°C, and the in situ generated 1-lithio-1-pentyne was sequentially reacted with DMPU and 
bromo substrate 4 to afford compound 5 in a satisfactory yield. Subsequent stereoselective 
hydrogenation of alkyne 5 was accomplished with Lindlar catalyst after optimization of reaction 
conditions to afford the desired Z-configuration of the alkene 6 as a sole isomer (see supporting 
information Table 2 for more details). It is noteworthy, that initial attempts to furnish alkene 6 led 
to a product that was contaminated (10-15%) with inseparable by-products. Careful analysis of 
1H-NMR spectra of the crude mixture identified these by-products as the E-configured alkene 
and the over reduced-product 1-bromopentadecane. Cleavage of the THP-protecting group in 6 
under acid-catalyzed ethanol treatment proceeded smoothly to provide the hydroxyl alkene 7 
which was subsequently subjected to Appel reaction with CBr4/PPh3 to furnish the Z-bromo-
alkene 8.  
                                                
† Manuscript in preparation 
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Figure 1-5: Synthesis of the 14Z-deoxy-sphingosine analogue. Reagents and conditions: a) DHP, PTSA (cat.), 
THF:DCM, 0°C-rt, 12 h. b) CBr4, PPh3, DCM, 0°C-rt, 4 h. c) (i) 1-Pentyne, tert-BuLi, toluene, -78°C, 1 h, and then (ii) 
DMPU, 4, THF, -78°C-rt, 7 h d) H2, EDA, Lindlar catalyst, 5% DMF in EtOAc, 0°C, 6 h. e) PPTS (cat.), EtOH, 62°C, 2 
h. f) (i) Mg, 1,2-DBE (drops), Et2O, reflux, 2 h, and then (ii) 2, MeMgBr, DCM:Et2O; reflux, 2 h. g) TBLAH, EtOH, -
78°C, 1 h  h) 4M HCl-Dioxane, 0°C, 3 h. 
Next, the obtained bromo-alkenyl chain 8 was converted into the corresponding Grignard 
reagent 9 and subsequently coupled to the Weinreb amide 2 (prepared from L-alanine in two 
steps, see the supporting information for details). Toward this end, Weinreb amide 2 was 
reacted with 0.9 equivalent of methylmagnesium bromide (as sacrificial base), followed by 
addition the Grignard reagent 9 to afford ketone 10 in 78% isolated yield. The subsequent 
diastereoselective reduction of the carbonyl group in 10 with lithium tri-(tert-butoxy)-aluminum 
hydride (TBLAH) (1.7 equiv.) in absolut ethanol at -78°C was accomplished without reduction of 
the double bond to furnish the desired anti-amino alcohol 11 as a mere stereoisomer. Acidic 
hydrolysis of the tert-butyl carbamate protecting group of 11 with 4M HCl-dioxane solution 
yieled the corresponding hydrochloric salt of SPH m18:1(14Z)(3OH) (.HCl). The desired product 
12 was finally obtained after neutralization workup in 71% yield. 
1.4.5 Retention-time correlation of native lipids with synthetic standards 
The RPLC retention times of the synthetic SPH m18:1(E)(3OH) standards with double bonds in 
positions 5E, 8E, 12E and14E, were compared. We observed an inverse logarithmic correlation 
(R2=0.96) between retention times and the double bond position (Figure 1-6A). The more the 
DB was positioned towards the omega end the earlier the molecule eluted from the column. The 
closest match in retention time between native 1-deoxySO and the synthetic standards was 
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seen again for SPH m18:1(14E)(3OH) although the elution time between the two compounds 
still differed by about 30 seconds (Figure 1-6B).  
 
Figure 1-6: (A) RPLC retention times for a set of synthetic SPH m18:1 standards having double bonds in positions 
(4E), (5E), (8E), (12E) and (14E). The position of the double bond within the alkyl chain showed a logarithmic 
correlation to the retention times (B) Comparing the retention times of native 1-deoxySO to the synthetic standards 
SPH m18:1 (14Z) and SPH m18:1 (14E) identified native 1-deoxySO as SPH m18:1 (14Z) ( **** p< 0.0001). (C) 
Comparison of the chemical structures of 1-deoxySO and Sphingadiene 
To further elucidate the DB configuration, we compared the retention times of native 1-deoxySO 
with the synthetic standard in (14Z) configuration (Figure 1-6B and supplementary Figure 3). 
The SPH m18:1(14Z) eluted at 13.0 min and was therefore coinciding with the elution time of 
native 1-doxySO. From these results we conclude that native 1-deoxySO bears a (14Z) double 
bond. 
1.5 Discussion 
1-deoxySO is an atypical sphingolipid, lacking the C1-hydroxylgroup of canonical sphingosine. It 
is a downstream metabolite of 1-deoxySA, which is formed by SPT due to its alternative activity 
with L-alanine. Because of the missing C1-hydroxyl group, 1-deoxySO cannot be 
phosphorylated to sphingosine 1-phosphate and therefore also not degraded by S1P-lyase 2. 
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Pathologically elevated 1-deoxySL play an important role in the inherited neuropathy HSAN1 
but were also found in other conditions like the metabolic syndrome and type 2 diabetes 3, 7. 
However, the metabolism of 1-deoxySLs and their molecular structures has not been 
investigated in detail yet. Comparing native 1-deoxySO to a synthetic SPH m18:1(4E) standard 
by RPLC we observed a significant deviation in retention time although m/z was identical for 
both molecules. Analyzing the DMDS derivatized adducts of native 1-deoxySO by MS2 revealed 
two specific fragments which indicated the double bond position at (Δ14) and therefore distinct 
to that of the canonical (Δ4)-position. The (Δ14)-position was further confirmed using differential 
mobility spectrometry combined with ozone-induced dissociation. Comparing retention times of 
native 1-deoxySO to a set of synthetic SPH m18:1 standards finally confirmed a (14Z) DB in 
native 1-deoxySO. 
During the sphingolipid de novo synthesis, the sphingolipid delta(4)-desaturase 1 (DES1) 
normally introduces a (4E) double bond into the sphingoid base backbone of dihydro-ceramide 
to form ceramide. The observation that native 1-deoxySO bears a (14Z) instead of (4E) DB, 
indicates that the metabolism of 1-deoxySL deviates from that of canonical sphingolipids. 
Interestingly, sphingadiene (SAdiene) a polyunsaturated downstream product of sphingosine 17 
has double bonds at both, (4E) and (14Z) positions (Figure 1-6C). The presence of a (14Z) 
double bond in both, SAdiene and native 1-deoxySO suggests that both metabolites are 
substrates of the same desaturase although the responsible enzyme is unknown so far 18. The 
fact that exogenously added D3-lableled 1-deoxySA is converted to D3-labeled 1-deoxySO also 
showed that the double bond is introduced downstream of 1-deoxySA and not formed by an 
SPT mediated incorporation of an desaturated acyl-CoA.  Interestingly, 1-
deoxymethylsphingosine (1-deoxymethSO), the corresponding downstream product of 1-
deoxymethylsphinganine which is formed by the condensation with glycine, seems to contain a 
(3E) DB. The m/z as well as RPLC retention time of native 1-deoxymethSO matched that of an 
synthetic m17:1 (3E)(2OH) standard (supplementary Figure 4). As 1-deoxymethSO contains 
only 17 carbons this equals the (4E) DB position of canonical SL.  
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In conclusion we provide strong evidences from multiple, orthogonal analytical techniques to 
unambiguously assign native 1-deoxySO as it is formed in HEK293 cells to be a SPH 
m18:1(14Z)(3OH) structure. This furthermore implies that 1-deoxy-ceramides are metabolized 
distinct from canonical sphingolipids. However, more detailed studies are needed to further 
investigate the enzymatic pathways and metabolic steps involved in the conversion of these 
lipids. 
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2 Chapter 2: The Metabolism of 1-
Deoxymethylsphingolipids 
Regula Steiner 
2.1 Abstract 
Canonical sphingolipids are formed by the condensation of palmitoyl-CoA and L-serine 
catalysed by serine palmitoyltransferase (SPT). Besides L-serine, SPT can also metabolize 
L-alanine and glycine. The conjugation with L-alanine forms 1-deoxysphingolipids, which lack 
the C1-OH group, whereas the conjugation with glycine forms 1-deoxymethylsphingolipids (1-
deoxymethylSL), which are devoid of the C1-methanolic group (R-C1-OH). They are natural 
lipids found in mammalian cells and human plasma but their biological role is not yet clear. 
Pathologically elevated 1-deoxySL and 1-deoxymethylSL cause the rare hereditary sensory 
neuropathy type 1 (HSAN1). 1-DeoxySL are toxic to primary sensory neurons in culture, lead 
to neurite retraction, and might contribute to beta cell failure and diabetic sensory 
neuropathy. 
1-DeoxymethylSL are assumed to be metabolised by the same enzymes as canonical 
sphingolipids, although they can neither be degraded nor converted to complex sphingolipids 
due to the missing C1-methanolic group. Here, we elucidated the metabolism of 1-
deoxymethylSL in comparison to the canonical sphingolipid pathway. 
HEK293 cells were supplemented with isotopic labelled 1-deoxymethylSA to study the 
metabolism of these lipids. Five new downstream metabolites of 1-deoxymethylSA were 
identified. 1-deoxymethylSL are converted to either mono- or di-desaturated species or 
alternatively are mono- or di-hydroxylated. The chemical structures were elucidated using 
liquid chromatography and high-resolution accurate mass spectrometry. Several enzymes of 
the canonical sphingolipid metabolism are involved in the formation of the desaturated or 
mono-hydroxylated species. The di-hydroxylated form is generated by a not yet known 
enzyme, which seems to be specific for 1-deoxymethylSL.  
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In summary, we demonstrated that 1-deoxymethySL follow partly the same but also other 
metabolic routes as canonical sphingolipids but also 1-deoxySL.   
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2.2 Introduction 
The de novo synthesis of sphingolipids (SL) typically starts by the condensation of L-serine 
and palmitoyl-CoA, a reaction catalyzed by serine-palmitoyltransferase (SPT). Besides these 
canonical substrates, SPT can use other acyl-CoAs but also glycine or L-alanine as 
alternative substrates and thereby generate a category of atypical 1-deoxysphingolipids (1-
deoxySL) and 1-deoxymethylsphingolipids (1-deoxymethylSL). These metabolites lack the 
C1-OH or even the C1-methanolic group of canonical sphingolipids 1, 2. 
Several missense mutations in SPT are associated with the inherited neuropathy HSAN1, a 
rare autosomal dominant inherited axonopathy which is clinically characterized by a 
progressive loss of pain and temperature sensation often accompanied by neuropathic pain 
attacks and skin ulcers 3. The missense mutations induce a permanent shift in the substrate 
specificity from L-serine to L-alanine and/or glycine resulting in increased 1-deoxySL and 1-
deoxymethylSL formation 3. 1-DeoxymethylSL have been found in mammalian cells and 
human plasma but their biological role is unknown so far.  
When following the canonical SL metabolic pathway, the condensation of glycine and 
palmitoyl-CoA trough SPT forms 1-deoxymethylSA which is converted to the N-acetylated 
form by ceramide synthases (CerS) and 1-deoxymethyldihydroCeramide is finally converted 
to 1-deoxymethylCeramide by the introduction of a double bond. From that stage the lipids 
are not metabolized further because of the missing C1-OH group. During catabolism, 1-
deoxymethylCeramdies are degraded by ceramidase to form 1-deoxymethylsphingosine (1-
deoxymethylSO) which in contrast to canonical SL cannot be phosphorylated to form the 
catabolic intermediate sphingosine-1-phosphate (S1P) 4. This prevents its cleavage to 
hexadecenal by S1P-lyase so that 1-deoxymethylSL cannot be degraded by the canonical 
catabolic pathway 1, 2.  
Previous studies showed that 1-deoxysphinganine (1-deoxySA), which arises from the 
condensation with L-alanine, has a different metabolism than canonical sphingolipids and 
that enzymes in the canonical sphingolipid pathway play a minor role in their metabolism. 
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Instead, a set of downstream metabolites were identified, which appear to be formed by of 
CYP 4F enzymes 5. For 1-deoxymethylSL it is currently unclear, whether they follow the 
canonical or an alternative pathway. 
We therefore compared the metabolism of the SPT products, which were formed by either 
the conjugation of L-serine, L-alanine or glycine. 
2.3 Material and Methods 
Unless stated differently, all solvents and reagents were purchased from Sigma-Aldrich 
Chemie GmbH (Buchs, Switzerland) excluding methanol, which was purchased from 
Honeywell specialty chemicals Seelze GmBH, Germany. 
2.3.1 Cell culture 
HEK293 cells were grown and maintained in DMEM (Sigma) with 10 % FBS (Fisher 
Scientific; FSA15-043) and 1 % penicillin / streptomycin (100 units per mL / 0.1 mg/mL, 
Sigma) at 37 °C and 5 % CO2. HEK293 cells were harvested in PBS. 
2.3.2 Transfection of DES 1/2 cells 
HEK293 wild type cells were transfected with plasmids containing wild type DES1 or DES2 
cDNAs. Stable cell lines were generated by propagating cells under geneticine (G418) 
selection. Expression of the DES1 or DES2 was confirmed by western blotting.  
2.3.3 Metabolic labelling assay 
D7-Sphingosine, D7-Sphinganine, D3-deoxysphinganine, D5-deoxymethylsphinganine and 1-
deoxymethylsphingosine were dissolved in ethanol (1mM). All sphingolipid standards were 
purchased from Avanti polar lipids (Avanti Polar Lipids, Alabaster, AL). 
HEK293 cells were fed with 0.5 µM of each lipid for kinetic assays or with 1 µM for inhibitor 
assays as indicated in the results section. In pulse-chase experiments, cells were fed with 
the specific lipid for 1 h, medium was exchanged to fresh medium without lipid supplement 
containing the respective inhibitor and cells were harvested up to 48 hours after medium 
change at different time points. 
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In steady state experiments, cells were fed with 1 µM lipid and the respective inhibitor and 
cells were harvested up to 48 hour after medium change at different time points. 
The following inhibitors were used: Fumonisine B1 6 (FB1, Sigma, 35 µM), Fenretinide 7 (4-
HPR, Tocris Bioscience, 2 µM), 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol 8 (SK I II, 20 
µM), HET0016 (Santa Cruz Biotechnology, 5 µM).  
HEK293 cells were harvested in PBS, counted (Z2 Coulter counter; Beckman Coulter, Brea, 
CA) and pelleted (1200 rpm, 5 min at 4 °C, Eppendorf 5424R). 
2.3.4 Cell extract 
From the harvested pellet, the whole sphingolipids were extracted and hydrolyzed to get the 
free sphingoid bases as described previously with some modifications 9-11. The cell pellet was 
dissolved in 100 µL of PBS. 500 µL methanol containing the internal standard D3-threo-1-
deoxySA (Avanti Polar Lipids, Alabaster, AL) was added to the dissolved pellet. Lipids were 
extracted for one hour under constant agitation at 37 °C in an Eppendorf Thermomixer. 
Samples were centrifuged at 16000 rpm for 5 min to pellet precipitated proteins and 500 µL 
of the supernatant was transferred into a new tube. Lipids were hydrolyzed by adding 75 µL 
of methanolic HCl (1 M HCl and 10 M H2O in methanol) and incubated for 16 h at 65 °C. By 
adding 100 µL of KOH (10 M) HCl was neutralized. 625 µL chloroform were added followed 
by 100 µL 2 M ammonium hydroxide and 0.5 mL alkaline water to reach phase separation. 
The sample was vortexed, centrifuged at 16000 rpm for 5 min, the upper phase discarded 
and the lower (organic) phase washed 3 times with alkaline water. The organic phase was 
finally dried under N2 and stored at −20 oC until analysis. 
2.3.5 LC-MS Method 
An LC-MS method described previously 10 was used to detect and quantify the hydrolyzed 
sphingolipid profile in the samples. Sphingoid bases were separated by RPLC on a C18-
column (Uptispere 120 Å, 5 µm, 125×2 mm; Interchim, Montluçon, France) and analyzed on 
a Q Exactive (Thermo, Reinach, BL, Switzerland) using an atmospheric pressure chemical 
ionization (APCI) interface. Mobile phases consisted of A: ultra-pure H2O / methanol 1/1 v/v 
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with 2.6 mM ammonium acetate and B: methanol. A linear gradient was set from 50 % B to 
100 % B within 25 min followed by 5 min 100 % B and 5 min of equilibration with 50 % B at a 
flow rate of 0.3 mL/min. For mass spectral detection, the following parameters were set on 
the APCI source: discharge current of 4 µA, vaporizer temperature of 450 °C, sheath gas 
pressure 20 AU, aux gas 5 AU and capillary temperature of 200 °C. The measured area 
under the peak curve was normalized to D3-threo-1-deoxySA and lipid concentrations were 
calculated by comparison to D3-threo-1-deoxySA and quantification was reported as pmol 
per million cells.  
2.3.6 Diol synthesis with potassium permanganate 
100 nmol 1-deoxymethylSO (m17:1 (3E)(2OH)) was dissolved in 10 µL ethanol. 100 µL 2 
mM KMnO4 (in H2O) and 75 µL 10 M NaOH was added to the tube, which was cooled to 4 °C 
on ice. After the solution changed the colour from purple to brown, 500 µL chloroform were 
added and the mixture was vortexed for 20 seconds. The chloroform phase was transferred 
into another tube and the water phase was re-extracted with another 500 µL of chloroform. 
The chloroform phases were combined and dried under N2. 
2.3.7 Statistical Analysis 
Experiments were always carried out in triplicates. Statistical significance was calculated 
using GraphPad Prism 6 software using a two-tailed t test or ANOVA. 
2.4 Results  
2.4.1 Identification of downstream metabolites 
To identify potential D5-1-deoxmethSA downstream products, HEK293 cells were fed with 
D5-1-deoxymethylSA (1 µM) or vehicle (ethanol) for 24 h. As D5-1-deoxymethlSA cannot be 
degraded via the S1P lyase, all metabolites bearing a D5 label were assumed to be formed 
downstream of D5-1-deoxymethylSA and should not be present in the ethanol treated control 
samples. With the help of SieveTM, but also with manual data review, high-resolution accurate 
mass patterns were identified bearing a D5 label.  
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Besides the already known downstream metabolite D5-1-deoxymethylSO, five additional 
metabolites were identified. Based on mass differences, one of the metabolites appeared to 
have a second double bond (1-deoxymethylsphingadiene), which would correspond to the 
canonical sphingadiene (SAdiene), a downstream product of SO which contains a (4E) and a 
(14Z) double bond. Additionally, four mono- or di-hydroxylated species were identified. We 
found a mono-hydroxylated and a di-hydroxylated metabolite of 1-deoxymethylSA but also 1-
deoxymethylSO. The di-hydroxylated metabolites were more abundant than the mono-
hydroxylated ones. The most abundant metabolite after 48 h was di-hydroxyl-1-
deoxymethylSA (SPH t17:0) having two additional hydroxyl groups. The exact position of the 
hydroxyl groups has not yet been unravelled.  
Among canonical sphingolipids the downstream metabolism of sphinganine requires N-
acylation of the free base. To test if the hydroxylated downstream products of 1-
deoxymethylspinganine are formed on the free base rather than on the N-acyl form, HEK293 
cells were supplemented with D5-1-deoxymethylSA (1 µM) for 24 h in the presence of 
Fumonisine B1 (FB1, 35 µM) a potent inhibitor of ceramide synthase (CerS). As seen in 
Figure 2-1, all identified downstream metabolites of D5-1-deoxymethylSA were less abundant 
in the presence of FB1 indicating that not the free base but the N-acyl form is metabolized. 
Therefore, the precursor of all downstream metabolites is the N-acetylated form for both the 
canonical SL and atypical SL. 
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Figure 2-1: HEK293 wells were fed with D5-1-deoxymethylSA for 24 h with and without FB1. Formation of 
downstream metabolites is drastically reduced with FB1. Statistical significance was tested using ANOVA. **= P < 
0.01, ***= P < 0.001, ****=P < 0.0001.  
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2.4.2 Kinetics 
To compare the metabolism and elimination of canonical sphinganine and 1-
deoxysphingolipids and 1-deoxymethylsphingolipids (formed from L-alanine and glycine, 
respectively), HEK293 cells were supplemented with a 1 h pulse of D7-sphinganine (D7-SA), 
D3-1-deoxysphinganine (D3-1-deoxySA) and D5-1-deoxymethylsphinganine (D5-1-
deoxymethylSA) (1 h, 0.5 µM each) followed by a 48 h chase. The formation of various 
isotopicly labeled downstream products was followed over time (Figure 2-2). Concentrations 
of the isotopic labeled lipids at time point zero was measured after medium exchange at the 
start of the chase period. 
The uptake of supplemented sphingoid bases was fast. Already a few minutes after addition 
of the isotopic labeled compounds an increase in the intercellular levels was detectable. At 
time point 0 h, D3-1-deoxySA levels were about two times higher than those of D7-SA or D5-
1-deoxymethylSA. Assuming that the uptake of all three LCBs was similar, this difference is 
likely explained by different velocity in the metabolic conversion during the 1 h pulse (Figure 
2-2A).  
For D7-SA this metabolic conversion was quite fast. Already 2 h after the medium exchange, 
more than 50 % of the initial pulse was converted into D7-SO or degraded (Figure 2-2B). 
Also, D7-SAdiene was mostly degraded after 24 h (Figure 2-2C). This rapid decrease in D7-
SA and its downstream metabolites can be explained by its conversion into sphingosine-1-
phosphate (S1P), which is then terminally degraded to hexadecenal by S1P lyase. 
In contrast, 1-deoxySA conversion was much slower. The maximum level of D3-1-deoxySO 
was only reached after 15 h (Figure 2-2B). Levels of the di-desaturated D3-1-deoxySAdiene 
were still increasing after 48 h. (Figure 2-2C). This, however, was different for D5-1-
deoxymethylSA. Surprisingly, we observed a faster conversion rate than for 1-deoxySA, 
similar to the one of D7-SA (Figure 2-2). 
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Figure 2-2: HEK293 cells were fed with D7-SA, D3-1-deoxySA and D5-1-deoxymethylSA (0.5 µM each) for 1 h, 
after 1 h the medium was replaced by un-supplemented medium and cells were cultured for 0 h, 2 h, 6 h, 15 h, 24 
h or 48 h. Cells were harvested and total sphingolipids were extracted and hydrolyzed as described. Kinetics of 
D7-SA and its downstream metabolites D7-SO or D7-sphingadiene was compared to the kinetics of D3-1-deoxySA 
or D5-1-deoxymethylSA and their respective downstream metabolites.  
2.4.3 Double bond position and the role of DES1 and DES2 in the metabolism 
of 1-deoxymethylSA 
Double bond position 
For the conversion of sphinganine to sphingosine, dihydroceramides are converted to 
ceramides by the introduction of a double bond at (4E) by the dihydroceramide Δ4-
desaturase 12 which is expressed in two isoforms, DES1 and DES2. Whereas DES1 primarily 
introduces the (4E) double bond, DES2 catalyses a two-step reaction by first adding a 
A B 
C 
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hydroxyl group at ∆4 position thereby forming phytosphingosine and introducing a (4E) 
double bond similar to DES1 13, 14. 
However, 1-deoxySO contains a (14Z) double bond in contrast to the canonical (4E) and was 
shown not to be formed by DES1 or DES2. However the role of DES1/2 in metabolising 1-
deoxymethylSA is not known. We first wanted to see whether 1-deoxymethylSO contains a 
canonical or a differently positioned double bond. We supplemented HEK293 cells with 
isotope labeled D5-1-deoxymethylSA and compared the formed D5-1-deoxymethylSO to a 
commercially available synthetic SPH m17:1(3E)(2OH) standard. Both compounds had the 
same mass-to-charge ratio (m/z) and also and overlapping retention time indicating that both 
compounds have the identical structure (Figure 2-3). This means, that in contrast to 1-
deoxySO, 1-deoxymethylSO contains a canonical double bond position. 
 
Figure 2-3: HEK293 cells were fed with labeled D5-1-deoxymethylSA (Avanti Polar Lipids, Alabaster, AL). Cells 
were harvested after 24 h and the whole sphingolipid extract was hydrolyzed to get the free sphingoid bases. 
Extract was treated with o-phthalaldehyde (OPA) to get the OPA derivative of sphingoid bases. Sphingoid bases 
were separated on a C18 column and detected on an HRAMS Q Exactive. Retention time and m/z of deuterium 
labeled D5-1-deoxymethylSO were compared to synthetic SPH m17:1(3E). Retention time of native D5-1-
deoxymethylSO was 21.73 min (B) and for SPH m17:1(3E) 21.73 min (A). m/z of native D5-1-deoxymethylSO was 
451.33832 (calculated 451.34011, < 5 ppm) and for SPH m17:1(3E) 446.30685 (calculated 446.30872, < 5 ppm) 
11. 
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This indicates that the double bond in both canonical SO and 1-deoxymethSO is also 
introduced by DES1/2 12. To proof that, we added 4-HPR, a potent inhibitor for DES1/2 
together with D5-1-deoxymethSO to HEK293 cells (24 h) and analyzed the labelled 
downstream metabolites. Supporting our hypothesis, the conversion of D5-1-deoxymethylSA 
to D5-1-deoxymethylSO was inhibited by 4-HPR. The concentration of D5-1-deoxymethylSA 
was significantly higher in cells treated with 4-HPR compared to controls. In contrast, D5-1-
deoxymethylSO was significantly lower for all time points in the presence of 4-HPR (Figure 
2-4A).  
Next, we overexpressed DES1 and DES2 in HEK293 cells and compared the conversion of 
D5-1-deoxymethylSA to D5-1-deoxymethylSO in the overexpressing cells to that in wild type 
(WT) cells. The concentration of D5-1-deoxymethylSO was not changed in the 
overexpressing cells. This might be due to the rapid degradation of 1-deoxymethylSO after 
increased formation in DES1/2 overexpressing cells (Figure 2-4B).  
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Figure 2-4: A: HEK293 cells were fed with D5-1-deoxymethylSA (1 µM) and DES was inhibited with HPR. 
Conversion of D5-1-deoxymethylspinganine to D5-1-deoxymethylSO is reduced with 4-HPR. Additionally, the 
conversion to the downstream metabolite of D5-1-deoxymethylSO, 1-deoxymethylsphingadiene is also inhibited 
with 4-HPR. B: HEK293 overexpressing DES 1 and DES 2 and HEK293 WT cells as control were fed with D5-1-
deoxymethylSA (1 µM). Levels of D5-1-deoxymethylSO were compared between cells overexpressing DES1 or 
DES2 and wild type cells. Formation of D5-1-deoxymethylSO is not changed in DES1 or in DES2 overexpressing 
cells compared to WT. Statistical significance was tested using ANOVA. **= P< 0.01, ***= P < 0.001, ****=P < 
0.0001. 
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Mono-hydroxylation 
Whereas DES1 introduces the ∆4 double bond in a single step reaction, DES2 acts in a two 
step reaction by first introducing a ∆4 hydroxylgroup, forming phytosphingosine (SPH t18:0), 
which can then be further converted to a (4E) double bond or released as hydroxylated 
species. Therefore, we also wanted to confirm, if DES2 is responsible for the formation of the 
newly identified mono-hydroxylated species of 1-deoxymethylSL. As it is not known from 
literature, if 4-HPR inhibits both of the DES isoforms, we also added SKI II, a sphingosine 
kinase inhibitor, which was published to also inhibit DES enzymes. With the inhibition of 
DES, the levels of hydroxyl-D5-1-deoxymethylSA and hydroxyl-D5-1-deoxymethylSO are 
significantly decreased at all time points (Figure 2-5A with 4-HPR, Figure 2-5B with SKI II). 
Therefore, the desaturase is involved in the formation of mono-hydroxylated species of 1-
deoxymethylSL.  
To exclude an unspecific effect of the two tested inhibitors, we finally overexpressed DES1 
and DES2 in HEK293 cells and supplemented the cells with D5-1-deoxymethylSA for 24 h 
and the hydroxylated downstream product was measured in the overexpressing cells. The 
formation of hydroxyl-D5-1-deoxymethylSA was significantly increased in cells 
overexpressing DES2 enzyme for all time points, whereas the formation of hydroxyl-D5-1-
deoxymethylSO was only increased after 24 hours in DES overexpressing cells (Figure 
2-5C). Therefore DES2 is most probably forming a mono-hydroxyl-1-deoxymethylSA, 
comparable to the Phyto-Sphingosine (t18:0) formed by DES2 from sphinganine by adding a 
hydroxyl-group at ∆4-C. The position for hydroxylation of 1-deoxymethylSA is not known, but  
can be assumed to be inserted at ∆3, which corresponds to the position in canonical 
hydroxyl-sphinganine (Phyto-Sphingosine t18:0). The formation of hydroxyl-1-
deoxymethylSO needs two independent reactions - the insertion of the alternative double 
bond (most probably (13Z)) and the ∆3-hydroxylation by DES2 - therefore hydroxyl-D5-1-
deoxymethylSO is not increased rapidly in cells overexpressing DES2. In Figure 2-5D the 
proposed structures are shown. 
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Figure 2-5: A: HEK293 were fed with D5-1-deoxymethylSA (1 µM) and DES1/2 was inhibited with 4-HPR. 
Formation of mono-hydroxylated metabolites is clearly inhibited by 4-HPR. B: HEK293 were fed with D5-1-
deoxymethylSA (1 µM) and DES1/2 was inhibited with SK I II, which was reported to also inhibit DES enzyme. 
Formation of mono-hydroxylated metabolites is clearly inhibited by SK I II. C: HEK293 overexpressing DES 1 and 
DES 2 and HEK293 WT cells as control were fed with D5-1-deoxymethylSA (1 µM). Levels of mono-hydroxylated 
D5-1-deoxymethylSL species were compared between cells overexpressing DES 1 or DES 2 to wild type cells. 
Formation of hydroxyl-D5-1-deoxymethylSA is increased in cells overexpressing DES 2 in all time points; 
formation of hydroxyl-D5-1-deoxymethlSO is increased after 24 hours in cells overexpressing any desaturase 
enzyme. Statistical significance was tested using ANOVA. **= P< 0.01, ***= P < 0.001, ****=P < 0.0001. D: 
Proposed structure for hydroxyl-1-deoxymethylspinganine (hydroxyl doxmethSA) and hydroxyl-1-deoxymethylSO 
(hydroxy doxmethSO ) 
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2.4.4 Alternative double bond insertion over unknown desaturase 
For sphinganine it is known that in addition to the (4E) double bond, a (14Z) double bond can 
be introduced. Further, 1-deoxysphingosine does not containing a (4E) but a (14Z) double 
bond. This (14Z) seems to be an alternative pathway, next to the desaturation by DES1 or 
DES2, but the corresponding enzyme is still unknown. Therefore, it was investigated, if this 
alternative double bond also exists in 1-deoxymethylSL.  
After feeding cells with D5-1-deoxymethylSA, we observed a small peak eluting before 1-
deoxymethylSO (Figure 2-3B). This peak has the same m/z as 1-deoxymethylSO and also 
contains a D5-label, suggesting the presence of an alternative form of 1-deoxymetSO, 
possibly containing a (13Z) double bond. 1-DeoxySL metabolism differs between cell types. 
The metabolism of 1-deoxySLs is faster and more diverse in MEF cells compared to HEK293 
cells. Also in MEF cells, this alternative peak was observed.  
Therefore, we tested in HEK293 and in MEF cells, if 4-HPR has an effect on the formation of 
this alternative 1-deoxymethylSO. In either cells line, a second 1-deoxymethylSO was 
formed and this alternative peak was increased in 4-HPR treated HEK293 (Figure 2-6A) and 
MEF (Figure 2-6B) cells indicating that the formation of this variant is increased after 
inhibition of DES1/2. This compensatory mechanism was not seen for 1-deoxySL, as they 
are no substrate for DES1/2 and therefore, only the (14Z) position is formed over the 
alternative pathway, but none of the (4E) form. 
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Figure 2-6: A: HEK293 cells were fed with D5-1-deoxymethylSA and DES was inhibited with 4-HPR. There were 
two different 1-deoxymethylSO identified and quantified. B: MEF cells were fed with D5-1-deoxymethylSA and 
DES was inhibited with 4-HPR. There were two different 1-deoxymethylSO identified and quantified. For both 
HEK293 and MEF cells, the formation of the alternative 1-deoxymethylSO was increased with the inhibition of 
DES, whereas the formation of the (3E) form was decreased. C. Proposed structures for 1-
deoxymethylspinhosine (3E) (doxmethSO 1) and 1-deoxymethylSO (13Z) (doxmethSO 2) 
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1-deoxymethylSAdiene 
We also identified a 1-deoxymethSA downstream metabolite which by mass bears two 
double bonds (1-deoxymethylSAdiene). This 1-deoxymethylSAdiene likely corresponds to 
the canonical SO metabolite Sphingadiene (SAdiene). In analogy to SAdiene we 
hypothesized that the two double bonds in 1-deoxymethylSAdiene are located in (3E) and 
(13Z) position. As demonstrated in Figure 2-4 the insertion of the (3E) double bond depends 
on DES1/2 whereas the second double bond is introduced independently of DES (Figure 
2-6). Based on our previous observations it is likely that the two double bonds are introduced 
in a sequential reaction by fist introducing the (3E) (by DES1/2) followed by the (13Z) (by an 
unknown desaturase) or vice versa.  
2.4.5 Di-hydroxylated 1-deoxymethylsphingolipids are formed by an unknown 
enzyme 
Di-hydroxylation downstream of 1-deoxymethylsphingosine 
Di-hydroxylation was not described for canonical sphingolipids 15, but it was seen in 1-
deoxySL, although in very low amounts 5. For 1-deoxymethylSLs, it is one of the most 
abundant downstream metabolites. Di-hydroxylated 1-deoxymethylSL could be formed 
directly from 1-deoxymethylSA or further downstream, e.g. as a sequential reaction after 
mono-hydroxylation or by the conversion of the double bond of 1-deoxymethylSO to a vicinal 
diol. To test if di-hydroxylation is downstream of 1-deoxymethylSA or 1-deoxymethylSO, we 
inhibited the conversion from fed D5-1-deoxymethylSA to D5-1-deoxymethylSO with 4-HPR to 
see if di-hydroxylated 1-deoxymethylSL were still formed.  
4-HPR inhibits the desaturation of added D5-1-deoxymethylSA, the levels of formed D5-1-
deoxymethylSO are significantly reduced with 4-HPR. Furthermore, di-hydroxylated 1-
deoxymethylSL are significantly decreased in presence of the 4-HPR inhibitor (Figure 2-7A). 
This might be explained by reduced formation of precursor metabolite D5-1-deoxymethylSO 
though inhibition of DES1/2. However, HEK293 cells which overexpress DES1 or DES2 were 
fed with D5-1-deoxymethylSA formation showed an increased formation of di-hydroxylated 1-
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deoxymethylSL species. There was no change seen in 1-deoxymethylSO formation after 
feeding D5-1-deoxymethylSA, but the di-hydroxylated forms were increasing after 15 hours in 
DES 2 overexpressing cells and after 24 h also in DES1 overexpressing cells compared to 
WT form (Figure 2-7B).  
As the di-hydroxylated 1-deoxymethylSL forms were increased in DES overexpressing cells 
and decreased with DES inhibition with 4-HPR they were formed most likely downstream of 
1-deoxymethylSO (Figure 2-7A and Figure 2-7B). For a proof, HEK293 cells were 
supplemented with synthetic 1-deoxymethylSO (1 µM) for up to 24 h in a steady state 
manner. As there was no deuterium labeled 1-deoxymethylSO available, also natively 
formed downstream metabolites are present in the cells. Levels of downstream metabolites 
formed from exogenous 1-deoxymethylSO have to be compared to endogenously formed 
levels of 1-deoxymethylSL (Figure 2-7C). All downstream metabolites are formed on the 1-
deoxymethylCer forms but not on the free base. To block the conversion of the free base 1-
deoxymethylSO to 1-deoxymethylCer ceramide synthase (CerS) inhibitor FB1 was added 
together with 1-deoxymethylSO. With the addition of FB1, exogenous 1-deoxymethylSO 
should not get converted further.  
Di-hydroxylation of 1-deoxymethySL and also 1-deoxymethylSAdiene were formed after 
feeding cells with 1-deoxymethylSO. With the addition of the CerS inhibitor FB1, the 
formation of 1-deoxymethylSAdiene, but also the di-hydroxylated species was significantly 
reduced and the exogenous 1-deoxymethylSO accumulated in the cell. In conclusion, the di-
hydroxylated forms were formed downstream of 1-deoxymethylSO. This reaction seems to 
be a unique reaction during 1-deoxymethylSL metabolism, as di-hydroxylated species of L-
serine based SL were not yet reported. Di-hydroxylated 1-deoxySL were formed but in much 
less than di-hydroxylated 1-deoxmethylSL.  
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Figure 2-7: A: HEK293 cells were fed with D5-1-deoxymethylSA for 24 h and DES1/2 inhibitor 4-HPR or ethanol 
as control was added. The formation of di-hydroxylated 1-deoxymethylSL species is reduced with 4-HPR, as the 
conversion to precursor 1-deoxymethylSO is blocked. B: Concentration of di-hydroxylated 1-deoxymethylSL after 
D5-1-deoxymethylSA treatment for 24 h in DES 1 or DES2 overexpressing HEK293 cells compared to WT cells. 
C: HEK293 cells were fed with 1-deoxymethylSO (1 µM) for up to 24 h and CerS was inhibited with FB1 as a 
control. To control for natively formed 1-deoxymethySL formed by the cells, cells were treated with Ethanol with 
and without FB1 only. Di-hydroxylated 1-deoxymethylSL are significantly elevated in cells fed with 1-
deoxymethylSO, whereas FB1 inhibits the formation of di-hydroxylated species. Statistical significance was tested 
using ANOVA. **= P< 0.01, ***= P < 0.001, ****=P < 0.0001. D: Proposed structure for di-hydroxyl-1-
deoxymethylspinganine (di-hydroxyl doxmethSA) and di-hydroxyl-1-deoxymethylSO (di-hydroxy doxmethSO ) 
It is suspected that 1-deoxySL are metabolized to their mono-hydroxylated forms by the 4F 
family of cytochrome P 450 (CYP) enzymes, an enzyme family with mostly monooxygenase 
activity. However, CYP 4F enzymes seem not to be involved in the canonical sphingolipid 
metabolism. We therefore tested, whether CYP 4F enzymes also contribute to the 
metabolism of 1-deoxymethylSL. As MEF cells metabolize 1-deoxySL more actively, we 
supplemented MEF cells with D5-1-deoxymethylSA in combination with the CYP 4A/F pan-
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inhibitor HET0016. In the presence of HET0016, the formation of di-hydroxyl forms was 
clearly reduced, whereas the levels of D5-1-deoxymethylSO, D5-1-deoxymethylSAdiene and 
mono-hydroxylated D5-1-deoxymethylSA was increased (Figure 2-8). With CYP 4A/F 
inhibition, D5-1-deoxymethylSO was accumulating but also converted to D5-1-
deoxymethylSAdiene. Also D5-1-deoxymethylSA was accumulated and converted to mono-
hydroxylated species. This indicated that CYP 4F reaction occurs downstream of 1-
deoxymethylSO. In Figure 2-7D, the proposed structures of di-hydroxy-1-deoxymethylSA and 
di-hydroxy-1-deoxymethylSO are shown. 
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Figure 2-8: MEF cells were fed with D5-1-deoxymethylSA for 24 h and CYP 4F family was inhibited with HET0016 
(or ethanol as control was added). Statistical significance was tested using ANOVA. **= P< 0.01, ***= P < 0.001, 
****=P < 0.0001. 
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2.4.6 Structural elucidations of di-hydroxy-1-deoxymethylsphinganine 
As di-hydroxyl-1-deoxymethylSA is formed downstream of 1-deoxymethylSO, it is likely that 
the double bond is cleaved and a vicinal diol is formed. To elucidate its structure, we tried to 
oxidize the double bond of 1-deoxymethylSO with potassium permanganate to form a vicinal 
diol (di-hydroxyl-1-deoxymethylSA m17:0 (2OH)(3OH)(4OH) and we compared the retention 
time in RPLC to the native formed di-hydroxyl-1-deoxymethylSA. Two different reaction 
products were formed (Figure 2-9B), corresponding to the two possible syn diols that can be 
formed from 1-deoxymethylSO. Figure 2-9A displays the native product formed from feeding 
HEK293 cells with D5-1-deoxymethylSA. The retention times of the different diols and the 
native product do not match possibly due to the fact that the native product could be an anti-
diol. The position of hydroxylation therefore remains elusive. 
 
Figure 2-9: Chromatogram of A natively formed di-hydroxyl-D5-1-deoxymethylSA and B the two syn-diols formed 
after the oxidation with potassium permanganate 
2.5 Discussion 
Based on the structural similarities it was assumed, that also atypical 1-deoxysphingolipids 
and 1-deoxymethylsphingolipids follow the same metabolic rout as canonical sphingolipids, 
except that, they cannot be converted to complex sphingolipids or phosphorylated to 
sphingosine-1-phosphate for degradation by sphingosine-1-phosphate-lyase, because of the 
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missing C1-hydroxyl group 1, 4. However, this assumption was not correct for 1-deoxySL 
which are formed from L-alanine and metabolized by a different enzyme as canonical 
sphingolipids 5. Here we showed that the metabolism of 1-deoxymethylSL partly but not 
entirely follows the canonical sphingolipid pathway. In  Figure 2-10 we show the proposed 
metabolic pathway for canonical and atypical sphingolipids with all likely branching points.  
The metabolism starts with palmitoyl-CoA, which is either conjugated to L-serine, L-alanine 
or glycine. All three reactions are catalyzed by the enzyme serine-palmitoyl-transferase 
(SPT) 16, 17. After the sphingoid backbone is formed, the canonical sphinganine (SA) is N-
acetylated to dihydroceramide and converted to ceramide by DES1 and DES2.  
For L-serine and glycine based sphingolipids, a desaturation at (4E) and (3E) respectively 
over DES1/2 is possible which leads to the second major sphingoid backbone sphingosine 
(SO) 12. For L-alanine based 1-deoxySL, this desaturation does not occur, but a double bond 
is introduced at (14Z) 11. This reaction also occurs for L-serine or glycine based 
sphingolipids, but seems to be a less frequently used alternative pathway of desaturation for 
these lipids. The two possibilities for desaturation in L-serine or glycine based sphingolipids 
lead to the formation of di-unsaturated sphingoid backbone sphingadiene (SAdiene) 18, which 
corresponds to the a downstream metabolite of sphingosine with (4E) and (14Z) double 
bond. As glycine based sphingolipids are based on 17 carbons, the corresponding 1-
deoxymethylSAdiene presumably contains a (3E) and a (13Z) double bond. The enzyme 
involved in the formation of the (14Z) double bond is as yet unknown.  
In addition to the three major sphingoid bases, SA, SO and SAdiene, sphingolipids can be 
converted to quantitatively minor backbone structures. SA can be hydroxylated by DES2 to 
phytosphingosine (t18:0) 12, 14. DES2, which is involved in the canonical sphingolipid 
pathway, is not involved in the metabolism of atypical 1-deoxysphingolipds, as mono-
hydroxyl-1-deoxySA is formed by CYP 4F enzymes 5. 
It remains the question on the involvement of DES in the double bond formation of atypical 
sphingolipids. SO and 1-deoxymethylSO but not 1-deoxySO are substrates for DES. 
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Therefore it is probably not the C1-hydroxylgroup which is responsible for the DES 
recognition and desaturation or hydroxylation of ∆4 19 except if 1-deoxySA is locally 
separated from DES within the cell compartments. Previous studies showed the different 
localization of the canonical sphingolipids and 1-deoxySL, the latter of which seems to be 
mostly located in mitochondria 20. 
As seen in  Figure 2-10 the metabolism of canonical sphingolipids as well as atypical 1-
deoxysphingolipids and 1-deoxymethylsphingolipids follow the same central metabolic 
pathway involving SPT, CerS, and Ceramidase. Furthermore, DES1 and DES2 metabolize 
canonical SL and 1-deoxymethylSL, but not 1-deoxySL, although, mono-desaturated 1-
deoxySO and mono-hydroxylated 1-deoxySA exist, however, they are metabolized by 
different enzymes than DES1/2. 
As 1-deoxySL and 1-deoxymethylSL are missing the C1-hydroxyl group, they can be neither 
converted to complex sphingolipids, nor phosphorylated and degraded via SK and SGPL. 
For 1-deoxySL, there seems to be an alternative downstream metabolic pathway involving 
CYP 4F enzymes. 1-Deoxymethylsphingolipids are di-hydroxylated by a reaction, which is 
not known for canonical sphingolipids. 
In summary, we showed, that despite some overlap the metabolism of glycine based 1-
deoxymethylsphingolipids differs from that of both canonical sphingolipids as well as atypical 
L-alanine based sphingolipids. 
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Figure 2-10: P
roposed m
etabolic pathw
ay for sphingolipids w
ith different am
ino acid starting points. S
tructures in black: R
oute for L-serine, L-alanine and glycine based 
sphingolipids. S
tructures in green: R
oute for L-serine and glycine based sphingolipids. S
tructures in blue: route only possible for L-serine based sphingolipids. S
tructures in violet: 
route only possible for L-alanine based 1-deoxysphingolipids. S
tructures in yellow
: route only possible for glycine based 1-deoxym
ethylsphingolipids. 
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3 Chapter 3: Online extraction using Turbulent Flow 
Chromatography 
Regula Steiner 
3.1 Abstract 
For applications of lipidomics to a large sample size, an automated high throughput analysis 
and well-defined workflows are essential. Sample preparation is one of the most critical steps 
in this process, as it can introduce biases. Therefore, a fast and robust sample preparation 
process is needed, which optimally covers a broad range of analytes varying in solubility, 
polarity and abundance. We evaluated the automated Thermo TLX online extraction system 
using turbulent flow chromatography, which bypasses manual sample preparation steps to 
speed up the preparation time. We established a TLX extraction protocol for various 
sphingolipid species and additionally, compared it to established manual liquid-liquid 
extraction procedures, like those of Folch, Bligh and Dyer, as well as a recently published 
single-phase methyl-tert-butyl-ether extraction protocol. We show that, although the TLX 
system allowed for robust extraction of various sphingolipid classes, the over-all lipid 
recovery is much lower compared to the liquid-liquid based extraction methods, varying 
between 12 % and 93 % for the different sphingolipid classes.  
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3.2 Introduction 
Novel biomarkers need validation and replication in large population-based studies, with 
sample numbers ranging from hundreds to several thousands. To analyze such large 
numbers of samples, an automated high throughput analysis and well-defined workflows are 
desired. For lipid analysis, sample preparation is the first and most critical step, as it can 
significantly influence the number, abundance and types of extracted lipid species in a 
specimen 1. The primary aim of the sample preparation is to enrich the analytes of interest 
and remove interfering impurities, such as proteins or salts 2. Chromatographic separation 
techniques usually do not tolerate the presence of proteins during analysis as they interact 
with the analytical column, interfere with the retention of the analytes, and might form 
precipitates, which block the flow through the column. Furthermore, proteins interfere with 
most of the detectors and can lead to ion suppression 3, which can be seen as a competition 
for ionization between molecules introduced into the MS source at the same time, and 
thereby reduces the signal for the analyte of interest. 
In lipidomics, several sample preparation strategies have been used. Proteins can be 
precipitated by the use of organic solvents, or analytes can be extracted using liquid-liquid 
extraction or solid phase extraction 2. However, none of the described precipitation 
techniques results in complete protein removal or is optimal for all metabolites of interest 4. 
Therefore, each extraction method has to be chosen separately according to the individual 
analytical needs. For protein precipitation, organic solvents such as methanol (MeOH), 
ethanol (EtOH), acetonitrile (ACN), acetone, or a combination thereof are used 4, 5. For the 
extraction of lipids, the protocols from Bligh and Dyer 6 or Folch 7 are considered as the gold 
standards, however, relatively new optimized protocols using methyl-tert-butyl-ether or other 
ether-based solvent systems have also been developed recently 8. 
Sample preparation methods improve the quality of the analysis, but also pose the risk to 
lose certain analytes during the extraction. Also, most of these techniques require 
evaporation and reconstitution steps, which can lead to the loss of analytes or an increase in 
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ion suppression. In addition and in general, manual extraction is more time-consuming and 
lowers sample throughput significantly 1.  
The workflow in our lab currently includes a manual two-step liquid-liquid extraction 9-13. This 
extraction step, as well as the semi-manual analysis of the identified metabolites, greatly 
limits the analytical throughput and the number of samples, which can be analyzed within a 
reasonable time. To circumvent these limitations, we wanted to establish an TLX based 
extraction method which allows the extraction of a great variety of lipid classes and species. 
Turbulent flow chromatography is a novel technique for sample preparation, which was 
initially established for the analysis of small molecules 14 and metabolites 15. The technique 
allows complete automation, as the samples can be serially injected into and extracted by 
the chromatographic system. This minimizes manual sample preparation steps and allows 
high throughput analysis 16, 17.  
The set-up requires a turbo flow extraction column with relatively large particle size, installed 
in series before the analytical column. Low molecular weight analytes diffuse into the pores 
of the extraction column and are retained, while lager matrix components are washed out of 
the column by a high turbulence flow (Figure 3-1). After elution, the retained analytes are 
directly loaded onto the analytical column for LC-MS analysis 18-20.  
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Figure 3-1: A turbulent flow extraction column consists of large pores, where the sample is run through with high 
flow. (Small particle size) analytes will diffuse into pores and are therefore retained, while (big size) matrix 
components will be flushed trough the column without retention.  
The extraction of analytes with turbulent flow chromatography is performed in a five steps 
process. In the first step, the sample is loaded onto the extraction column, while the 
analytical column is preconditioned with the loading solvent. Therefore, the extraction column 
is connected to the loading pump and waste, whereas the analytical column is autonomous 
and connected to the eluting pump (Figure 3-2 a). In the second step, the sample is eluted 
backward from the extraction column by attaching a loop filled with elution solvent and 
thereby changing the direction of flow. The sample is loaded onto the analytical column by 
setting the two columns in line. The solvent streams of loading and elution pumps are 
therefore combined (Figure 3-2 b). As a third step, the separation on the analytical column 
starts by applying the eluent from the elution pump, which is directly connected to the 
analytical column. To establish the chromatographic separation in an autonomous system 
the, extraction column is disconnected from the analytical system (Figure 3-2 c). In the forth 
step, the extraction column is washed with a strong organic solvent. At the same time, the 
gradient on the analytical column is set to reach a maximum of 100 % elution mobile phase, 
and the analytical column is washed with 100 % elution solvent. Next, the loop on the 
extraction system needs to be refilled again with the eluting solution, while the analytical 
column is set back to starting conditions for re-equilibration (Figure 3-2 c). 
Chapter 3: Online Extraction using Turbulent Flow Chromatography 
93 
In the fifth step, the refilled loop is disconnected from the extraction column and the 
extraction, but also the analytical column is re-equilibrated for a next run (Figure 3-2 a).  
 
Figure 3-2: a) Valve A: Extraction column connected to loading pump and waste for loading sample or re-
equilibrating extraction column. Valve B: Analytical column connected to the eluting pump and the detector for LC-
run. b) Valve A: Extraction column elution by changing flow direction and connecting additional loop with eluting 
solvent. Valve B: Analytical column set in line with extraction column to load the sample onto analytical column.  
c) Valve A: Loop was filled again with the eluting solvent for the next run. Valve B: Chromatographic separation is 
started on analytical column. 
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3.3 Materials and methods 
A TLX system (Thermo Fisher Scientific, Reinach, Schweiz) with two accela pumps (loading 
and eluting) was used. For extraction, a TurboFlow XL C8 0.5 x 50 mm (Thermo Fisher 
Scientific, Reinach, Schweiz) was used. Unless stated otherwise, all solvents and reagents 
were purchased from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland). Methanol was 
obtained from Honeywell specialty chemicals (Seelze GmBH, Germany). All lipid standard 
were purchased from Avanti Polar Lipids (Alabaster, USA). 
3.3.1 Liquid chromatography 
For chromatographic separation an Accucore C30 column (2.6 µm, 150 × 2.1 mm, Thermo 
Fischer Scientific) was used. The following mobile phases were used: 
Eluting A: water / acetonitrile 80 / 20 v/v with 10 mM ammonium acetate and 0.1 % formic 
acid, eluting B: isopropanol / acetonitrile 90 / 10 v/v with 10 mM ammonium acetate and 0.1 
% formic acid and eluting C: methanol.  The gradient profile is shown in Table 3-1. 
Table 3-1: Chromatographic details for LC separation on C30 Accucore column. ‡ 
Step Grad time [min] Flow % A % B % C 
Load Step 1.5 0.3 70 20 10 
Elute Ramp 17 0.3  100  
Wash Step 7 0.3  100  
Re-cond Ramp 1 0.3 70 20 10 
Re-equ Ramp 4 0.3 70 20 10 
 
3.3.2 Mass spectrometry 
Samples were analyzed on a Q Exactive (Thermo, Reinach, BL, Switzerland) using a heated 
electrospray ionization (HESI) interface. For mass spectral detection, the following 
parameters were set on the HESI source: spray voltage 3.5 kV, a vaporizer temperature of 
300 °C, sheath gas pressure 20 AU, aux gas 8 AU and a capillary temperature of 320 °C. 
The detector is set to an MS2 method using a top10 approach with a 140k resolution for full 
                                                
‡ Mobile phase A consists of water / acetonitrile 80 / 20 v/v with 10 mM ammonium acetate 
and 0.1 % formic acid, mobile phase B consists of isopropanol / acetonitrile 90 / 10 v/v with 
10 mM ammonium acetate and 0.1 % formic acid and mobile phase C is 100 % methanol. 
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spectrum and 17.5k for MS2, where a full scan is followed by fragmentation spectra of the ten 
most intense ions per full scan with stepped collision energy between 25 and 30. For the 
selection of ion fragmentation, a dynamic exclusion filter was applied which excludes ions 
after fragmentation for 20 seconds.  
3.3.3 Method development 
Standards used for method development 
For method development, a set of different synthetic sphingoid bases and ceramides were 
used (Table 3-2). All standards were used at a concentration of 2 µM.  
Table 3-2: Synthetic standards used for online extraction method development. § 
Sub-Class Species 
Sphingoid bases SPH d17:1 
SPH d17:0 
D7-SPH d18:1 
D7-SPH d18:0 
SPH d18:1 
SPH d18:0 
SPH t18:0 
SPH m17:1 
D5-SPH m17:0 
SPH m18:0 
D3-SPH m18:0 
SPH m18:1 
SPH d20:1 
SPH d20:0 
SPH d18:2 
Ceramides Cer d18:1 / 12:0 
Cer d18:1 / 14:0 
Cer d18:1 / 17:0 
Cer d18:1 / 18:1 
Cer d18:1 / 20:0 
Cer d18:1 / 22:0 
Cer d18:1 / 24:0 
Cer d18:1 / 24:1 
Cer d18:0 / 12:0 
                                                
§ All standards were mixed and used with a final concentration of 2 µM. 
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Cer d18:0 / 24:0 
Cer m18:0 / 12:0 
Cer m18:0 / 24:1 
Cer m18:1 / 16:0 
Cer m18:1 / 24:1 
 
Turbulent flow column selection and loading solvent evaluation 
Nine different turbulent flow columns (Table 3-3) obtained from Thermo Scientific (Reinach 
BL, Switzerland) were tested for optimal retention of sphingoid bases and ceramides. All nine 
columns were tested in combinations with three different mobile phases: 
- water with 0.1 % formic acid (pH 3) 
- water with 10 mM ammonium acetate (pH 6)  
- water with 10 mM ammonium acetate, adjusted to pH 8 with ammonium hydroxide.  
Methanol was used for elution during the column selection and solvent evaluation step.  
Table 3-3: Turbulent flow columns and characteristics. Information adapted from Thermo Scientific TurboFlow 
Method Development Guide.  
Column Properties 
C18 C18 bonded silica, very high hydrophobicity 
C18-P C18 bonded silica, high hydrophobicity 
C8 C8 bonded silica, high hydrophobicity 
Fluoro Alkyl fluoro bonded silica, slight hydrophobicity 
Cyclone Styrene / divinyl benzene copolymer bead, very high hydrophobicity 
Cyclone-P Styrene / divinyl benzene copolymer bead with polar modification, high 
hydrophobicity 
CycloneMCX Styrene / divinyl benzene copolymer with sulfonic acid modification, moderate 
hydrophobicity 
CycloneMCX2 Styrene / divinyl benzene copolymer with sulfonic acid modification, moderate 
hydrophobicity, lower ion exchange capacity than CycloneMCX 
CycloneMAX Styrene / divinyl benzene copolymer with quaternary ammonium, moderate 
hydrophobicity 
 
Each column was tested using the three different water mobile phases (pH 3, pH 6 and pH 8) 
for optimal retention, minimal breakthrough, maximally sharp elution, and minimal loss during 
the wash phase. Breakthrough is observed when part of the sample travels with the injection 
band through the column without interacting with the stationary phase. 
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A short chromatographic method on the extraction column was used to evaluate and 
optimize the different steps of the online extraction (Table 4).  
Table 3-4: Chromatographic setting for method development for online extraction method. 
Step Time [min] Flow [mL/min] % A % B Loop 
1. Load 30 1.5 100  out 
2. Elute 60 0.3 100  in 
3. Wash 60 1.5  100 in 
4. Loop fill 60 1.5 100  in 
5. Equilibrate 60 1.5 100  in 
 
- Step 1: The standard mix (10 µL) was injected into the turbulent flow column (mobile 
phase A) at a high flow rate (30 sec, 1.5 mL/min).  
- Step 2: The retained metabolites were eluted by connecting the loop, which was filled 
with methanol (1 min, 0.3 mL/min).  
- Step 3: The column was washed with methanol (B) for one minute at 1.5 mL/min  
- Step 4: The loop was refilled with methanol (B) for one minute at 1.5 mL/min. 
- Step 5: After disconnecting the loop, the column was re-equilibrated for one minute 
with water mobile phase at 1.5 mL/min flow. 
Mass spectra were recorded for 4.5 minute to evaluate the retention capacity for all synthetic 
standards. To ensure a constant flow trough the detector, the flow of the loading pump (used 
for the online extraction column) was combined with the flow of the eluting pump and the 
combined flow was kept at 1.5 mL/min. The combined flow was divided into waste and 
detector using a T connector. 
Sample elution and transfer 
Further, the optimal percentage of organic solvent (methanol, ethanol, and acetonitrile) in the 
elution was assessed by testing conditions with 20, 40, 60, 80, 90 and 100 % of organic 
solvent against water containing 0.1 % formic acid as mobile phase. Therefore, the loop was 
filled with the corresponding solvent composition during the loop-filling step (Step 4, Table 
3-4). The method was optimized for total extraction where the total amount of organic solvent 
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should stay as low as possible to avoid a breakthrough of the analytes on the analytical 
column.  
The transfer of the sample to the analytical column during the second elution step was 
optimized for flow during transfer and the time needed for a complete transfer in the 
corresponding flow rate. Therefore, flow rates of 0.1 mL/min, 0.2 mL/min, 0.3 mL/min, 0.4 
mL/min and 0.5 mL/min during elution (Step 2, Table 3-4) were tested and the corresponding 
time for complete transfer was measured.  
3.3.4 Protocol for online turbulent flow extraction  
The following mobile phases were used:  
Loading A: 0.1 % formic acid in water, Loading B: Methanol, Loading D: Acetonitrile / 
Isopropanol / Methanol 1/1/1 v/v/v 
Eluting A: Water / Acetonitrile 80/20 v/v with 10mM ammonium Acetate and 0.1 % formic 
acid and Eluting B: Isopropanol / Acetonitrile 90/10 v/v with 10mM ammonium Acetate and 
0.1 % formic acid and Eluting C: MeOH.  
See further details of solvent composition, gradient, and flow in Table 3-5. 
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Table 3-5: Chromatographic details for the online extraction method using a TLX system with loading and eluting 
pumps and a C8 TLX turbulent flow column (connected to loading pump) and an analytical Accucore C30 column 
(connected to the eluting pump). ** 
Step time [min] 
Loading pump Eluting Pump 
Flow % A % B % D Loop Flow Grad % A 
% 
B 
% 
C 
Load on TLX 0 1.5 100   out 0.3 step 70 20 10 
Elute to LC 0.5 0.1  100  in 0.2 step 70 20 10 
LC gradient 1.5 0.0  100  in 0.3 ramp  100  
Wash TLX and LC 18.5 0.5   100 in 0.3 step  100  
Loop fill TLX, start cond. LC 25.5 1.5  100  in 0.3 ramp 70 20 10 
Loop fill TLX, re-equilibrate LC 26.5 1.5  100  in 0.3 step 70 20 10 
Re-equilibrate TLX and LC 28.5 1.5 100   out 0.3 step 70 20 10 
End 30.5 1.5 100   out 0.3 step 70 20 10 
 
3.3.5 Method validation 
Linearity 
For method validation, linearity of the measured area under the peak and concentration was 
measured using the TLX system.  
A standard mix of 65 lipids, including species from various classes of sphingolipids, 
phospholipids, and cholesteryl esters in five different concentrations were tested for the 
concentration dependent linearity of the signal. To achieve an optimal detection range, lipid 
standards varying 50 fold in concentration from 0.1 to 5 µM were used. The details for the 
standards used are depicted in table 4. 
Table 3-6: Synthetic lipid species included in standard mix for online extraction method validation 
Sub-Class Species 
Sphingoid bases SPH d17:1 
SPH d17:0 
D7-SPH d18:1 
D7-SPH d18:0 
                                                
** Mobile Phases on the loading pump are A: 0.1 % formic acid in water, B: Methanol, D: 
Acetonitrile / Isopropanol / Methanol 1/1/1 v/v/v. On the eluting pump, mobile phases are A: 
Water / Acetonitrile 80 / 20 v/v with 10mM ammonium Acetate and 0.1 % formic acid and B: 
Isopropanol / Acetonitrile 90 / 10 v/v with 10mM ammonium Acetate and 0.1 % formic acid 
and C: MeOH. 
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Sub-Class Species 
SPH d18:1 
SPH d18:0 
SPH t18:0 
SPH d20:1 
SPH d20:0 
SPH d18:2 
1-Deoxy sphingoid bases m17:1 
D5-m17:0 
m17:0 
m18:0 
D3-m18:0 
m18:1 
Spingosine-1-phosphate S1P d18:1 
S1P d17:1 
S1P d17:0 
D7-S1P d18:1 
Ceramides Cer d18:1 / 12:0 
Cer d18:1 / 14:0 
Cer d18:1 / 17:0 
Cer d18:1 / 18:1 
Cer d18:1 / 20:0 
Cer d18:1 / 22:0 
Cer d18:1 / 24:0 
Cer d18:1 / 24:1 
Cer d18:0 / 12:0 
Cer d18:0 / 16:0 
Cer d18:0 / 24:0 
D7-Cer d18:1 / 16:0 
D7-Cer d18:1 / 24:0 
1-Deoxyceramides Cer m18:0 / 12:0 
Cer m18:0 / 24:1 
Cer m18:1 / 12:0 
Cer m18:1 / 16:0 
Cer m18:1 / 24:1 
Cer m17:0/16:0 
Cer m17:1/16:0 
Cer m17:0/24:1 
Cer m17:1/24:1 
Sphingomyelins SM 18:1 / 24:0 
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Sub-Class Species 
SM 18:1 / 24:1 
SM 18:0 / 12:0 
SM 18:1 / 12:0 
SM 18:1 / 16:0 
D9-SM 18:1 / 18:1 
Glucosylceramides 
GluCer 18:1 / 8:0 
GluCer 18:1 / 16:0 
GluCer 18:1 / 24:1 
D5-GluCer 18:1 / 18:1 
Phospholipids PC 16:0 / 18:2 
PC 14:0 / 14:0 
PC 24:0 / 24:0 
LPC 16:0 
LPC 17:0 
PE 14:0 / 14:0 
PE 18:0 / 18:0 
LPE 17:1 
PG 16:0 / 16:0 
PG 17: 17:0 
PA 14:0 / 14:0 
PA 17:0 / 17:0 
Cholesteryl esters D7-ChE 16:0 
 
Recovery 
A mix of 65 different lipid species (Table 3-6) was injected with and without the use of the 
TLX column. Recovery was calculated for all lipid species (5 µM concentration), by 
calculating the percentage of the area measured with the TLX column applied to the area 
measured with bypassing the online extraction. 
Online extraction in comparison to manual liquid-liquid extraction 
Different lipid extraction methods were compared for the extraction of lipids from plasma 
samples. Four different volumes (3 µL, 5 µL, 10 µL and 20 µL) of pooled plasma from healthy 
donors were used. Volume was filled up to 20 µL with PBS for all samples. Internal standards 
were added to the samples (D7-SPH 18:0, D7-SPH 18:1, Cer d18:0 / 12:0, Cer 18:1 / 12:0, 1-
deoxyCer m18:0 / 12:0, 1-deoxyCer 18:1 / 12:0, HexCer 18:1 8:0, SM 18:1 / 12:0 and D7-
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S1P d18:1) and the sphingolipidome was analyzed by the different extraction methods. 
Recovery was evaluated for 20 µL plasma samples. The Bligh and Dyer protocol was used 
as a reference extraction method for relative comparison.  
For Folch-based extraction, 1 mL of methanol/chloroform (2/1 v/v) was added to the samples. 
Samples were extracted at 37 °C for 1 hour using an Eppendorf Thermo shaker at 1400 rpm. 
After the addition of 0.5 mL of chloroform, samples were vortexed for 20 seconds, followed by 
addition of 200 µL of alkaline water and again vortexed for 20 seconds. Finally, the samples 
were centrifuged at 16000 rpm for 5 min for phase separation. The aqueous phase was 
aspirated and the organic phase dried under a stream of N2 after washing with alkaline water. 
For ether-based extraction, 1 mL of EtOAc / 2-propanol (85/15 v/v) was added to the samples. 
After vortexing for 20 seconds, 0.5 mL of water and 50 µL of concentrated formic acid were 
added. Samples were extracted at 37 °C for 20 min using the Eppendorf Thermo shaker at 
1400 rpm. Finally, the samples were centrifuged at 16000 rpm for 5 min for phase separation. 
The organic phase was transferred to a fresh tube and dried under a stream of N2. 
For the Bligh- and Dyer-based protocol, 375 µL of methanol/chloroform (2/1 v/v) was added 
to the sample and vortexed for 20 seconds. Afterwards, 125 µL of chloroform were added 
and vortexed again for 20 seconds. Then 125 µL of water were added, and samples were 
shaken for 20 min at 37 °C in an Eppendorf Thermo shaker with 1400 rpm. Finally, samples 
were centrifuged at 16000 rpm for 5 min for phase separation. The organic phase was 
transferred into another tube and the water phase was re-extracted with 250 µL of 
chloroform. Both organic phases were combined, and samples were dried under a stream of 
N2. 
For the MMC protocol, 1mL of methanol / MTBE / chloroform (MMC) 1.33/1/1 v/v/v was 
added to the sample and the sample was vortexed for 20 seconds. The mixture was agitated 
for 20 min in an Eppendorf Thermo shaker at 37 °C at 1400 rpm. The protein precipitate was 
pelleted by centrifuging for 5 min at 16000 rpm at 24 °C, and 1 mL of the supernatant was 
transferred to another tube. The solvent was dried under a stream of N2.  
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For analysis with LC-MS, the samples were re-suspended in 100 µL methanol and 
transferred to MS vials and 25 µL injected into the LC system. 
For online extraction, different protein precipitation solvents were used. As most of the lipids 
are bound to lipoproteins 21-23, these proteins need to be denatured to release the lipids for 
quantification with LC-MS. Therefore, plasma proteins were precipitated with methanol, 
acetonitrile or a mix of methanol/acetonitrile 1/1 (v/v). The organic solvent was added in a 1:5 
plasma to solvent ratio. 100 µL of the solution was added to 20 µL plasma, vortexed for 20 
seconds and extracted at 37 °C for one hour. The samples were centrifuged at 16000 rpm for 
5 min and the supernatant was transferred into the MS vials. For LC-MS analysis, 25 µL of 
the samples were directly injected into the turbulent flow column. 
3.4 Results  
3.4.1 Method development 
Nine different extraction columns with different column chemistry were tested. This included 
the C18 or C8 bonded silica with different modifications, alkyl fluoro bonded silica, 
styrene/divinylbenzene copolymer bead with and without polar change or cationic/anionic 
exchange. For each column, three different loading solvents, varying in pH from 3 to 8 were 
evaluated.  
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Figure 3-3: Loading solvents were evaluated on a C8 XL column for ceramides and sphingoid bases. 
Chromatograms for C12 ceramide (Cer d18:1 / 12:0) and a 1-deoxysphingoid base (SPH m18:1) are depicted as 
an example. The C8 XL column was evaluated with three different loading mobile phases, water containing 0.1 % 
formic acid (pH 3) or 10 mM ammonium acetate (pH 6) and water with 10 mM ammonium acetate adjusted to pH 
8 with ammonium hydroxide. Best retention was achieved on C8 XL column using water with 0.1 % formic acid.  
Breakthrough happens when not all lipids were retained by the column. This breakthrough is 
typically seen in a pre-peak directly after sample injection. The retained lipids were eluted 
from the column within 0.5 minutes in a narrow peak. If retention was too high, a second 
peak eluting at 2.2 minutes is seen during the column wash step (Figure 3-3). For ceramides, 
a breakthrough was observed for all the tested columns and for all three different mobile 
phases. The best retention of sphingoid bases and ceramides was obtained using the C8 XL 
column with water and 0.1% formic acid (pH 3) as loading mobile phase (Figure 3-3). No 
breakthrough and very low elution during the washing step were seen for sphingoid bases 
and a minor breakthrough and elution during washing were seen for ceramides compared to 
the other mobile phases. These conditions were chosen for further method development.  
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Figure 3-4: Elution solvent (ethanol (EtOH), methanol (MeOH) and acetonitrile (ACN)) was evaluated for 
sphingoid bases and ceramides. Organic solvents, methanol, ethanol and acetonitrile were tested in mixture with 
water 0.1 % formic acid in 20 %, 40 %, 60 %, 80 %, 90 % and at 100 % organic solvent. Ceramide Cer d18:1 / 
12:0 was eluted at 0.7 minutes with eluting solution or if incomplete elution occurred at 2.1 min during the washing 
step. Maximal elution was measured with 100 % methanol or ethanol. 
Next, the optimal elution solvent was defined. Methanol, ethanol and acetonitrile were tested 
for maximal elution of sphingolipids with minimal use of organic solvent. Best elution results 
for sphingoid bases and ceramides were reached on the C8 XL using 100 % ethanol or 100 
% methanol for elution. With a lower percentage of organic solvent, the elution was not 
complete. This is shown for the elution of Cer d18:1 / 12:0 (Figure 3-4). Finally, 100 % 
methanol was chosen as the eluent because methanol had less influence on the peak shape 
and resolution on the analytical column compared to ethanol.  
After selecting the appropriate elution solvent, the elution flow and time was adjusted. For 
this, flow rates between 0.1 mL/min and 0.5 mL/min were tested and the time for complete 
elution was measured for all flow rates (Figure 3-5).  
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Figure 3-5: Elution time and flow rate were evaluated for sphingoid bases and ceramides. Flow rates between 0.1 
mL/min and 0.5 mL/min were tested and the corresponding elution time measured. For all five tested flow rates, 
elution time was 30 seconds and elution efficiency did not differ between the tested conditions.  
We did not observe any significant difference between the flow rates for elution efficiency 
and transfer time (Figure 3-5). Maximal elution was reached within 30 seconds for all flow 
rates. We therefore chose a minimal transfer flow of 0.1 mL/min to minimize the organic 
solvent transferred to the analytical column thereby decreasing the risk for a breakthrough on 
the analytical column. Transfer time was set to 60 seconds to ensure complete elution. 
3.4.2 Method validation 
Linearity of extraction efficiency using of online extraction 
The linearity of the extraction efficiency of all different sphingolipid classes, phospholipids, 
and cholesteryl ester was measured using the TLX system. Synthetic standards were 
injected and extracted on the TLX column and the linearity verified by comparing R2 values 
(Figure 3-6).  
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Figure 3-6: Linear regression of different sphingolipids, phospholipids and cholesteryl ester after TLX extraction in 
0.1, 0.5, 1, 2 and 5 µM concentration. 
For most of the analyzed lipid species, we obtained a linear relationship with an R2 >0.95. 
Linearity was less pronounced for phosphatidylglycerol (R2 >0.91) and for Phosphatidic acid 
the curve was not linear (R2 = 0.75) (Table 3-7). 
Table 3-7: Linearity (R2) and relative recoveries (%) of indicated lipid species. 
Sub-Class Species Linearity (R2)†† Rel. Recovery [%]‡‡ 
Sphingoid bases SPH d18:2 0.9919 32.6 
SPH d17:1 0.9909 32.1 
SPH d17:0 0.9897 46.0 
SPH t18:0 0.9849 49.7 
D7-SPH d18:1 0.9886 38.2 
SPH d18:1 0.9875 37.2 
D7-SPH d18:0 0.9842 44.3 
SPH d18:0 0.9860 43.5 
SPH d20:1 0.9773 40.0 
SPH d20:0 0.9738 43.3 
1-Deoxy sphingoid bases SPH m18:1 0.9901 36.3 
                                                
†† Linearity was determined by calculation of linear coefficients of correlation (see Figure 
3-6) 
‡‡ Recoveries were assessed at a concentration of 5 µM. 
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Sub-Class Species Linearity (R2)†† Rel. Recovery [%]‡‡ 
SPH m17:1 0.9886 35.2 
D5-SPH m17:0 0.9836 42.6 
SPH m17:0 0.9834 42.0 
D3-SPH m18:0 0.9672 47.6 
SPHm18:1 0.9679 48.3 
Ceramides Cer d18:1 / 12:0 0.9875 64.7 
Cer d18:0 / 12:0 0.9841 46.3 
Cer d18:1 / 14:0 0.9789 64.3 
D7-Cer 18:1 / 16:0 0.9842 49.9 
Cer d18:1 / 18:1 0.9881 52.7 
Cer d18:0 / 16:0 0.9867 52.3 
Cer d18:1 / 17:0 0.9834 55.9 
Cer d18:1 / 20:0 0.9777 47.8 
Cer d18 1:24:1 0.9757 46.3 
Cer d18:1 / 22:0 0.9803 46.3 
D7-Cer d18:1 / 24:0 0.9645 43.6 
Cer d18:1 / 24:0 0.9684 41.0 
Cer d18:0 / 24:0 0.9851 25.8 
1-Deoxyceramides doxCer m18:1 / 12:0 0.9729 67.9 
doxCer m18:0 / 12:0 0.9671 71.0 
doxmetCer m17:1 / 16:0 0.9804 51.9 
doxCer m18:1 / 16:0 0.9736 54.8 
doxmetCer m17:0 / 16:0 0.9829 41.3 
doxmetCer m17:1:24:1 0.9753 43.4 
doxCer m18:1 / 24:1 0.9638 47.3 
doxmetCer m17:0 / 24:1 0.9587 46.1 
doxCer m18:0 / 24:1 0.9712 43.9 
Sphingomyelins SM 18:1 / 12:0 0.9794 48.3 
SM d18:0 / 12:0 0.9828 47.3 
SM 18:1 / 16:0 0.9804 43.4 
D9-SM d18:1 / 18:1 0.9767 45.4 
SM 18:1 / 24:1 0.9778 27.6 
SM:d18 1:24 0 0.9806 23.1 
Glucosylceramides GluCer d18:1 / 8:0 0.9749 56.4 
GluCer d18:1 / 16:0 0.9810 48.1 
D5-GluCer d18:1 / 18:1 0.9809 62.7 
GluCer d18:1 / 24:1 0.9760 48.4 
Phospholipids LPC 16:0 0.9817 44.1 
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Sub-Class Species Linearity (R2)†† Rel. Recovery [%]‡‡ 
LPC 17:0 0.9808 38.1 
PC 14:0 / 14:0 0.9824 44.3 
PC 16:0 / 18:2 0.9833 42.4 
PC 24:0 / 24:0 0.9547 8.7 
LPE 17:1 0.9532 76.1 
PE 14:0 / 14:0 0.9870 63.9 
PE 18:0 / 18:0 0.9723 49.1 
PA 14:0 / 14:0 0.9206 53.0 
PA 17:0 / 17:0 0.7574 32.7 
PG 16:0 / 16:0 0.9160 55.2 
PG 17:0 / 17:0 0.9469 42.1 
Cholesteryl ester D7 ChE 16:0 0.9748 3.9 
Sphingosine-1-phosphate S1P d17:1 0.9847 84.9 
S1P d17:0 0.9803 94.0 
D7-S1P d18:1 0.9784 88.1 
S1P d18:1 0.9911 93.6 
 
Recovery for online extraction 
Recovery for the individual species was determined by comparing the signal intensity of 
directly injected standards with those after liquid-liquid or TLX extraction (Table 3-7). 
Recovery was tested for 5 µM concentration of the standards. Although online TLX extraction 
was linear among the sphingolipids and phospholipid classes, the total recovery of injected 
standard ranged between 39.2% and 90.2% depending on the different sphingolipid and 
phospholipid classes. The best recovery was obtained for sphingosine-1-phosphate (average 
recovery of 90.2 %)  
PC 24:0 / 24:0 and D7-cholesteryl ester 16:0 were not retained by the C8 TLX column, 
resulting in a recovery below 10 %.  
A poor recovery might be acceptable for the further analysis, if the loss of lipid is linear 
throughout different concentrations, but it increases the lower limit of quantification in the 
method. A method with poor recovery is then applicable for highly abundant analytes.  
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TLX extraction compared to manual liquid-liquid extraction 
Using a human plasma sample, the recovery of the TLX extraction methods was compared 
to four widely used liquid-liquid extraction protocols. Recoveries were compared in relation to 
the Bligh and Dyer method (100 %). 
We tested three precipitation solvents (methanol, acetonitrile and methanol / acetonitrile 
mixture) prior to online extraction for the release of lipid bound in plasma lipoproteins. 
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Figure 3-7: Recovery for sphingolipid classes with turbulent flow online extraction (TLX) compared to the Bligh & 
Dyer (set as 100%), MMC protocol, Folch, or acidic ether protocol. For TLX, three different precipitation solvents 
for sample preparation were used (TLX_MeOH: Methanol, TLX_ACN: Acetonitrile, TLX_MeOH_ACN: Methanol / 
Acetonitrile 1/1 v/v). Recovery in Bligh & Dyer protocol was set to 100% for comparison. 
The MMC protocol showed the best overall coverage for all sphingolipid classes. In general, 
the protocols from Folch and Bligh & Dyer and the MMC single-phase extraction protocol 
reached comparable recoveries for all the different sphingolipid classes. The MMC protocol 
showed overall the best coverage for all sphingolipid classes. The ether-based protocol was 
lower in recovery for (1-deoxy)ceramides and hexosylceramides, but better for 
sphingomyelins and S1P compared to the Bligh & Dyer protocol. The MMC protocol showed 
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the least variation, especially for S1P. Therefore, in comparison to the manual extraction with 
the Bligh and Dyer protocol, MMC shows superior results.  
The three tested precipitation solvents for online extraction resulted in different recoveries. 
Whereas recovery for methanol and methanol/acetonitrile (1/1 v/v) was comparable for all 
sphingolipid classes, recovery after acetonitrile precipitation was lower for N-acetylated 
sphingolipids and higher for S1P. This is caused by the incompatibility of the precipitation 
solvents with the retention of lipids on the turbulent flow extraction column. The best recovery 
of the three different precipitations solvents was seen for methanol. 
Table 3-8: Recovery [%] for sphingolipid classes extracted with different extraction protocols compared to Bligh & 
Dyer protocol as reference. TLX_MeOH: Methanol, TLX_ACN: Acetonitrile, TLX_MeOH_ACN: Methanol / 
Acetonitrile 1/1 v/v §§ 
Mean Recovery 
[%] Ceramides 
1-deoxy-
ceramides Hexosylceramides Sphingomyelins S1P 
Folch 84.56 95.71 113.13 92.18 - 
MMC 103.66 108.85 106.05 102.71 109.09 
Ether 71.39 63.41 63.38 136.02 117.81 
TLX_ACN 8.18 7.06 35.70 17.38 152.11 
TLX_MeOH 25.76 12.84 52.79 55.01 93.04 
TLX_MeOH_ACN 15.23 10.62 54.83 49.41 97.18 
 
In comparison to liquid-liquid extraction, online extraction showed poor recovery for most of 
the sphingolipid classes. Only for S1P, online extraction gave comparable results (with a 
recovery around 93 % for methanol precipitation) to manual Bligh and Dyer extraction. For 
other lipid species, recoveries were below 55 %. 
  
                                                
§§ Next to liquid-liquid extraction protocols (Folch and Bligh & Dyer), a single phase MMC 
protocol was used. Online extracton with turbulent flow chromatography (TLX) was 
compared to other extraction protocols. For online extraction, three different precipitation 
solvents were tested. 
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3.5 Discussion 
Compared to manual liquid-liquid extraction (e.g. Bligh and Dyer) or the single phase 
extraction MMC 8, TLX extraction has several advantages: 1. shorter sample preparation 
protocol with less manual steps, 2. no need for sample drying and 3. no sample 
reconstitution before analysis. This should lead to a less lipid loss from the sample, and allow 
high throughput approaches needed for general lipidomic studies 1. However, with regard to 
the recovery, the other liquid-liquid extraction and the single-phase MMC protocols were 
superior to the TLX method in our hands. For the TLX extraction with methanol precipitation, 
recoveries ranged between 12.0 % and 93 % (for different lipid classes) compared to Bligh 
and Dyer extraction method, in turn yielded similar recoveries as other manual extraction 
methods. S1P showed the highest recovery (93 % for methanol precipitation with TLX 
extraction compared to Bligh and Dyer).  
This difference in recovery using TLX extraction for certain lipid classes seems to be 
associated with the difference in polarity. Recovery was better for polar lipid species such as 
S1P and low for relatively apolar ceramides and 1-deoxyceramides.This might be because 
ceramides are mostly bound to lipoproteins, whereas S1P is also transported by albumin in 
plasma. In this context, it is interesting that several turbulent flow applications for the 
extraction of small molecule analytes have been reported, with the aim to reduce 
phospholipids during extraction to reduce the effect of ion suppression during the MS 
analysis 24, 25. Michapopoulos et. al. 16 compared turbulent flow chromatography against 
protein precipitation in a metabolomics context and found that turbulent flow is a stable 
approach compared to protein precipitation, but extracted phospholipids were reduced by up 
to 60 % of their concentration 16.  
A critical aspect for the use of the TLX turbulent flow chromatography technology in 
lipidomics is, that in contrast to polar metabolites, lipids are hydrophobic and not transported 
free in plasma but as part of lipoproteins (HDL, LDL, VLDL etc) or other lipid binding proteins, 
notably albumine. Lipoproteins are spherical particles with a size of 7-70 nm 26 and might 
therefore be lost during turbulent flow extraction 16, as due to time limitations, they do not 
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cross the boundary layer, whereas smaller molecules do this relatively efficiently and are 
therefore retained by the turbulent flow column. Thus larger molecules such as proteins go 
directly to waste and the smaller molecules are adsorbed to the retentive stationary phase 
contained within the turbulent flow column 16. Even though proteins are supposed to 
precipitate before injection into the turbulent flow column, a complete precipitation and 
release of bound lipids from these proteins is not achieved, with solvent ratios to 1:5 of 
solvents we used 5. The solvent ratios cannot be further increased, which would help in the 
protein precipitation. But this would increase the loss of lipids during loading step because of 
breakthrough of lipids, which are not retained by the turbulent flow column because of 
organic solvent present. These effects contribute to the lower recovery with the turbulent flow 
extraction protocol. 
In conclusion, the TLX extraction protocol offers an automatic, fast, one-step sample 
preparation protocol, however at the cost of much lower recoveries of lipids in plasma 
compared to the established liquid-liquid extraction protocols. The use of the TLX method in 
lipidomics might therefore be justified for a quick and general qualitative comparison of 
samples where recovery and exact quantification is not essential. However, the need for a 
preceding protein precipitation (MeOH or ACN) makes the manual extraction effort more 
time-consuming and almost comparable to those of single-phase extraction procedures like 
the MMC protocol. In conclusion, the TLX extraction technology for lipidomic analysis is not 
advantageous compared to other, more established protocols.  
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4 Chapter 4: Lipidomics Method Development 
Regula Steiner 
4.1 Abstract 
Lipidomics is defined as the study of the structure and function of the complete set of lipids 
(the so called lipidome) in a given cell or organism as well as the interactions with other 
lipids, proteins and metabolites in healthy and pathological conditions. (Un)targeted 
lipidomics not only provides a comprehensive overview of lipid metabolism and its 
physiological function but also allows the identification of diagnostic biomarkers in different 
disease conditions liked to lipid metabolism. Dyslipidaemia is linked to a significant number 
of diseases, like atherosclerosis, diabetes or cancer with an increasing number of affected 
patients worldwide.  
Within this project we aimed to unify and further expand these existing LC-MS2 based 
methods towards a more comprehensive and untargeted lipidomics approach. The method 
allows a detailed analysis of sphingolipids including ceramides, sphingomyelin, 
glycosphingolipids and sphingosine-1-phosphates, glycerolipids including 
gylcerophospholipids and their lyso-forms, as well as neutral acylglycerols cholesterols, 
neutral glycerolipids and free fatty acids in an LC-MS2 run of 25 minutes. A reversed phase 
chromatographic separation on a Accucore C30 column and a data dependent acquisition 
with high-resolution accurate mass spectrometry were used for separation and detection of 
lipid species. For semi-quantitative data analysis, Lipid searchTM was evaluated, which 
showed some problems of over-identification for atypical sphingolipids. Furthermore, a Trace 
finderTM quantification method was implemented for the quantification of typical but also low 
abundant atypical sphingolipids. The newly developed method allows accurate and precise 
highthroughput analysis for both biomarker discovery and validation in human body fluids as 
well as for the recording of dynamic lipid changes in cells and tissues from expermental 
models.  
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4.2 Introduction 
The number of patients suffering from metabolic diseases is increasing worldwide. Although 
several risk factors for diabetes or cardiovascular diseases are known, it is still difficult to 
predict the individual risk for developing a metabolic disease or to diagnose metabolic 
diseases at a subclinical stage. An increasing number of patients with metabolic diseases 
demands novel biomarkers which allows an early diagnosis and risk prediction as well as the 
monitoring of therapeutic and lifestyle interventions 2. 
A comprehensive analysis of lipids is an important tool to understand disease mechanisms, 
make diagnoses and prognoses, and evaluate therapeutic efficacy 3, 4. The term 
“metabolomics” typically describes an unbiased approach to analyse the whole set of 
metabolites and metabolic changes in biological systems. As a sub-speciality, lipidomics 
focuses specifically on the profiling of lipids 4. Mass spectrometry based tools are currently 
the most widely used technique for lipid profiling and quantification 5. 
Lipids are highly diverse and the most abundant metabolites in human plasma, followed by 
carbohydrates (sugars), free amino acids and nucleic acids 6. Lipids are defined as 
hydrophobic or amphipathic small molecules, which are soluble in organic solvents but not or 
only to limited degree in water 7. They originate partly or entirely from the condensation of 
fatty acids with other molecules such as glycerols or sphingoid bases. They are classified as 
simple lipids if they are built of maximally two building blocks (a combination of fatty acids or 
sphingoid base) or as complex if they are made from three components (e.g., by the addition 
of a head group) 7. By these building blocks, lipids are sub-classified into different classes. 
The major classes are fatty acids, glycerolipids (conjugation of one to three fatty acid to a 
glycerol backbone), glycerophospholipids (conjugation of one or two fatty acids to a glycerol 
backbone and a phosphate containing head group), sphingolipids (conjugation of a fatty acid 
to a sphingoid base backbone with or without headgroup), isoprenoids, saccharolipids and 
polyketides 6-8. Of these individual lipid classes, sphingolipids are the most heterogeneous 
group and encompassing the biggest number of different species 9. Sphingolipids are 
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involved in various biological processes like senescence, inflammation, and apoptosis and 
are relevant for diseases like Alzheimer's, diabetes and atherosclerosis 10, 11. 
Lipids of the different classes are typically analysed using a combination of chromatographic 
separation (LC) combined with tandem mass spectrometry (MS2). The combination of these 
two techniques allows to separate and annotate not only the different lipid classes but also to 
identify individual lipid species. Particularly isobaric lipids can be separated by liquid 
chromatography and structurally defined using high resolution accurate mass spectrometry 
(HARMS) with or without the fragmentation of the molecules (MS2) 12. 
The high resolution of HARMS allows to determine the exact mass of lipid molecules and to 
resolve molecules with very similar mass but different atomic composition. High-resolution 
accurate mass instruments are typically equipped with Orbitrap or Time of Flight (TOF) 
detectors. With MS2, selected lipid ions can be further fragmented and characterized gaining 
information about the building blocks, like fatty acid chain length of conjugated head groups 
13. Table 4-1 shows an overview of various lipid classes and their typical fragmentation 
pattern. 
Additionally, high-resolution accurate mass instruments typically offer the option of data 
dependent acquisition (DDA) features. In the DDA mode, fragmentation data is not obtained 
from pre-defined ions (as in multiple reaction monitoring in triple quadrupole instruments) but 
the fragmented ions are dynamically selected from full scan data within the individual 
samples. Typically, a fixed number of the most abundant ions per scan are identified and 
selected for fragmentation. These fragmentation data provide information about building 
block composition and help in identifying and annotating individual lipid species. Although 
this technique has a bias towards the identification of more abundant lipid species, it also 
opens the possibility of untargeted discoveries and the identification of new species 13. 
The exact annotation of lipids is a critical step in lipidomics analysis 14. The first step is to 
assign a measured feature to a specific lipid class. Lipid classes differ in their building block 
composition, their ionization properties and main fragment ions (for example differences in 
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the head group) which allows the assignment of specific lipid species. The second step is the 
annotation of the building block composition (for example the chain length of a fatty acid 
group and the number of double bonds within the different fatty acid groups). This annotation 
is typically more critical as the mass and elemental composition of two isomers within a lipid 
class can be identical (isobaric) although the distribution of double bonds or chain length is 
different. For such an annotation, a clear fragmentation spectrum is required to conclude 
more than the total chemical composition of a molecule i.e a ceramide with a total [M+H]+ = 
650.6445 m/z can be annotated as Cer d42:1. The use of fragmentation information allows to 
distinguish it as Cer d18:0 / 24:1 or d18:1 / 24:0. In reporting of data, it has to be stated to 
which extent an annotation was proven 14.  
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In our previous methods, lipid classes like glycophospholipids, or sphingolipids or even single 
lipid species like sphingosine-1-phosphate were each analysed by individual methods. The 
aim of this project was to combine and further expand our existing LC-MS2 based methods 
into a more comprehensive unified lipidomics approach, covering apolar and polar lipids. The 
goal was to cover a great variety of lipid classes optimally in conjunction with related 
metabolites of the central energy and carbohydrate metabolism. The method shall allow to 
investigate dynamic changes in metabolic pathways in response to internal and external 
stimuli and to distinguish between healthy and pathological conditions for the identification of 
new biomarkers and novel therapeutic targets. The significance and clinical relevance of 
novel biomarkers is then typically validated in larger population based studies. Therefore a 
well-defined and (semi) automated high throughput workflow is essential to be able to 
analyse large numbers of clinical samples. In this respect, we also expanded our analytical 
workflow by the introduction of two software tools (Lipid Search TM and TraceFinderTM), which 
allow the semi automated analysis of lipidomics data.  
4.3 Material and Methods 
Unless stated differently, all solvents and reagents were purchased from Sigma-Aldrich 
Chemie GmbH (Buchs, Switzerland) excluding methanol, which was obtained from 
Honeywell specialty chemicals (Seelze GmBH, Germany). All lipid standards were obtained 
from Avanti polar lipids (Alabaster, USA). 
4.3.1 Liquid chromatography 
Initially, a C18 Uptispere (120 Å, 5 µm, 125 × 2 mm) column (Interchim, Montluçon, France) 
and the following mobile phases were used: Eluting A: water / acetonitrile 80 / 20 v/v with 10 
mM ammonium acetate and 0.1 % formic acid and eluting B: isopropanol / acetonitrile 80 / 20 
v/v with 10 mM ammonium Acetate and 0.1 % formic acid. See further details of solvent 
composition and flow in Table 4-2. 
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Table 4-2: Chromatographic details for LC separation on C18 Uptispere column. *** 
Step Grad time [min] Flow % A % B 
Load Step 1.5 0.3 70 30 
Elute Ramp 17 0.3  100 
Wash Step 7 0.3  100 
Re-cond Ramp 1 0.3 70 30 
Re-equ Step 4 0.3 70 30 
 
As we observed persisting resolution problems, the column was replaced by an Accucore 
C30 column (2.6 µm, 150 × 2.1 mm, Thermo Fischer Scientific). In combination with small 
adaptations in the mobile phases, the resolution could be improved. Finally, the following 
mobile phases were used: 
Eluting A: water / acetonitrile 80 / 20 v/v with 10 mM ammonium acetate and 0.1 % formic 
acid and eluting B: isopropanol / acetonitrile 90 / 10 v/v with 10 mM ammonium acetate and 
0.1 % formic acid and eluting C: methanol.  The gradient profile is shown in Table 3-1. 
Table 4-3: Chromatographic details for LC separation on C30 Accucore column. ††† 
Step Grad time [min] Flow % A % B % C 
Load Step 1.5 0.3 70 20 10 
Elute Ramp 17 0.3  100  
Wash Step 7 0.3  100  
Re-cond Ramp 1 0.3 70 20 10 
Re-equ Ramp 4 0.3 70 20 10 
 
4.3.2 Mass spectrometry method 
Samples were analyzed on a Q Exactive (Thermo, Reinach, BL, Switzerland) using a heated 
electrospray ionization (HESI) interface. For mass spectral detection, the following 
parameters were set on the HESI source: spray voltage 3.5kV, vaporizer temperature of 
                                                
*** Mobile phase A consists of water / acetonitrile 80 / 20 v/v with 10 mM ammonium acetate 
and 0.1 % formic acid and mobile phase B consists of isopropanol / acetonitrile 80 / 20 v/v 
with 10 mM ammonium acetate and 0.1 % formic acid. 
††† Mobile phase A consists of water / acetonitrile 80 / 20 v/v with 10 mM ammonium acetate 
and 0.1 % formic acid, mobile phase B consists of isopropanol / acetonitrile 90 / 10 v/v with 
10 mM ammonium acetate and 0.1 % formic acid and mobile phase C is 100 % methanol. 
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300°C, sheath gas pressure 20 AU, aux gas 8 AU and capillary temperature of 320 °C. The 
detector was set to an MS2 method using a data dependent acquisition with top10 approach, 
fragmenting the 10 most intense ions per full scan with stepped collision energy between 25 
and 30. A 140000 resolution was used for the full spectrum and a 17500 for MS2. For the 
selection of ions to be fragmented, a dynamic exclusion filter was applied which will exclude 
the same ions from fragmentation for 20 seconds.  
Spectrum was recorded using a heated electrospray ionization and was in positive and 
negative mode to reach the best coverage for all lipid classes. Table 4-1 shows an overview 
of the lipid classes analysed as well as the particular adduct used for quantification and 
fragments identification.  
4.3.3 Synthetic external standards 
Linearity was tested on the C18 column using a mix of Phospholipids in different level (see 
Table 4-4) including an internal standard for all classes. 
Table 4-4: Composition of Phospholipid calibration mix. ‡‡‡ 
 
Concentration [µM] 
Species PC 16:0/18:2 
SM 
18:1/16:0 LPC 16:0 
PE 
18:0/18:0 
Cer 
18:1/14:0 
PG 
16:0/16:0 
MW 758,1 703,0 495,6 748,1 509,9 745,0 
Cal1 0,82 0,89 2,52 2,01 2,45 1,68 
Cal2 1,65 1,78 5,04 4,01 4,90 3,36 
Cal3 3,30 3,56 10,09 8,02 9,81 6,71 
Cal4 6,60 7,11 20,18 16,04 19,61 13,42 
Cal5 9,89 10,67 30,26 24,06 29,42 20,14 
Cal6 13,19 14,22 40,35 32,08 39,23 26,85 
 
Our external standard consisted of 65 isotope labelled or non-natural lipid species (5µM 
each, Table 3-6). 
                                                
‡‡‡ For linearity test, a calibration Mix of phospholipids was used. Per class, an internal 
standard and a calibrator compound was measured in specified concentrations. All lipid 
standards were purchased from Avanti polar lipid (Alabaster, USA) 
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In some experiments the commercial isotopic labelled lipidomics standard mixture "splash 
LipidoMix” (Avanti polar lipids, Alabaster, USA) was used for further glycolipids and 
glycophospholipid species (Table 4-5). 
Table 4-5: Composition of splash LipidoMix (Avanti Polar Lipids, Alabaster, USA) 
Lipid Species Concentration [µg/mL] 
15:0-18:1(D7) PC 160 
15:0-18:1(D7) PE 5 
15:0-18:1(D7) PS 5 
15:0-18:1(D7) PG 30 
15:0-18:1(D7) PI 10 
15:0-18:1(D7) PA 7 
18:1(D7) LPC 25 
18:1(D7) LPE 5 
18:1(D7) Chol Ester 350 
18:1(D7) MG 2 
15:0-18:1(D7) DG 10 
15:0-18:1(D7)-15:0 TG 55 
18:1(D9) SM 30 
Cholesterol (D7) 100 
 
The complete standard mix consisted of total 65 different lipid species was tested for linearity 
over a concentrations range of 0.1 to 5µM (concentrations: 0.1, 0.5, 1, 2 and 5 µM). Linearity 
was confirmed by calculating R2 for each lipid species. 
4.3.4 Internal standards 
The use of internal standards controls for the loss during the extraction, differences in 
ionization and matrix effects. Each lipid class is represented by one or more non-natural, 
synthetic internal standard which were included in the extraction buffer. Optimally, internal 
standards are isotopically labeled lipids which have exactly the same chemical properties for 
extraction, chromatography and ionization as their native counterparts. However, as isotope 
labelled standards are not available for all lipid classes in our analytical profile, we also used 
lipid species with non-natural fatty acid composition. The lipid classes and the corresponding 
internal standards are summarized in Table 4-6.  
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Table 4-6: Internal standards used for extraction and quantification of lipidomics samples. §§§ 
Lipid class Internal standard Concentration 
(1-deoxy)Sphinganine D7-SPH d18:0 100pmol/sample 
(1-deoxy)Sphingosine D7-SPH d18:0 100pmol/sample 
(DH)ceramide Cer d18:0 / 12:0 100pmol/sample 
Ceramide Cer d18:1 / 12:0 100pmol/sample 
1-Deoxy(DH)ceramide Cer m18:0 / 12:0 100pmol/sample 
1-Deoxyceramide Cer m18:1 / 12:0 100pmol/sample 
Hexsosylceramide GluCer d18:1 / 12:0 100pmol/sample 
Sphingomyelin SM d18:1 / 12:0 100pmol/sample 
Sphingosine-1-phosphate D7-S1P d18:1 50pmol/sample 
Cholesterol D7-Cholesterol 500pmol/sample 
Cholesteryl ester D7-CE 16:0 200pmol/sample 
Phosphocholine PC 14:0 / 14:0, PC 24:0 / 24:0 100pmol/sample 
Lyso-Phosphocholine LPC 17:0 100pmol/sample 
Phosphatic acid PA 17:0 / 17:0 100pmol/sample 
Phosphoethanolamine PE 14:0 / 14:0 100pmol/sample 
Lyso-Phosphoethanolamine LPE 17:1 100pmol/sample 
Phosphoglycerol PG 17:0 / 17:0 100pmol/sample 
Free fatty acid D3-FA 16:0 10nmol/sample 
 
For quantification of the lipid species, the area under the peak (AUC) of each compound and 
internal standard is calculated. The AUC for lipids of each class is then normalized to the 
AUC of the respective internal standard, which was added in a known concentration. The 
concentration of the lipid species is therefore calculated via the following equation: 
Concentration = !"# !"#$%&' ∗ !"#! !"AUC IS ∗ Sample volume  
4.3.5 Sample extraction 
Extraction started from either 20 µL of serum/plasma, 20 µL of tissue in PBS (1mg/dL) or a 
cell pellet consisting of 1-3 Mio cells suspended in 20 µL PBS. Extraction was done 
according to the MMC protocol described by Pellegrino et al. 15. The samples were extracted 
                                                
§§§ Per lipid class, one internal standard is added to a sample in the specified amount of 
internal standard. Internal standard is used to control for losses during extraction and 
calculate the concentration of specific lipid species. All lipid standards were purchased from 
Avanti polar lipids (Alabaster, USA) 
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in 2 mL Eppendorf tubes by adding 1 mL of a methanol / MTBE / chloroform (MMC 1.33/1/1 
v/v/v) mixture containing the respective internal standards. The mix was vortexed for 20 
seconds and agitated for 20 min in a thermo shaker (Eppendorf) at 37 °C at 1400 rpm. 
Precipitated proteins were pelleted by centrifuging for 5 min at 16000 rpm at 24 °C. The 
supernatant (1 mL) was transferred into a separate tube and the solvent dried under a 
stream of N2. For analysis, the sample was re-suspended in 100 µL methanol and 
transferred to a PP-MS vial. Of each samples, 25 µL were injected.  
For quality control, a standard sample was created, by pooling 5µL of each sample in an 
extra tube. From the pool, 2.5 µL, 5 µL, 10 µL, and 20 µL were aliquoted into a new tube and 
filled with PBS to 20 µL. These QC samples were treated the same way as other samples for 
extraction. 
4.3.6 Semi-automated analysis evaluation 
For a qualitative analysis of the raw data, we used the tool Xcalibur Qual Browser (Thermo) 
and for quantitative analysis the software tool TraceFinderTM (Thermo). In TraceFinderTM, a 
method was implemented covering sphingolipid species including the corresponding 
fragment information. 
For the sphingolipid subclasses (e.g. ceramides, hexosylceramides, sphingomyelins, etc.), 
the full mass and the presences of an indicative set of fragments was used as the signatures. 
Each lipid species was identified with an accurate mass accuracy for the full mass of < 5ppm 
and the presence of the determining fragments. The main ions for full mass and the 
fragmentation details per lipid class are summarised in Table 4-1. The combination of exact 
full mass, an indicative fragmentation spectrum and the retention time (RT), allows the 
annotation to a specific lipid metabolite. In most cases, this combination also allowed to 
identify isomeric and isobaric species. 
4.3.7 Lipid Search TM evaluation 
The standard mix (2 µM each, Table 3-6) was measured in triplicates in positive and negative 
mode and the dataset was analysed using the software tool “Lipid Search TM”. All lipids were 
Chapter 4: Lipidomics Method Development 
132 
aligned and filtered with the following filter criteria: S/N >10, no oxidized lipids, the area ratio 
of sample to blank > 1.5 and retention time between 5 and 26 min, area relative standard 
deviation < 30 and peak height > 5E6 and peak area > 1E6.  
4.3.8 Quality Control and statistics 
For each batch of samples, a set of quality control was included to control for accuracy and 
precision of the batch but also to check the linearity of all analytes measured. 
Quality control (QC) samples are a pool of each sample of a batch measured in 1:8, 1:4, 1:2 
and 1:1 dilution and measured at least three times within each batch.  
The QC allowed to calculate the linearity of the analysis for each of the lipid species, for 
shifts in RT within the batch, the standard deviation and carry over and the ratios between 
blank and sample to check for impurities. The criteria to pass quality control within the 
normalized data are for linearity an R2> 0.8, for precision a CV < 20% and a sample to blank 
ratio of >1.5. Lipid species, which did not fulfil these criteria, were excluded from the analysis. 
4.3.9 Plasma samples from healthy donors 
Six control plasma samples from healthy donors were extracted as described in 4.3.5 
Sample extraction. The Sphingolipidome of these samples was analysed using the 
TraceFinderTM method for quantification of sphingolipid species. 
4.3.10 Changes in sphingolipid metabolism with FB1, 4-HPR and myriocin 
NIH3T3 cells were grown and maintained in DMEM (Sigma) with 10 % FBS (Fisher 
Scientific; FSA15-043) and 1 % penicillin / streptomycin (100 units per mL / 0.1 mg/mL, 
Sigma) at 37 °C and 5 % CO2. Cells were treated for 24h with different inhibitors for 
sphingolipid metabolizing enzymes (myriocin (myr) 16-18, fumonisine B1 (FB1) 19-21 and 
fenretinide (4-HPR) 22, 23) and harvested in PBS, counted and extracted as described (4.3.5 
Sample extraction). Myrocin (Cayman Chemicals) in was used in 2.5 nM, Fumonisine B1 
(FB1, Sigma) in 7 µM and Fenretinide 22 (4-HPR, Tocris Bioscience) in 2 µM. Levels of 
different sphingolipid classes were analyzed with TraceFinderTM. 
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4.3.11 Method comparison 
36 human plasma samples from the Hepadip cohort (randomly taken) were split and 
analysed for their total sphingolipid base profile after hydrolysis and in parallel whit a full 
sphingolipidomics approach.  
Sphingoid base profile: 
100 µL of each plasma were transfered to 2 mL Eppendorf tubes for acid base hydrolysis. 
500 µL methanol including the internal standards D7-sphingosine and D7-sphinganine (Avanti 
Polar Lipids, Alabaster, AL) were added. Lipids were extracted for one hour under constant 
agitation at 37 °C in an Eppendorf Thermomixer. Samples were centrifuged at 16000 rpm for 
5 min to pellet precipitated proteins, and 500 µL of the supernatant were transferred to a new 
tube. Lipids were hydrolyzed by adding 75 µL of methanolic HCl (1 M HCl and 10 M H2O in 
methanol) and incubated for 16 h at 65 °C. By adding 100 µL of KOH (10M), HCl was 
neutralized. 625 µL chloroform were added followed by 100 µL of 2M ammonium hydroxide 
and 0.5 mL alkaline water to reach phase separation. The sample was vortexed, centrifuged 
at 16000 rpm for 5 min, the upper phase discarded and the lower (organic) phase washed 
three times with alkaline water. The organic phase was finally dried under N2 and stored at 
−20oC until analysis. 
Sphingoid bases were separated by RPLC on a C18-column (Uptispere 120 Å, 5 µm, 125×2 
mm; Interchim, Montluçon, France) and analyzed on a TSQ Ultra (Thermo, Reinach, BL, 
Switzerland) using an atmospheric pressure chemical ionization (APCI) interface. Mobile 
phases consisted of A: ultra-pure H2O / methanol 1/1 v/v with 2.6 mM ammonium acetate 
and B: methanol. The gradient was set from 50 % B to 100 % B within 25 min followed by 5 
min 100 % B and 5 min of equilibration with a flow rate of 0.3 mL/min. For mass spectral 
detection, the following parameters were set on the APCI source: discharge current of 4 µA, 
a vaporizer temperature of 450 °C, sheath gas pressure 20 AU, aux gas 5 AU and a capillary 
temperature of 200 °C. The measured area under the peak curve was normalized, and lipid 
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concentrations were calculated by comparison to D7-sphingosine and quantification was 
reported in pmol per sample.  
Lipidomics Analysis: 
20 µL of plasma were extracted using the MMC protocol (4.3.5 Sample extraction) and 
measured using the C30-column based lipidomics method (3.3.1 Liquid chromatography). 
4.4 Results: Method Development 
4.4.1 Separation of lipid classes 
We developed a novel LC-MS2 lipidomics method for the analysing of a great number of lipid 
species. Figure 4-1 shows the chromatographic separation of some selected sphingolipid 
species included in the internal standard. 
 
Figure 4-1: Chromatograms of different sphingolipid. Each chromatogram was acquired in positive mode. Internal 
standards are shown, which were spiked to a plasma from a healthy donor. 
In reversed phase chromatography, separation is based on the hydrophobicity of the 
molecule. Lipids are separated based on the number of (hydrophobic) carbon atoms and the 
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presence of polar structures such as double bonds, sulfates or hydroxyl group. Therefore, 
free sphingoid bases elute earlier than ceramides which contain a N-linked fatty acid, 
whereas retention times of SPH d18:1 and S1P d18:1 do not differ much. Also, 
dihydroceramide Cer d30:0 elutes later than ceramide Cer d30:1 because of hydrophilic 
double bond whereas 1-deoxyceramide (Cer m30:1) elutes later than ceramide Cer d30:1, 
because of its missing C1-hydroxyl group (Figure 4-1).  
Figure 4-2 shows the separation of different phospholipid species included in the splash 
LipidoMix. The standard was spiked into and extracted from a control plasma sample. For 
LPG and LPS the native lipid present in plasma is shown. 
Figure 4-2: Chromatogram of different phospholipid. Each chromatogram was acquired in positive mode. Splash 
lipidoMix was spiked to a plasma from a healthy donor and for LPS and LPC a native species are shown. 
The retention time of phospholipids on the C30 column is mostly determined by the number 
of carbons atoms and hydrophobic groups whereas the different polar head groups have 
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minor influence. Therefore, different phospholipid sub-classes (PC, PE, PG, PS) with the 
same numbers of carbons (e.g. 33:1) elute all in a narrow time window of about 30 seconds. 
Figure 4-3 shows the chromatogram of free D7-cholesterol which elutes within 15.9 min from 
the C30 column. It is ionized as [M+H]+ but also as [M+NH4]+. But these two ions are low 
abundant compared to the in-source fragmented [M-H2O+H]+. The water loss represents the 
most abundant ion and which is also used for quantification.  
Figure 4-3: Chromatogram for free cholesterol with different ions with adducts ([M+H]+ [M+NH4]+ and [M-H2O]+). 
The chromatogram was acquired in positive mode. Synthetic D7-cholesterol was used as a standard. [M-H2O]+ is 
the most abundant ion present for free cholesterol. 
Figure 4-4 displays the chromatogram of D7-cholesteryl ester 16:0. The labelled synthetic 
standard was spiked to plasma from a healthy individual donor. Cholesteryl esters elute later 
than free cholesterol, because of the additional fatty acid attached to the cholesterol 
backbone. During ionization of cholesteryl esters, an in-source fragmentation occurs and 
more than 50 % of the molecules are fragmented to the free cholesterol fragment (minus 
water) by losing the fatty acid in the source during ionization.  
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Figure 4-4: Chromatogram for cholesteryl ester with [M+H]+ ion but also the in source fragmented ion (loss of the 
fatty acid). The Chromatogram was acquired in positive mode. Internal standards are shown, which were spiked 
to a plasma from a healthy donor. 
Figure 4-5 shows the chromatogram of D3-palmitic acid spiked into a control plasma sample. 
As fatty acids showed higher signal intensity in negative mode the shown chromatogram was 
acquired in negative mode. 
Figure 4-5: Chromatogram for free fatty acid palmitate. The chromatogram was acquired in negative mode. 
Internal standards are shown, which were spiked to a plasma from a healthy donor. The signal before 2.5 minutes 
is considered as noise, as the LC flow is directed into waist before 2.5 minutes.  
In Figure 4-6 some examples of chromatograms of different glycerolipid classes are shown. 
To display the chromatographic resolution of glycerolipid classes, the splash LipidoMix was 
spiked to control plasma sample.  
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Figure 4-6: Chromatogram of different glycerolipid classes. The chromatogram was acquired in positive mode. 
Splash lipidoMix is shown, which was spiked to a plasma from a healthy donor. For LPS and LPC a native 
species is shown. 
Glycerolipid sub-classes consist of one, two or three fatty acids conjugated to a glycerol 
backbone. Mono-acyl glycerols elute earlier than di- or triacyl glycerols. The retention time 
depends on the number of fatty acids, total carbon atoms and number of double bonds. 
The here used C30 column allows the separation of a large number of lipid within a total 
runtime of 25 minutes using a gradient of organic solvents. The individual lipid species are 
well separated and show symmetric peak shapes without significant tailing. Using these 
conditions, it is possible to detect and quantify a wide variety of lipids species.  
4.4.2 Semi-Automated data analysis with TraceFinderTM 
TraceFinderTM offers a software tool, which allows a targeted and quantitative analysis of MS 
datasets. A method was set up in TraceFinderTM, allowing the comprehensive identification 
and quantification of typical and atypical sphingolipid species including isotope labelled lipids 
standards and isotopically labelled lipid metabolites. 
First, a theoretical compound library was setup for sphingolipids. The nominal mass of 
sphingolipids, with C16-C20 sphingoid backbones with no, one or two double bonds in 
combination with fatty acids between C8 and C26 containing no or one double bond or as free 
base were calculated. Furthermore, head groups as choline, glucose or phosphate were also 
combined to all the possible theoretical combinations. Finally, also 1-deoxysphingolipids and 
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1-deoxymethylsphingolipids with C18 or C17 backbone respectively were added to the 
compound library. For all these theoretical masses, the parent masses with the respective 
[M+H]+ adducts and fragmentation ions were calculated (Table 4-1). 
Furthermore, the library was extended to isotopically labelled compounds, if isotopically 
labelled precursors such as D4-L-alanine or D3N15-L-serine or isotopically labelled free bases 
(eg D7-sphinganine, D7-sphingosine, D3-1-deoxysphinganine or D5-1-
deoxymethylsphinganine) were added to cells in metabolic conversion assays. This resulted 
in a compound library containing several thousand theoretical combinations of sphingolipids.  
Retention times of all sphingolipids present in the external standard mix (Table 3-6) were 
determined using the newly developed C30 LC-MS2 method (Table 3-1). From these known 
retention times, a theoretical retention time was estimated for other sphingolipids, applying a 
linear (logarithmic) correlation between retention time and number of carbons and double 
bonds in a sphingolipid. 
Human plasma samples, but also HEK293 or NIH3T3 cell samples were than measured 
using the C30 LC-MS2 method (see 3.3.1 Liquid chromatography and 4.3.2 Mass 
spectrometry method). In these samples, sphingolipids from the theoretical compound library 
were searched and identified using a TraceFinderTM search method and finally manually 
validated using Thermo Xcalibur Qual browser. All compounds with matching parent mass 
and confirming fragments (Table 4-1) and a retention time within a range of 30 sec to the 
estimated one, were included in a TraceFinderTM quantification method. Isobaric compounds 
were searched and identified in a separate step shown in the next paragraph. Overall, the 
method allowed the quantification of about 150 different sphingolipid species including the 
typically used internal standards. 
4.4.3 Separation of isobars and isomers 
Due to the building block like nature of lipids, lipid species are often occurring in isobaric or 
isomeric forms. Isobaric means they have the same nominal mass but different elemental 
composition (isobars) whereas isomeric means they have the same elemental composition, 
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but vary in the steric orientation, the composition of fatty acids or the position of a double 
bond. For example, a ceramide d42:1 can be Cer d18:0 / 24:1, Cer d18:1 / 24:0 or Cer d16:1 
/ 26:0. For these isomers, the elemental composition is the same but the steric structure is 
different (e.g. the double bond is either in the sphingoid backbone or in the fatty acid) which 
results in the same m/z but a different RT and different fragmentation pattern. 
This often small difference allows to distinguish between individual isomers, e.g. Cer d18:0 / 
24:1 and Cer d18:1 / 24:0 (Figure 4-7A). NIH3T3 cells were treated with 4-HPR 22, an 
inhibitor of dihydroceramide desaturase which leads to the accumulation of Cer d18:0 / 24:1 
as the conversion to the primary metabolite Cer d18:1 / 24:1 is blocked. 
 
Figure 4-7: A: Chromatogram of Cer d42:1 from NIH3T3 cells treated with or without 4-HPR. B: Fragmentation 
pattern of Cer d18:0 / 24:1 (Peak at 18.59 min) C: Fragmentation pattern of Cer d18:1 / 24:0 (Peak at 18.98 min) 
As seen in Figure 4-7A, there are two peaks with the full mass of Cer d42:1 eluting between 
18.5 and 19.0 minutes. Without 4-HPR treatment, the peak at 18.59 minutes is very low 
abundant whereas the peak at 18.98 minutes is the major one. In the presence of 4-HPR, the 
peak at 18.59 increases to the same level as the peak at 18.98. However, the fragmentation 
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pattern of the two peaks at 18.59 and 19.98 are different, as seen in Figure 4-7B for the peak 
at 18.59 and Figure 4-7C for the peak at 18.98. From fragmentation pattern, the peak at 
18.59 corresponds to Cer d18:0 / 24:1 and the peak at 18.98 to Cer d18:1 / 24:0. This also 
matches the biological interpretation of an accumulation of dihydroceramides in the presence 
of 4-HPR. In addition, the shift in RT is as expected as more polar compounds are eluting 
earlier in reversed phase chromatography. The cis double bond in the fatty acid moiety of 
Cer d18:0 / 24:1 seems to be more polar than the ∆4 trans double bond in the sphingoid 
base backbone of Cer d18:1 / 24:0. As a further example, Figure 4-8A shows the 
chromatogram of Cer d42:2 which could corresponds to Cer d18:1 / 24:1 (peak at 18.4 min) 
or Cer d18:2 / 24:0 (peak at 18.59 min). Also here, the fragmentation pattern is different for 
Cer d18:1 / 24:1 Cer d18:2 / 24:0 (Figure 4-8B and C). 
Figure 4-8: A: Chromatogram of Cer d42:2 from NIH3T3 cells without any treatment. B: Fragmentation pattern of 
Cer d18:1 / 24:1 (Peak at 18.4 min) C: Fragmentation pattern of Cer d18:2 / 24:0 (Peak at 18.59 min) 
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4.5 Results: Method validation 
4.5.1 Linearity, Precision and Carry-over 
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Figure 4-9: Calibration curves for different phospholipids to test linearity. Samples were dissolved in 100µL 
methanol with an injection volume of 25µL. All measured phospholipids show a linear correlation of concentration 
to measured ratio of AUC.  
For all classes, the concentration of the calibrator shows a linear correlation to the area 
under the peak in the range specified in Table 4-4 with an R2> 0.95. The specific R2 values 
are shown in Figure 4-9. 
However we observed some persisting resolution problems, primarily for long chain 
sphingomyelins, S1P, and PC species. These species were eluting with long tailing over 
three minutes. Therefore, we replaced the C18 column with an Accucore C30 column.  
Accucore C30 column 
The linearity of calibration curves, precision and carry-over for all different sphingolipids, 
phospholipids and cholesteryl ester are shown in Table 4-7.  
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Table 4-7: Linearity, imprecision and carry over of LC-MS Method with C30 column 
Sub-Class Species R2**** CV [%]†††† Carry-over [%]‡‡‡‡ 
Sphingoid Bases SPH d18:2 0.9977 1.06 0.41 
SPH d17:1 0.9978 1.43 0.76 
SPH d17:0 0.9966 1.76 0.97 
SPH t18:0 0.9965 1.28 0.95 
D7-SPH d18:1 0.9966 0.94 0.78 
SPH d18:1 0.9970 1.00 0.84 
D7-SPH d18:0 0.9923 1.02 0.22 
SPH d18:0 0.9909 0.20 0.27 
SPH d20:1 0.9950 0.72 0.39 
SPH d20:0 0.9951 1.73 0.11 
1-Deoxysphingoid bases m18:1 0.9856 1.84 0.30 
m17:1 0.9866 2.16 0.34 
D5-m17:0 0.9735 0.75 0.41 
m17:0 0.9779 1.02 0.38 
D3-m18:0 0.9336 1.45 0.33 
m18:1 0.9297 2.05 0.43 
Ceramides Cer d18:1 / 12:0 0.9901 1.45 0.08 
Cer d18:0 / 12:0 0.9957 1.54 0.08 
Cer d18:1 / 14:0 0.9553 2.22 0.16 
D7-Cer 18:1 / 16:0 0.9867 2.59 0.15 
Cer d18:1 / 18:1 0.9686 2.25 0.14 
Cer d18:0 / 16:0 0.9734 1.19 0.18 
Cer d18:1 / 17:0 0.9698 1.48 0.21 
Cer d18:1 / 20:0 0.9476 1.41 0.50 
Cer d18 1:24:1 0.9412 2.55 0.62 
Cer d18:1 / 22:0 0.9471 3.38 0.72 
D7-Cer d18:1 / 24:0 0.9262 1.37 0.69 
Cer d18:1 / 24:0 0.9385 2.06 1.08 
Cer d18:0 / 24:0 0.9867 4.44 0.76 
1-Deoxyceramides doxCer m18:1 / 12:0 0.9475 1.91 0.35 
doxCer m18:0 / 12:0 0.8923 2.28 0.59 
doxmetCer m17:1 / 16:0 0.9263 1.61 0.70 
doxCer m18:1 / 16:0 0.9651 0.99 0.59 
                                                
**** Linearity was determined by calculation of linear coefficients of correlation 
†††† Impresicion was calculated by the relative coefficient of variation from measured 
triplicates.  
‡‡‡‡ Carry-over was determined in blank methanol samples measured after 5 µM standard 
mix.  
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doxmetCer m17:0 / 16:0 0.9709 0.98 0.59 
doxmetCer m17:1:24:1 0.9171 1.53 1.44 
doxCer m18:1 / 24:1 0.9366 1.85 1.52 
doxmetCer m17:0 / 24:1 0.8719 1.92 1.71 
doxCer m18:0 / 24:1 0.9100 1.35 1.48 
Sphingomyelines SM 18:1 / 12:0 0.9777 3.17 0.15 
SM d18:0 / 12:0 0.9769 1.27 0.15 
SM 18:1 / 16:0 0.9625 1.23 0.23 
D9-SM d18:1 / 18:1 0.9497 2.23 0.27 
SM 18:1 / 24:1 0.9776 1.12 0.29 
SM:d18 1:24 0 0.9734 1.71 0.55 
Glucosylceramides GluCer d18:1 / 8:0 0.9975 2.32 0.01 
GluCer d18:1 / 16:0 0.9917 1.75 0.00 
D5-GluCer d18:1 / 18:1 0.9788 1.77 0.04 
GluCer d18:1 / 24:1 0.9756 2.09 0.15 
Sphingosine-1-phosphate S1P d17:1 0.9964 1.15 5.03 
S1P d17:0 0.9977 3.19 7.84 
D7-S1P d18:1 0.9989 1.48 8.42 
S1P d18:1 0.9991 0.80 8.50 
Phospholipids LPC 16:0 0.9813 0.95 0.07 
LPC 17:0 0.9859 1.42 0.06 
PC 14:0 / 14:0 0.9731 2.89 0.25 
PC 16:0 / 18:2 0.9538 1.81 0.35 
PC 24:0 / 24:0 0.9658 9.49 6.94 
LPE 17:1 0.9709 0.89 0.06 
PE 14:0 / 14:0 0.9956 2.34 0.25 
PE 18:0 / 18:0 0.9602 1.89 3.30 
PA 14:0 / 14:0 0.9541 0.50 24.84 
PA 17:0 / 17:0 0.8005 2.23 66.41 
PG 16:0 / 16:0 0.7247 2.30 0.93 
PG 17:0 / 17:0 0.8559 3.00 1.29 
Cholesteryl ester D7 ChE 16:0 0.9941 3.04 0.00 
 
4.5.2 Semi-Automated Data analysis with Lipid searchTM 
Lipid Search TM is a software tool that allows the semi-quantitative annotation of lipid species 
based on a database with more than 1.5 million lipid ions and their predicted fragmentation 
pattern. The MS2 datasets are automatically analysed by algorithms and identified based on 
product ion, precursor ion, and neutral loss scans. 
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Figure 4-10: Lipid Search TM analysis software. Example of Cer 18:1 / 17:0 is shown. Alignment of a standard mix 
in different concentration from 0.02 to 10µM was done; samples were measured in triplicates in positive mode. 
Panels show samples and identified molecule, the alignment of all the samples, the area measured per sample 
group, the product spectra and the fragments used to identify the molecule. 
In a first validation and proof of principle assay, we analysed whether the Lipid Search TM is 
capable to identify all lipid species included in the external standard mix. The software was 
capable to identify 59 out of 65 species in the standard. Six species were not identified. This 
included phytosphingosine (SPH t18:0) and the isotope labelled species D3-SPH m18:0, D5-
SPH m17:0, D7-Cer d18:1 / 16:0, D7-Cer d18:1 / 24:0, D9-SM 18:1 / 18:1, which is explained 
by the fact that the isotope labelled masses were not yet included in the Lipid Search TM 
database in this version (from Lipid SearchTM version 4.2 on, the isotope labelled commercial 
SplashMix standard is included in the database). Also D7-ChE 16:0, although present as 
deuterated form in the database, was not identified as no fragment spectrum was generated 
in the data dependent acquisition.  
Four species were identified twice. For Cer 18:1 / 22:0, LPC 16:0 SM 18:1 / 12:0 and SM 
18:1 / 24:1 this might be explained by the presence of a small pre-peak, which elutes shortly 
before the main peak (Figure 4-11). 
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Figure 4-11 Chromatogram of twice identified species out of the 65 lipid standard mix (4.3.3 Synthetic external 
standards) in lipid search, which all show a small pre peak eluting before the main peak. A: Cer 18:1 / 22:0, B: 
LPC 16:0, C: SM 18:1 / 12:0, D: SM 18:1 / 24:1 
As fifth example SPH d17:0 was identified twice. In this case is was a false-positive 
identification, as the SPH d17:0 main ion was identified as [M-H2O +H]+, which has the same 
elementary composition as SPH m17:1 [+H]+. Interestingly, the Lipid Search TM made this 
false-positive identification of SPH m17:1 in just one of the triplicate samples. In other 
samples, the ion was correctly annotated. Unfortunately, in the alignment, the correct 
identification of SPH m17:1 and the false positive SPH d17:0 were identified as separate 
patterns, and the peak was annotated twice although retention time, main area and the peak 
height of both species were identical for either ion (see Figure 4-12).  
Figure 4-12: SPH d17:0 false-positive identification in Lipid Search TM. SPH m17:1 was identified correctly as SPH 
m17:1 but also with false annotation as SPH d17:0-H20. 
Based on the theoretical isomers  also other misidentifications occurred:  
- Cer d18:1 / 8:0 identified as Cer m18:2 8:0 
- Cer d18:1 / 12:0 identified as Cer m18:2 12:0 
- Cer d18:1 / 14:0 identified as Cer m18:2 14:0 
- Cer d18:1 / 17:0 identified as Cer m18:2 17:0 
- Cer d18:1 / 18:1 identified as Cer m18:2 18:1 
- Cer d18:1 / 20:0 identified as d Cer m18:2 20:0 
- Cer d18:1 / 22:0 identified as Cer m18:2 22:0 (two peaks, see Figure 4-11A) 
- Cer d18:1 / 24:1 identified as Cer m18:2 24:1 
- Cer d17:0 / 16:0identified as Cer m17:1 / 16:0 
- GluCer d18:1 / 16:0 identified as Cer m18:2 16:0 (whit loss of head group) 
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Most of these misinterpreted species are not occurring in significant amounts in nature and 
were therefore excluded as false positive. 
We also found an impurity in the GluCer d18:1 / 8:0 standard which turned out to also 
contain Cer d18:1 / 8:0  
Deuterated ceramides are not included in the Lipid Search TM database. Therefore, Lipid 
SearchTM misidentified two deuterated standards. D7-Cer d18:1 / 16:0 (or its –H2O ion) was 
identified as 1-deoxyCer m33:0 [M+NH4]+ and D7-Cer d18: 1/ 24:0 (or its –H2O ion) as 1-
deoxyCer m41:0 [M+NH4]+. However, the fatty acid composition could not be annotated, 
because Lipid Search TM did not find the sphingoid base fragments for the 1-deoxyCer 
species (as this is a false annotation). Furthermore, the software identified a SPH d22:0, 
which seems to be a real positive result. It might be a contamination in one of the standards, 
from a synthesis artefact. In summary, Lipid Search TM correctly identified and annotated 59 
out of 65 lipids in the standard mix. Three lipids were not detected, because they were not 
present in the database, for D7-ChE 16:0 (which is present in the database) the concentration 
was too low for data dependent fragmentation, which is required by the algorithm for 
identification. Two deuterated ceramides were detected but not correctly annotated by Lipid 
Search TM. 17 Lipids were identified twice. Four because of a pre-peak with the same mass 
and 13, because of a double identifications of the same ion. This double integration is an 
unsolved problem in Lipid Search TM.  
The double identification is created because Lipid Search TM first tries to identify a pattern (full 
scan data plus the corresponding fragmentation data) in the chromatogram, which fits best to 
a spectrum in the database and therefore it annotates the spectra in each sample. This 
creates a list of annotated patterns in the sample. In a second step, Lipid Search TM aligns 
different measurements of the same sample, e.g. positive and negative mode of the sample 
but also data from measured (biological) replicates. If in one sample that was aligned, the 
pattern identification was incorrect, this creates two different annotations within the 
alignment. The alignment algorithm will now search for full scan data with the corresponding 
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ion in the other samples and integrate them in all the aligned samples, leading to two 
annotated species for the same peak. To improve the Lipid Search TM algorithm, a control 
step should be implemented in the alignment step, which checks for peaks which are present 
in the aligned samples at the same retention time, where the same pattern was annotated 
differently and either implement an algorithm to choose the correct annotation or to ask the 
user which annotation fits better. This control step could avoid double identification of ion-
patterns. This issue was reported to the Lipid Search TM product manager at Thermo. So far, 
it is not possible to reliably filter these wrongly assigned peaks. Therefore, a manual 
validation is still necessary to validate the results. 
4.5.3 Lipidome in plasma from healthy donors 
Human plasma from six healthy individuals were extracted as described in 4.3.5 (Sample 
extraction) and analysed with TraceFinderTM. The average sphingolipidome from the six 
samples is shown in Figure 4-13. Sphingomyelins inculde the most abundant species in 
plasma making up 92 % of the total plasma sphingolipidome. The second most abundant 
sphingolipids are ceramides with 4 % and hexosylceramides with 3 %. S1P species and 1-
deoxyceramides are very low abundant making 0.3 % for S1P and 0.2 % for 1-
deoxyceramides. 
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Figure 4-13: Six different plasmas from healthy donors were extracted and whole sphingolipidome was analyzed 
using the TraceFinderTM quantification software. The average value from the six samples per sphingolipid class is 
shown. HexCeramides represent hexosylceramides, doxCeramides 1-deoxyceramides and S1P stands for 
sphingosine-1-phosphate. 
The distribution of the individual subspecies is shown in Figure 4-14. All species fulfilled the 
quality criteria and were normalized to internal standards of the respective sub-class. 
The most abundant ceramide species in plasma is Cer d18:1 / 24:0 followed by Cer d18:1 / 
22:0, Cer d18:1 / 24:1 and Cer d18:2 / 24:0. The same distribution of fatty acids was seen for 
dihydroceramide. For 1-deoxceramides, the most abundant species are the 1-deoxy(DH)Cer 
(m18:0 or m18:1) with 24:0, 24:1 or 22:0 fatty acids.  
The most abundant hexosylceramide species were HexCer d18:1 / 24:0, HexCer d18:1 / 
22:0, HexCer d18:1 / 24:1 and HexCer d18:2 / 16:0. Conentraction of Hex(DH)ceramides 
were very low and therefore did not meet the quality criteria. 
Interestingly, in contrast to ceramides is the most abundant SM and (DH)SM species were 
d18:1 /16:0 and d18:0 / 16:0 respectively. Second most abundant species was SM d18:1 / 
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0.26% 
doxCeramides 
0.23% 
Sphingolipidome 
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24:1 followed by SM d18:1 / 22:0, Cer and SM d18:1 / 24:0. This is due to the fact, that 
ceramide transport protein (CerT) prefers C16:0 fatty acid ceramide species, whereas C22:0 
and C24:1 fatty acid ceramide species are transferred at ∼40 % of the rate of the shorter 
fatty acid ceramides, and the transfer of C24:0 fatty acid ceramide is negligible. CerT is 
responsibly to transport ceramides from ER to Golgi, where sphingomyelins are formed from 
ceramides 24.  
Chapter 4: Lipidomics Method Development 
151 
Cer
uM
Ce
r(d
18
:0/
18
:0)
Ce
r(d
18
:0/
20
:0)
Ce
r(d
18
:0/
22
:0)
Ce
r(d
18
:0/
22
:1)
Ce
r(d
18
:0/
24
:0)
Ce
r(d
18
:0/
24
:1)
Ce
r(d
18
:1/
16
:0)
Ce
r(d
:18
:1/
18
:0)
Ce
r(d
18
:1/
20
:0)
Ce
r(d
18
:1/
22
:0)
Ce
r(d
18
:1/
22
:1)
Ce
r(d
18
:1/
24
:0)
Ce
r(d
18
:1/
24
:1)
Ce
r(d
18
:2/
22
:0)
Ce
r(d
18
:2/
24
:0)
Ce
r(d
18
:2/
24
:1)
0
1
2
3
4
5
S1P
uM
S1
P(
d1
6:1
)
S1
P(
d1
8:1
)
S1
P(
d1
8:2
)
0.0
0.1
0.2
0.3
0.4
doxCer
uM
do
xC
er(
m1
8:0
/20
:0)
do
xC
er(
m1
8:0
/22
:0)
do
xC
er(
m1
8:0
/24
:0)
do
xC
er(
m1
8:0
/24
:1)
do
xC
er(
m1
8:1
/20
:0)
do
xC
er(
m1
8:1
/22
:0)
do
xC
er(
m1
8:1
/24
:0)
do
xC
er(
m1
8:1
/24
:1)
0.00
0.05
0.10
0.15
0.20
0.25
HexCer
uM
He
xC
er(
d1
8:0
/22
:0)
He
xC
er(
d1
8:0
/24
:0)
He
xC
er(
d1
8:1
/16
:0)
He
xC
er(
d1
8:1
/18
:0)
He
xC
er(
d1
8:1
/20
:0)
He
xC
er(
d1
8:1
/22
:0)
He
xC
er(
d1
8:1
/22
:1)
He
xC
er(
d1
8:1
/24
:0)
He
xC
er(
d1
8:1
/24
:1)
He
xC
er(
d1
8:2
/22
:0)
He
xC
er(
d1
8:2
/24
:1)
0
1
2
3
4
SM
uM
SM
(d_
18
_0
 _ 
16
_0
)
SM
(d_
18
_0
 _ 
18
_0
)
SM
(d_
18
_0
 _ 
20
_0
)
SM
(d_
18
_0
 _ 
22
_0
)
SM
(d_
18
_0
 _ 
22
_1
)
SM
(d_
18
_0
 _ 
24
_0
)
SM
(d1
8:0
/24
:1)
SM
(d1
8:1
/16
:0)
SM
(d1
8:1
/18
:0)
SM
(d1
8:1
/18
:1)
SM
(d1
8:1
/20
:0)
SM
(d1
8:1
/20
:1)
SM
(d1
8:1
/22
:0)
SM
(d1
8:1
/22
:1)
SM
(d1
8:1
/24
:0)
SM
(d1
8:1
/24
:1)
SM
(d1
8:2
/16
:0)
SM
(d1
8:2
/20
:0)
SM
(d1
8:2
/22
:0)
SM
(d1
8:2
/24
:1)
0
10
20
30
40
 
Figure 4-14: Sphingolipidome of plasma from healthy donors. Species were identified and quantified with 
spingolipid TraceFinderTM method. For each class of sphingolipids, the individual species are shown which fulfilled 
the quality criteria.  
For reference values see the sphingolipidome measured by Samar R. Hammad 25 or Oswald 
Quehenberger 6. 
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4.5.4 Biological verification of the identified sphingolipid species 
To verify that our method correctly identified the assigned sphingolipid species, we compared 
the sphingolipid profile in cells, which were treated with different inhibitors of the sphingolipid 
metabolic pathway. We used three well-established inhibitors of the pathway. 
1. Myriocin is a potent inhibitor of SPT and blocks the de novo synthesis of sphingolipids. It is 
expected that total sphingolipid levels are decreased in the presence of myriocin compared 
to control. 
2. Fumosin B1 ( FB1) is an inhibitor of the Ceramide Synthases (CerS). Inhibiting CerS 
blocks the conversion of sphinganine and sphingosine to (dihydro)ceramide and leads to the 
accumulation of the free sphingoid bases. As a consequence, (dihydro)ceramide but also 
complex sphingolipids like hexosylceramides and sphingomyelines should be decreased and 
free bases and S1P should be increased.  
3. Inhibiting dihydroceramide desaturase 4-HPR should cause the accumulation of saturated 
sphingolipids like dihydroceramide, but also saturated hexosyl(DH)ceramides and 
(DH)sphingomyelins.  
NIH3T3 cells were treated with the three inhibitors for 24 hours §§§§. Myriocin reduced the 
levels of all analysed species including 1-deoxyCer except for S1P d18:0. Total sphingolipids 
levels were reduced indicating a significant turnover and degradation of sphingolipids in the 
cells. FB1 had a minor effect on most species but increased significantly the free sphingoid 
bases and its phosphorylated forms (SPH d18:1, S1P d18:1). Interestingly, although by trend 
most species were slightly elevated in the presence of FB1, some species with an C16 fatty 
acid (e.g. HexCer d18:0;16:0, HexCer d18:1;16:0, 1-deoxyCer d18:1;16:0) were rather 
reduced (Figure 4-15). 4-HPR caused increases of all saturated species except 1-deoxyCer. 
As demonstrated in Chapter 1, 1-deoxyceramides contains a (14Z) double bond and are 
therefore no substrate for DES1/2. Therefore, 4-HPR has no impact on the 1-deoxyCer 
formation (Figure 4-15C). 4-HPR also increased the saturated free sphingoid base 
                                                
§§§§ Cells were cultured, harvested and extracted by Gergely Karsai 
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sphinganine and sphinganine-1-phosphate, and decreased the desaturated free sphingoid 
bases and sphingosine-1-phosphate (Figure 4-15D). 
In summary we observed a change in the sphingolipidome in response to inhibitor treatment. 
This strongly indicated that the sphingolipid species were identified correctly by our method. 
Surprisingly we observed that with the inhibition of FB1 all C16:0 acetylated species are 
decreased but it had only a minor effect on the other species. FB1 is known to inhibit in 
concentrations around 35 µM, in this experiment, 7 µM was used to avoid toxic effects of 
FB1 on the sensitive NIH3T3 cells. This might have resulted in an incomplete inhibition of the 
individual CerS isoforms. 
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Figure 4-15: NIH3T3 cells were treated with myriocin (myr, SPT inhibitor), fumonisine B1 (FB1, ceramide 
synthase inhibitor) or fenretinide (4-HPR, dihydroceramide desaturase inhibitor) to interfere with the sphingolipid 
metabolism. Species are shown in as log10(fold changes) of inhibitor to ethanol control. A: Hexsosylceramides, B: 
Sphingomyelins, C. (1-deoxy)Ceramides, D: free base sphingolipids and S1P 
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4.5.5 Method comparison 
In the past, sphingolipidome was determined in our lab with a method for the hydrolysed 
sphingoid bases. Therefore, we compared the sphingolipid profile measured with the 
established acid-base hydrolysed protocol with the newly developed sphingolipidomics 
approach. In 36 human plasma samples from the Hepadip cohort, the sphingoid base profile 
was measured after acid base hydrolysis and in parallel a full sphingolipidomics analysis was 
performed (see 3.3.1 Liquid chromatography and 4.3.2 Mass spectrometry method). With 
acid base hydrolysis, sphingoid bases are released and total levels reflect all sphingolipids, 
which were formed on the particular backbones. Hydrolysis provides a comprehensive 
readout of the SPT product spectrum and the total sphingolipid levels in a sample. However, 
after hydrolysis any information on the N-acyl chain or head groups is lost. We therefore 
compared the two methods to see how they perform in relation to each other. For 
comparison all C18 based sphingolipids measured with the lipidomics approach were added 
up independently of the sub classes (e.g. all the d18:0, d18:1, d18:2 or m18:0 and m18:1 
from all classes summed up) and compared to the C18 sphingoid base levels obtained after 
hydrolysis (C18 Sphinganine, C18 Sphingosine, C18 Sphingadiene, 1-deoxysphinganine and 1-
deoxysphingosine).  
For the measured d18:0 based sphingolipids, we saw a linear correlation between the 
hydrolysis method, whereas for the bases with one (d18:1) or two double bonds (d18:2), this 
correlation was not as strong (Figure 4-16). Interestingly, 1-deoxysphingolipids (m18:0 and 
m18:1) showed a much better correlation between the methods than the canonical C18 
sphingolipids (Figure 4-16). The general bias towards lower levels in the hydrolysis method 
might be due to incomplete hydrolysis.  
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Figure 4-16: Correlation between (1-deoxy)sphingoid bases measured after acid base hydrolysis or as sum of the 
(1-deoxy)sphingoid bases in different sphingolipid classes (free base, sphingosine-1-phosphate, ceramides, 1-
deoxyceramides, hexosylceramides and sphingomyelines) after sphingolipidomic analysis.  
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One possible reason for the observed differences could be, that the sphingoid bases were 
normalized either on D7-SPH d18:0 or D7-SPH d18:1 whereas in the lipidomics method uses 
a variety of different internal standards according to the class of the species (4.3.4 Internal 
standards). As these internal standards are often non-natural variant of FAs they do not 
necessarily elute at the same time as the quantified species – particularly not in reverse 
phase chromatography. This will affect the calculated concentration by introducing more 
variance.  
Further, after hydrolysis, all the different sphingolipid species will elute as one sphingoid 
base peak, and therefore, sum up all the species to one peak. With this, also minor species 
contribute to the concentration, whereas in the lipidomics method, minor species might not 
be detected if they were below the detection limit. In addition, in the lipidomics methods, only 
the known species were included in the quantification, therefore, some species, which 
contribute to the hydrolysed peak, were presumably not included in the quantification of the 
lipidomics data.  
Moreover, isobaric compounds were cleaved to different sphingoid bases during hydrolysis, 
whereas in the lipidomics method, isobars might overlap and therefore contribute to the 
quantification. This might explain the better correlation of saturated d18:0 compared to d18:1 
and d18:2, because the additional double bond increases the possible number of isobaric 
species.  
4.6 Discussion 
Lipids represent a significant part of the metabolome. A technique to determine a 
comprehensive lipid profile becomes more and more important in systems biology but also in 
medicine. Lipidomics techniques provide a broad profile of biological lipid molecules and 
allow extensive pathway analysis and interpretation of their physiological role 5. As a 
significant number of diseases are associated with changes in the lipid profile, lipidomics is 
an important tool to understand disease mechanisms, and search for biomarkers, which help 
in diagnostics of diseases, risk stratification and monitoring of therapeutic interventions 13.  
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In this work, we developed a quantitative data dependent acquisition LC-MS2 method for 
different sub-classes of sphingolipids, such as free sphingoid bases, S1P, ceramides, 
hexosylceramides and sphingomyelins. The method allows the differentiation between 
different isomeric sphingolipid subspecies (e.g. Cer d18:0 / 24:1 vs. Cer d18:1 / 24:0) and is 
also unique as it includes  atypical and low abundant sphingolipid species like atypical chain 
length sphingolipids and 1-deoxysphingolipids. Further, the method can be used to quantify 
glycerophospholipids, free cholesterol and cholersteryl esters. Additionally, also neutral 
glycerolipids and free fatty acids are separated and can be (semiquantitively) analysed. 
With this lipidomics method, it is possible to map the metabolic pathways of individual lipid 
classes and particular species. The here established method showed a good separation and 
resolution of the various lipid classes. Sphingolipids, glycerophospholipids, S1P but also 
cholesterol species, free fatty acids and neutral gycerolipids could be reliably detected. It 
remains demanding to acquire a comprehensive lipid profile covering apolar to polar lipids 
but also very low and high abundant lipids in a broad dynamic range. In an earlier version of 
the method we started using a C18 instead of an C30 column. Using these conditions, we 
obtained a decent separation of the species but observed a significant peak tailing for some 
species, in particular for long chain PCs and S1Ps. Switching to C30 column and slight 
adaptations in the LC conditions solved these issues. The analysis time of our method is 
rather long (30min) and separated into two runs for positive and negative ionisation mode. 
Several other methods are reported in the literature, Basit et al 10 describes a reversed phase 
method using a C18 column for a rapid evaluation of 25 sphingolipid species within nine 
minutes, where free sphingoid bases, S1P species, (DH)ceramides, sphingomyeline and 
glucosylceramide are covered. Although dihydroceramides are covered, Basit and co-
authors do not report (DH) species for sphingomyeline or glucosylceramide, nor do they 
report any minor N-acetyl fatty acid chain length like 20:0 or 22:0 for ceramide. Further, 
atypical 1-deoxysphingolipids were not included. Compared to the method published by Basit 
10, the here presented method needs longer in LC separation, but covers more species. 
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Mi et al. 26 reported a similar method using RPLC with a C18 column, which covers the major 
sphingolipid classes and species, neither show low abundant species nor separates or 
quantifies isobaric species.  
Scherer et al. 27 published a very rapid method of 4.5 minutes for the analysis of different 
sphingolipid classes using a HILIC column. As sphingolipids co-elute with the internal 
standard, matrix effects can be largely avoided, but isobaric species are not resolved in this 
approach. Furthermore, co-elution of species and an isotopic overlay of different species is 
possible and needs to be corrected by post-analysis calculation methods to avoid 
overestimation. This is due to the fact that isotopes of co-eluting desaturated species may 
overlap with saturated species. Especially in case of 1-deoxysphingolipids the [M+H]+ ion of 
1-deoxyceramides will overlap with [M-H2O+H]+ species of canonical dh-ceramides. With 
such a method, it is difficult to reliably identify and quantify minor 1-deoxysphingolipids.  
Although a C30 stationary phase is much less used in untargeted profiling of lipidome, its 
potential has been demonstrated in separation of phospholipids and recently also for 
complex lipidomics studies 28, 29. In a comparison of C18 and C30 columns by Narvaez-Rivas 
and co-authors 28, the C30 column showed the narrowest peaks, highest theoretical plate 
number, excellent peak capacity and retention time reproducibility. They also demonstrated, 
that the C30 column separates cis and trans isomeric lipid species.  
Few authors do mention the measurement of 1-deoxysphingolipids like Shaner et al. 30 or 
Sullards et al. 31, but they do not comment on how to reliably identify or quantify these 1-
deoxysphingolipids. As most of the natively occurring 1-deoxysphingolipids are present in 
their N-acetylated form, this might explain why these compounds were often overseen in 
general sphingolipid analysis, because their [M+H]+ is overlapping with [M-H2O+H]+ of typical 
dh-ceramide species 32.  
Most of the so far published sphingolipidomics methods are targeted approaches using a 
triple quadrupole mass spectrometer in multiple reaction monitoring (MRM) mode 25-27, 30, 31, 
33. MS analysis with MRM enables the detection of specific lipid species based on their 
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unique parent/fragment ion transitions. A MRM method provides highly selective and very 
sensitive determination of individual lipid species in the complex lipid mixture. However MRM 
requires prior knowledge about the fragmentation patterns of lipids analysed and a 
predefined list of species of interest. It is not possible to search for unknown species or to re-
analyse data for further compounds. Recently, also methods using high-resolution accurate 
mass spectrometer (HRAMS) were published. Bilal et al. 34 showed a method to quantify 
sphingolipid with LC-HRAMS using full scan data for identification and quantification, with the 
limitation, that no fragmentation data is acquired and therefore, not used for identification of 
the lipid species 34.  
In our work, we demonstrated the use of HRAMS with data dependent acquisition, where full 
scan but also fragmentation data is acquired, based on the signal intensity of the measured 
species. This is limiting the detection of low abundant species in the MS2 level. On the other 
hand, it allows to search for unknown species and a re-analysis of data for new compounds 
of interest. Each run takes about 31 minutes. In combination with the MMC extraction 
protocol, this method provides a fast and comprehensive tool for lipidomics analysis.  
After the acquisition of hundreds of MS2 features, these need to be annotated to lipid classes 
and species. It is rather difficult to obtain exact annotation for all molecules, even in the 
limited categories of metabolites such as lipids, especially because of the huge number of 
isobars possible for lipids. Fragments of fatty acyl anions from the sn- 1 and sn- 2 positions 
and neutral loss of water or fatty acids are very important for identification of individual 
molecular species. Fragment ions of polar head groups or specific neutral loss from each 
class are also very important for identification of each different category of polar lipids. High 
coverage of detected fragments results in identification that is more accurate. 
Lipid search TM offers an automated search engine that can indicate the most probable 
candidates for each MS2 feature. The database consists of theoretical m/z values of lipid ions 
with different adducts for positive and negative mode and their fragment ions for different 
lipid classes. This database is theoretically constructed, calculating the fragment data for lipid 
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species. Patterns of ion fragmentation have been theoretically constructed and improved by 
using experimental data obtained from synthesized standards and various natural samples 
35. The implemented algorithm in Lipid Search TM is based on a feature identification in 
different samples, where the best match is annotated to a measured feature. Afterwards, 
different samples can be aligned and the identified species will be overlaid and peaks are 
integrated over the whole sample set. This alignment produces a number of false positive 
identifications, where an quality check for double annotation of a specific ion feature is 
missing. For a high throughput approach, an automated annotation and quantification would 
be necessary. Lipid Search TM provides such features, but because of a high percentage of 
false-positive annotation, a time-consuming validation process is needed which is not 
feasible yet for a high throughput analysis. 
In summary, we developed a comprehensive method for the analysis of the total 
sphingolipidome, including the high abundant sphingolipid classes, but also the low abundant 
1-deoxysphingolipid species. With this method, it is possible to analyse the sphingolipidome 
in different matrices and to follow metabolic changes in different (disease) conditions or 
treatments.   
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4.7 Protocol for lipidomics 
The following protocol was developed and validated for whole sphingo- and 
phospholipidomics analysis. 
4.7.1 Extraction 
Cells, plasma or tissue sample, is aliquot to 20µL volume. For quality control, a pooled 
sample is mixed by taking 3µL of each sample to pool. The extraction buffer (methanol / 
chloroform / MTBE 4/3/3 v/v/v) is combined with internal standards for all lipid classes. From 
pool sample, four different quality control samples are aliquot by taking 1/8, ¼, ½, and 1 of 
the sample volume. 
Samples and quality controls are mixed with 1mL of extraction buffer (containing an internal 
standard for all lipid classes), vortexed for 20 seconds and then shacked for 20 min at 37 °C 
with 1400 rpm. After samples are centrifuged at 24 °C for 5 min at room temperature, the 
supernatant is transferred to new Eppendorf tube and samples dried down under N2. 
Samples can be stored at -20 °C until measurement. 
For LC-MS measurement, samples and quality controls are dissolved in 100µL methanol. 
4.7.2 LC-MS 
For chromatographic separation, an Accucore C30 (150 Å, 2.6 µm, 150 × 2.1 mm) column 
(Thermo Fischer Scientific, Reinach, Schweiz) is used. Mobile Phase A: Water / Acetonitrile 
80 / 20 v/v and B: Isopropanol / Acetonitrile 90/10 v/v both containing 10mM ammonium 
Acetate and 0.1 % formic acid and C: Methanol. Samples are loaded with 70 % A, 20 % B, 
and 10 % C for 1.5 min and then separated for 17 min in a gradient to 100 % B and finally 
eluted for another 7 min at 100 % B. After the column is set back to start conditions and re-
equilibrated for 5min. Samples are measured in singles in the positive and negative mode in 
a top 10 data dependent acquisition mode with heated electrospray ionization on a Q 
Exactive (Thermo Fisher). Quality controls are measured minimally in triplicates in positive 
and negative mode, distributed over the sequence, e.g., in the beginning, in the middle and 
at the end of the series. 
Chapter 4: Lipidomics Method Development 
164 
4.7.3 Lipid identification 
Samples are semi-automatically analysed, and lipids are annotated with Lipid Search TM 
software (Thermo Fisher). Quality control samples are aligned in Lipid Search TM, and lipid 
annotation is validated with these samples.  
The following filter criteria are applied to quality control samples: 
- S/N threshold 10 
- Area of QC 1/ Area blank >1.5 
- Base Retention time > 5 min and < 26 min 
- Relative standard deviation < 30 within QC triplicates 
- Peak height in QC1 > 5e5 
The aligned and filtered results are checked for:  
- Peak shape: did it identify a real peak or just noise? 
- Do the QC samples follow an increasing linear pattern? 
- Did Lipid Search TM find all internal standards added to the sample and do they show 
the same area within all QC samples? 
- Were lipids identified more than once? 
- Sort for RT: are their Lipids identified with same RT which could be the same 
molecule (e.g., d-species – H2O vs. m-species plus double bond) 
Also, some known impurities of internal standards are excluded from results like Cer d18:1 / 
8:0 (impurity coming from glucosylceramide 18:1 / 8:0 standard) or SPH d15:0 (Impurity 
coming from internal STD)  
4.7.4 Lipid quantification 
This search gives a list of molecules that have to be quantified in TraceFinderTM. Parent Ion, 
fragments ions, identifies peaks and RT. TraceFinderTM integrates peak area. Results can be 
exported to excel. 
Calculate Concentration of lipids by correction to the internal standard. 
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Lipid Sub-Class Internal standard to correlate 
Dh-Cer Cer d18:0 / 12:0 
Cer (also diene) Cer d18:1 / 12:0 
Dh-1-deoxyCer 1-deoxyCer m18:0 / 12:0 
1-deoxyCer 1-deoxyCer m18:1 / 12:0 
Sphinganine bases D7-SA 
Sphingosine bases D7-SO 
1-Deoxybases D7-SO 
HexCer GlucosylCer d18:1 / 8:0 
SM SM 18:1 / 12:0 
Free Cholesterol D7 cholesterol 
ChE D7 ChE 
 
4.7.5 Data Validation  
Exclude compounds with a duplicate area from further analysis, e.g., d18:0 / 24:1 and d18:1 / 
24:0 (check which compound is correct with fragmentation data and delete duplicate). 
Exclude compounds with CV % of QC 1 is higher than > 20 % 
Eliminate compounds with R2 of QC is smaller than < 0.8 
Remove compounds with a ratio of Area Sample / Area blank (methanol) is lower than 1.5.  
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5 Chapter 5: Applications on Lipidomics method to 
biological samples 
The newly established lipidomics method described in Chapter 4, was used for the following 
collaborative projects 
1. Mutation in SGPL1 cause CMT Neuropathy  
S1P and sphingoid bases were profiled in samples of patients with a mutation in the gene 
encoding for sphingosine-1-phosphate lyase (SGPL1) and leading to peripheral sensory 
neuropathy. Lipid analysis allowed insights into changes in the S1P levels and potential 
disease mechanism. 
2. Roux-en-Y gastric bypass (RYGB) as a therapy of morbid obesity  
Sphingolipidomic studies were performed in mice undergoing gastric bypass surgery to 
evaluate the effect of surgery on changes in (lipid) metabolism. 
3. Regulation of sphingolipid metabolism through ORMDL3 
The sphingolipidome was determined in ORMDL3 knock-out mice as well as in mice with 
transgenic overexpression of human ORMDL3 to study the effect of ORMDL3 on 
metabolism and regulation of sphingolipids in the context of asthma. 
4. Effect of ABCA1 and ABCG1 in age-related macula degeneration (ADM)  
Unbiased lipidomics was applied to a mouse model for age-related macular 
degeneration. Retina-specific Abca1/Abcg1 knock out mice were suspected to accumule 
lipids in their macula and features of ADM. Therefore, cholesteryl esters, retinyl esters, 
and sphingolipid were measured in eye samples of these mice. 
 
Author contributions: Steiner R did all the sample extraction, lipid analysis and quantification, 
whereas the individual collaborators were responsible to obtain the samples for analysis.  
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5.1 S1P levels in Sphingosine-1-phosphate lyase deficient patient 
In collaboration with A.Jordanova (VIB, Antwerp, BE) 
Results were published by Atkinson, D., Nikodinovic Glumac, J., Asselbergh, B., Ermanoska, 
B., Blocquel, D., Steiner, R., Estrada-Cuzcano, A., Peeters, K., Ooms, T., De Vriendt, E., 
Yang, X. L., Hornemann, T., Milic Rasic, V., Jordanova, A., Sphingosine 1-phosphate lyase 
deficiency causes Charcot-Marie-Tooth neuropathy, Neurology, 2017;88:533-542. 
Author contribution: Steiner R did the sphingolipid analysis.  
In collaboration with the group of A. Jordanova (VIB, Antwerp, BE) we analysed the plasma 
lipid profile in two patients with an atypical form of axonal peripheral neuropathy, 
characterized by an acute or subacute onset and episodes of recurrent mono-neuropathy. 
Next genome sequencing revealed compound heterozygous mutations in the SGPL1 gene, 
which encodes sphingosine-1-phosphate lyase (SGPL). These mutations co-segregate with 
the described pathology and are absent in controls. One of the mutations (p.Ser361*) 
introduces a premature stop codon in the C-terminus and triggers nonsense-mediated decay 
of the mRNA transcript. The second one is a missense mutation (p.Ile184Thr) which possibly 
leads to proteasomal protein degradation 1. SGPL1 catalyses the irreversible degradation of 
sphingolipids by the terminal cleavage of S1P into hexadecenal and ethanolamine phosphate 
2 and thus provides the only exit route for the sphingoid bases from the de novo biosynthetic 
pathway. In addition, S1P is a potent agonist of five G-protein coupled receptors. Thus, 
SGPL1 expression and activity is essential for the maintenance of physiological levels of S1P 
and normal growth in mammals. In this context, we were interested to see whehter and how 
much these mutations cause alterations in the plasma sphingoid base and S1P profile of the 
patients. We thus determined sphingoid base and S1P profiles in patients and non-affected 
genetically related family members. 
First, we sought to look at the total sphingoid base profiles in the patients. For this, lipids 
were extracted and acid-hydrolyzed to release free sphingoid bases as described previously 
3-5. It is noteworthy to mention here that this method releases sphingoid bases from all 
sphingolipids and thus, provides a comprehensive readout of the sphingoid backbone profile. 
However it does not provide any information on the levels or types of different subclasses of 
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sphingolipids. For details of the analysis, see 3.3.1 (Liquid chromatography) and 4.3.2 (Mass 
spectrometry method). 
Second, we analysed S1P levels in plasma from the two patients, two unaffected family 
members and 24 unrelated control samples. Extraction of 50uL of plasma was performed 
using the MMC protocol, as described in 4.3.5 using D7-S1P as the internal standard. For 
chromatographic separation, a C18-column-based method was used as described in 3.3.1. 
The sphingolipid profiles were compared between the two index patients, the unaffected 
parents and three unrelated healthy control individuals. Total sphinganine was significantly 
lower in the patients compared to unaffected parents or unrelated controls (Figure 5-1A). In 
contrast, total sphingosine was not significantly different but by trend lower in the patient 
samples (Figure 5-1B). The ratio of sphingosine to sphinganine was significantly elevated in 
patients but not different between controls and parents (Figure 5-1C). 
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Figure 5-1: Sphingoid base profiles (hydrolyzed) from patients with mutations in the SGPL1 gene, the unaffected 
parents, and unrelated healthy controls. A: C18-sphinganine (SA) levels, B: C18 sphingosine (SO) levels and C: the 
ratio between C18 sphingosine to sphinganine. ANOVA was performed to check for statistical differences. ***= 
p<0.001, ns = not significant 
Plasma sphingosine-1-phosphate levels were increased in the patients compared to control 
and unaffected family members. S1P levels in the parents were significantly lower compared 
to the average of the 24 control samples (Figure 5-2A). 
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Figure 5-2: Sphingosine-1-phosphate profile from patients with mutations in the SGPL1 gene, the unaffected 
parents and unrelated healthy controls (n=24). A: C18-sphingosine-1-phosphate levels and B: C18 Sphinganine-1-
phosphate levels. ANOVA test was performed to check for statistical differences. **= p<0.01, ***= p<0.001, ns = 
not significant 
The significant decrease in sphinganine in patients could be due to a negative feedback loop 
of elevated S1P that inhibits the formation of sphinganine. As conversion from sphinganine to 
sphingosine is rather fast, we would expect to see its too. However, in view of the 15 times 
higher levels of sphingosine the conversion of 3 uM sphinganine into sphingosine caused 
only a small and not significant reduction in sphingosine levels. 
The mutation in SPGL1 leads to a change in sphingoid base profile and an increase in 
plasma sphingosine-1-phosphate. The clinical data suggests that SGPL deficiency is 
associated with a distinct form of the Charcot-Marie-Tooth disease. This new association 
would extend the currently recognized clinical and genetic spectrum of inherited peripheral 
neuropathies. This data emphasizes the importance of SGPL1 and sphingolipid turnover in 
neuronal function 1. This together with the other reports that link mutations in SGPL1 to other 
pathological conditions opens a new area of investigation for SGPL1 functions and hitherto 
unknown functions of the sphingosine-1-phosphate molecule itself. For example, Janecke et 
al. 6 describe two distinct mutations in SGPL1 (c.1513C>T; p.Arg505*) and c.934delC 
(p.Leu312Phefs*30)) which lead to a congenital nephrotic syndrome and congenital adrenal 
calcifications in human subjects. As expected, the levels of S1P and sphingosine were 
increased in the patient plasma as well as in fibroblasts derived from these patients 6. On a 
similar note, Prasad et al. 7 describe a primary adrenal insufficiency syndrome and steroid-
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resistant nephrotic syndrome caused by loss-of-function mutations in sphingosine-1-
phosphate lyase. They identified four different homozygous mutations, c.665G>A (p.R222Q), 
c.1633_1635delTTC (p.F545del), c.261+1G>A (p.S65Rfs*6), and c.7dupA (p.S3Kfs*11), in 
eight investigated patients; some of them also showed other symptoms including ichthyosis, 
primary hypothyroidism, neurological symptoms, and cryptorchidism 7. However, so far, the 
authors did not report the sphingolipid profiles in these patients. Lovric et al. 8 also reported 
nine different recessive mutations in SGPL1, which are associated with the steroid-resistant 
nephrotic syndrome, facultative ichthyosis, adrenal insufficiency, immunodeficiency, and 
neurological defects. All mutations resulted in reduced or absent SGPL1 protein and/or 
enzyme activity 8. 
Also in some of the nephrotic syndrome patients, neurological symptoms were reported, but 
mostly in older patients, whereas the nephrotic symptoms already occurred in younger 
patients 7, 8. It seems that different mutations in SGPL1 lead to various clinical symptoms and 
that there is a difference in the pathology of these different mutations. 
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5.2 Sphingolipidomics in mice undergoing bariatric surgery 
In collaboration with Erika Tarasco and Thomas Lutz, Institute of Veterinary Physiology 
University of Zürich 
Author contribution: Steiner R did the sphingolipid analysis.  
Obesity (BMI>30 kg/m2) is an increasing healthcare problem worldwide. In particular, visceral 
obesity is one of the leading factors for hypertension, insulin resistance, metabolic syndrome 
(MetS) and type 2 diabetes mellitus (T2DM), but also hypertriglyceridemia and low levels of 
high-density lipoprotein cholesterol (HDL) 9, 10. Bariatric surgery and in particular the Roux-en 
Y gastric bypass (RYGB) is the most effective treatment for obesity regarding long-term 
maintenance of body-weight loss and in particular for the improvement of obesity-related 
comorbidities 11, 12. Patients undergoing gastric bypass surgery show a reduction in appetite 
and an increase in glycaemic control. Dyslipidaemia and cardiovascular function improve 
rapidly after RYGB, independent of changes in body weight 13. Further, patients show 
improvements in insulin resistance or even a complete remission from T2DM 14, 15. 
Double transgenic mice expressing human CETP and the ApoE*3Leiden mutation 
(ApoE3L.CETP) were used for this study. The expression of the human Cholesteryl Ester 
Transfer Protein (CETP), which is usually not expressed in wild-type mice, mediates the 
transfer of cholesteryl ester from HDL to VLDL and LDL in exchange for triglycerides. 
ApoE3L.CETP mice present a human-like lipoprotein metabolism with higher concentrations 
of VLDL and LDL and relatively low concentrations of HDL when fed a 60 % high fat plus 
0.25 % cholesterol diet (HFDC) 10, 16. 
To test the effect of gastric bypass surgery, the mice were divided into three groups. One 
group obtained Roux-en-Y gastric bypass (RYGB) surgery whereas the control group 
underwent laparotomy - an abdominal section without any surgical intervention but with the 
same post-surgery treatment and wound healing processes. These control groups were 
subdivided into a body weight-matched group (BWm), which were under food restriction to 
match the same body weight as the RYGB group and the other control group could access 
food ad libitum (ShamAL). The body weight-matched group controls for the effects of weight 
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loss caused by gastric bypass because of the limited gastric capacity to monitor changes, 
which are caused by the weight loss and not by the gastric bypass itself.  
A lipidomics profiling was done in 20 µL mouse plasma as described in Chapter 4, using the 
C18-column-based method. The following commercially available lipids (Avanti Polar Lipids, 
Alabaster USA) were used as internal standards: D7-sphinganine, D7-sphingosine, Cer d18:0 
/ 12:0, Cer d18:1 / 12:0, 1-deoxyCer m18:0 / 12:0, 1-deoxyCer m18:1 / 12:0, SM d18:1 / 
12:0, GluCer d18:1 / 8:0, D7-S1P, PA 17:0 / 17:0, PE 14:0 / 14:0, LPE 17:1, PG 17:0 / 17:0, 
PC 14:0 / 14:0, PC 24:0 / 24:0, LPC 17:0. Quality control samples were made as described 
in 4.3.8 and included in the analysis. For chromatographic separation and MS analysis, the 
C18-column-based method was used (see 3.3.1 and 4.3.2).  
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Figure 5-3: Sphingolipid profiles in mice after bariatric surgery. ANOVA statistical test was performed to check for 
differences. ***= p<0.001, **= p<0.001, *= p<0.05, ns = not significant. Cer: Ceramides, doxCer: 1-
deoxyCeramides, S1P: Sphingosine-1-phosphate, HexCer: hexosylCeramides, SM: Sphingomyelin 
The individual sphingolipid classes were calculated by summing up all the particular 
sphingolipid species belonging to each class (Figure 5-3). Compared to ShamAL group, 
Ceramides, 1-deoxyceramides, S1P and sphingomyelin, were significantly lower in the 
RYGB group. In contrast, hexosylceramides were not significantly different between these 
Chapter 5: Application of Lipidomics Method 
175 
two groups. Compared to the BWm group, only ceramides and 1-deoxyceramides were 
significantly reduced in the RYGB treated animals. If BWm group is compared to ShamAL, 
there was no significant reduction in ceramides seen. 
From previous studies it is known that high-fat diet and obesity enhances the de novo 
sphingolipid metabolism 17. Therefore, ShamAL mice on high fat diet were expected to have 
elevated sphingolipid levels. Here we showed, that gastric bypass has a significant effect on 
sphingolipid profiles in mice. The ceramide and 1-deoxyceramide levels are significantly 
lowered in mice, which underwent a gastric bypass surgery compared to the body weight-
matched group, but also to the group without food restriction. However, ceramide levels are 
not changed with food restriction. Therefore, these changes in sphingolipid profile is not due 
to weight loss only, but specifically due to effect of gastric bypass surgery. Possibly, these 
changes in sphingolipid metabolism are responsible for the better metabolic outcomes of this 
surgical procedure compared to weight loss only 18. Also in a human study done by Kayser et 
al., patients who underwent RYGB surgery, showed a change in sphingolipid profile 18. 
Therefore, the benefit of RYGB surgery is to reverse the increase of sphingolipids due to 
high fat diet, which could not be seen with weight loss only.  
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5.3 Sphingolipidomics in ORMDL3 knock out mice 
In collaboration with Nincy Debeuf and Sophie Janssens, Gent University 
Author contribution: Steiner R did the sphingolipid analysis.  
In yeast, ORM 1 and ORM 2 proteins are negative regulators of serine palmitoyl-transferase 
(SPT) which regulates de novo sphingolipid synthesis in response to multiple metabolic 
signals 19, 20. Human genome encodes three proteins, ORMDL1-3, that share a significant 
sequence homology to the yeast ORM proteins. More importantly, genome-wide association 
studies (GWAS) identified single nucleotide polymorphisms at the ORMDL1-3 loci, which 
alter expression of these three genes. They have been shown to be strongly linked with the 
development of asthma in multiple ethnic populations 21-24. These reports led to the 
hypothesis that perturbations in sphingolipid metabolism might be directly implicated in the 
development of asthma in humans. However, whether mammal orthologues ORMDL1-3 are 
also involved in SPT regulation is still a matter of debate 25-28, and the effect of ORMDL 
associated SNPs on SPT activity and its link to asthma remain unclear as well 29. Ormdl3-
knockout (Ormdl32/2) and transgenic (Ormdl3Tg/wt) mice were generated by collaborators at 
Gent University to study the role of ORMDL3 in the development of asthma and its role in the 
sphingolipid metabolism in general. The effect of ORMDL3 knockout and over-expression on 
sphingolipid levels was analysed in detail by quantification of sphingolipid profiles from 
plasma and mice tissues including lung, liver, white and brown adipose tissue as well as 
bronchial lavage fluid (BAL) 28. Additionally, mice underwent asthmatic sensitization through 
exposure to house dust mite (HDM). HDM fecal pellets of Dermatophagoides pteronyssinus 
contain various allergens that belong to the major triggers of allergic asthma worldwide. This 
has led to the development of a clinically relevant mouse model based on the inhalation of 
HDM extracts to study the molecular mechanisms of allergic sensitization. In a first step, 
mice were sensitized (intra-tracheal treatment) with house dust mite (HDM) whereas control 
mice just received PBS treatment. Six to ten days after sensitization, mice were challenged 
again to reach the acute phase. Only the HDM sensitized mice develop asthma, whereas the 
PBS sensitized ones did not 30. Mice were sacrificed after 14 days and lung, liver, white 
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adipose and brown adipose tissue were homogenized using 0.1 % Triton (TX100). The 
tissue was extracted at 4 °C for 1 hour and the insoluble debris was pelleted at 16000 rpm. 
The protein content of these lysates was determined using the Bradford protein assay. A 
lipidomics profiling was done in 20 µL mouse plasma, 20 µL of bronchial lavage fluid (BAL) 
or 20 µg of homogenate from each mouse tissue (lung, liver, white adipose and brown 
adipose tissue). The samples were extracted using the MMC protocol as described in 4.3.5. 
D7-sphinganine, D7-sphingosine, Cer d18:0 / 12:0, Cer d18:1 / 12:0, 1-deoxyCer m18:0 / 
12:0, 1-deoxyCer m18:1 / 12:0, SM d18:1 / 12:0, GluCer d18:1 / 8:0, D7-S1P, PA 17:0 / 17:0, 
PE 14:0 / 14:0, LPE 17:1, PG 17:0 / 17:0, PC 14:0 / 14:0, PC 24:0 / 24:0, LPC 17:0 were 
used as the internal standards. The C18-column-based method for chromatographic 
separation and MS analysis was used, as described in 3.3.1 and 4.3.2.  
The individual sphingolipid groups were calculated by summing up all the particular 
sphingolipid species belonging to each group. The levels were compared between ORMDL3 
knockout, ORMDL3 transgenic and wild-type animals with and without asthmatic challenge. 
In general, sphingolipids were increased in the ORMDL3 knock out animals and decreased 
in the transgenic ORMDL3 overexpressing mice, but this was significantly different neither for 
all the different tissues nor between the asthmatic or non-asthmatic challenged groups. The 
most significant effect of ORMDL3 knock-out on sphingolipid levels was observed in plasma, 
followed by liver and the adipose tissues. In plasma, we observed a significant increase in 
ceramides and sphingomyelin levels for KO mice, whereas the Tg mice showed a significant 
decrease compared to the wild-type animals. Hexosylceramides, 1-deoxyceramides, and 
S1P followed the same trend in plasma (Figure 5-4). We also observed a similar increase in 
the liver derived tissue lysates although the increase was not as prominent and not 
significant (Figure 5-5). Interestingly, there was no significant change in sphingolipids seen in 
lung tissues (Figure 5-6) and BAL fluid (Figure 5-7). 
In adipose tissues (BAT, Figure 5-8 and WAT, Figure 5-9), sphingomyelin and 
hexosylceramide as well as ceramides and S1P were not altered. However, 1-
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deoxyceramides were increased in both BAT and WAT of ORMDL3 knockout mice, 
independently of the treatment with HDM, as they increased to the same extent in both the 
asthmatic and non-asthmatic mice. This elevation in 1-deoxyceramides is unusual, as in the 
adipose tissue, 1-deoxyceramides but not canonical ceramide levels increased whereas in 
the other tissues, ceramides and 1-deoxyceramides increased in parallel. This suggests, that 
1-deoxysphingolipids were either formed more pronounced in adipose tissue compared to 
other tissues, or, that they accumulated in the fat tissue and therefore do not correlate 
anymore with canonical sphingolipid levels. Our data indicates that ORMDL3 expression in 
mice has a tissue specific function that alters lipids profiles differently in various tissues. It 
seems that ORMDL3 protein affects sphingolipid metabolism or regulation, and its deletion 
leads to an increase in sphingolipid levels whereas the overexpression leads to a decrease. 
Previous studies which measured hydrolyzed sphingolipid profiles did not observe any 
general effect on sphingolipid levels (C18 sphinganine (SA) and C18 sphingosine (SO)), with 
the exception of small but significant increase in SA in ORMDL3 KO mice 28. This could be 
due to the fact that overall sphingolipids in ORMDL3 knockout mice are generally similar to 
wild type mice and the hydrolysis method that cleaves sphingoid bases from all the 
sphingolipids thus masks the differences in ceramide levels, which arise as a result of loss in 
ORMDL3 function. This points to the possibility that ORMDL3 integrates the synthesis or 
levels of ceramides thus acting downstream of the SPT enzyme. This view is further 
corroborated by the fact that others and we have observed increased S1P levels in the 
plasma of ORMDL3 KO mice whereas these levels decrease in the transgenic mice (Figure 
5-4 and Miller et al. 31). 
Additionally, it has been show that decreasing ORMDL3 expression in mammalian cells 
increased ceramide levels and whereas, modest increases in ORMDL3 expression decrease 
ceramide levels by reducing de novo synthesis 32. However, high ORMDL3 levels had the 
opposite effect and significantly increased ceramide levels.  This increase was mainly due to 
increased salvage/recycling of sphingolipids to ceramide and not to de novo biosynthesis 32. 
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Similarly, downregulation or overexpression of ORMDL3 in HEK293 cells alone did not affect 
ceramide levels, or the de novo biosynthesis 25, 28.  
  
Chapter 5: Application of Lipidomics Method 
180 
plasma_Ceramide
uM
wt
_n
on
_a
sth
ma
tic
KO
_n
on
_a
sth
ma
tic
Tg
_n
on
_a
sth
ma
tic
wt
_a
sth
ma
tic
KO
_a
sth
ma
tic
Tg
_a
sth
ma
tic
0.0
0.5
1.0
1.5
2.0
2.5
ns
ns
** ****
***
****
plasma_1-deoxyCeramide
uM
wt
_n
on
_a
sth
ma
tic
KO
_n
on
_a
sth
ma
tic
Tg
_n
on
_a
sth
ma
tic
wt
_a
sth
ma
tic
KO
_a
sth
ma
tic
Tg
_a
sth
ma
tic
0.00
0.01
0.02
0.03
****
ns
** ****
ns
****
plasma_HexCeramide
uM
wt
_n
on
_a
sth
ma
tic
KO
_n
on
_a
sth
ma
tic
Tg
_n
on
_a
sth
ma
tic
wt
_a
sth
ma
tic
KO
_a
sth
ma
tic
Tg
_a
sth
ma
tic
0
1
2
3
4
5
ns
ns
ns ns
*
***
plasma_SM
uM
wt
_n
on
_a
sth
ma
tic
KO
_n
on
_a
sth
ma
tic
Tg
_n
on
_a
sth
ma
tic
wt
_a
sth
ma
tic
KO
_a
sth
ma
tic
Tg
_a
sth
ma
tic
0
50
100
150
**
ns
*** ****
*
****
plasma_S1P
uM
wt
_n
on
_a
sth
ma
tic
KO
_n
on
_a
sth
ma
tic
Tg
_n
on
_a
sth
ma
tic
wt
_a
sth
ma
tic
KO
_a
sth
ma
tic
Tg
_a
sth
ma
tic
0.0
0.5
1.0
1.5
2.0
ns
ns
ns ***
ns
****
Figure 5-4: Sphingolipid profile in plasma of Ormdl3 (KO) and transgenic (Tg) mice compared to wild-type (wt) 
littermates. Mice were sacrificed without any asthmatic challenge or after exposure to house dust mite (HDM), 
which is considered as a model for allergic asthma. ANOVA statistical test was performed to check for 
differences. ***= p<0.001, **= p<0.01, *= p<0.05, ns = no significance. 
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Figure 5-5: Sphingolipid profile in liver tissue of Ormdl3 (KO) and transgenic (Tg) mice compared to wild-type (wt) 
littermates. Mice were sacrificed without any asthmatic challenge or after exposure to house dust mite (HDM), 
which is considered as a model for allergic asthma. ANOVA statistical test was performed to check for 
differences. ***= p<0.001, **= p<0.01, *= p<0.05, ns = no significance. 
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Figure 5-6: Sphingolipid profile in lung tissue of Ormdl3 (KO) and transgenic (Tg) mice compared to wild-type (wt) 
littermates. Mice were sacrificed without any asthmatic challenge or after exposure to house dust mite (HDM), 
which is considered as a model for allergic asthma. ANOVA statistical test was performed to check for 
differences. ***= p<0.001, **= p<0.01, *= p<0.05, ns = no significance. 
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Figure 5-7: Sphingolipid profile in BAL fluid of Ormdl3 (KO) and transgenic (Tg) mice compared to wild-type (wt) 
littermates. Mice were sacrificed without any asthmatic challenge or after exposure to house dust mite (HDM), 
which is considered as a model for allergic asthma. ANOVA statistical test was performed to check for 
differences. ***= p<0.001, **= p<0.01, *= p<0.05, ns = no significance. 
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Figure 5-8: Sphingolipid profile in Brown adipose tissue (BAT) of Ormdl3 (KO) and transgenic (Tg) mice 
compared to wild-type (wt) littermates. Mice were sacrificed without any asthmatic challenge or after exposure to 
house dust mite (HDM), which is considered as a model for allergic asthma. ANOVA statistical test was 
performed to check for differences. ***= p<0.001, **= p<0.01, *= p<0.05, ns = no significance. 
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Figure 5-9: Sphingolipid profile in white adipose tissue (WAT) of Ormdl3 (KO) and transgenic (Tg) mice compared 
to wild-type (wt) littermates. Mice were sacrificed without any asthmatic challenge or after exposure to house dust 
mite (HDM), which is considered as a model for allergic asthma. ANOVA statistical test was performed to check 
for differences. ***= p<0.001, **= p<0.01, *= p<0.05, ns = no significance.  
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5.4 Lipidomics in mice with Abca1 and Abcg1 knock out in retina 
In collaboration with Federica Storti and Christian Grimm, Ophthalmology Department, 
University of Zurich 
Author contribution: Steiner R did the lipid analysis in the eye tissue.  
Age-related macula degeneration (AMD) is caused by the accumulation of extracellular 
deposits known as drusen 33, 34. Lipids and apo-lipoproteins accumulate with age on both 
sides of the retinal pigment epithelium (RPE) and form extracellular deposits associated with 
AMD. This process eventually destroys RPE cells and photoreceptors, which finally results in 
a progressive loss of vision and blindness 33. Genes involved in the lipoprotein metabolism 
(ABCA1, APOE, CETP, LIPC) are genetically linked to AMD 35. The RPE handles enormous 
amounts of lipids every day coming from the phagocytosis of the outer segments of 
photoreceptors. It, therefore, relies on efficient lipid metabolism, that coordinates both 
synthesis and turnover of the involved lipids. Lipids, such as cholesterol and phospholipids 
are abundant components of drusen 36. Since ABCA1 and its partner ABCG1 mediate lipid 
efflux 37, the function of the ABCA1/G1 pathway in the RPE was investigated using a tissue-
specific knockout (KO) mouse model. RPE-specific ABCA1-ABCG1 double KO mice were 
generated to investigate possible functional consequences for the retina in vivo 38, 39. 
Already at six weeks of age, the RPE of KO mice was filled with lipid droplets, as seen by 
light and electron microscopy and Oil Red O staining. With age (>8 months) photoreceptors 
started to degenerate. To investigate the effect of the lack of the two genes in the RPE in the 
lipid profile, the lipidome of retinal tissue from ABCA1/G1 knock out mice to wild-type mice 
was compared.  
ABCA1 and ABCG1 gene were selectively knocked out in retinal pigment epithelium (RPE) 
tissue in mice. Four KO mice and six WT controls were included. For each animal, neural 
retina, RPE, and remaining posterior eyecup were collected from the two pooled eyes. For 
preparation of protein lysates, tissues were homogenized using 0.1 % Triton (TX100). The 
tissue was extracted at 4 °C for one hour and the resulting lysate centrifuged at 16000 rpm 
for 5 min. 25 µg of RPE protein lysate and posterior eye cup and 50 µg of the neural retina 
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were transferred into a 2 mL Eppendorf tube. Tissue lysates were extracted using the MMC 
protocol described in 4.3.5. D7-sphinganine, D7-sphingosine, Cer d18:0 / 12:0, Cer d18:1 / 
12:0, 1-deoxyCer m18:0 / 12:0, 1-deoxyCer m18:1 / 12:0, SM d18:1 / 12:0, GluCer d18:1 / 
8:0, D7-S1P, PA 17:0 / 17:0, PE 14:0 / 14:0, LPE 17:1, PG 17:0 / 17:0, PC 14:0 / 14:0, PC 
24:0 / 24:0, LPC 17:0, D7-cholesterol, D7-CE 16:0 were used as the internal standards. For 
each analysis, a quality control series was prepared as described in 4.3.8. For LC-MS 
analysis, the C30-column-based method was used as described in 3.3.1 and 4.3.2.  
To evaluate more comprehensively the types of lipids altered in the KO tissue, eye-specific 
retinyl esters were quantified in addition to the sphingolipids and cholesterol. Retinyl esters 
are part of the retinoid cycle, which is essential for photoreceptor function. 11-cis-retinal is a 
chromophore in the photoreceptor, which is converted to all-trans-retinal by the absorption of 
a photon of light through photo isomerization. All-trans-retinal is reduced to all-trans-retinol 
which diffuses into the RPE where it is esterified. These retinyl esters are stored in lipid 
droplet-like structures called retinosomes to prevent aggregation. The all-trans-retinyl esters 
are reconverted to 11-cis-retinol, which are then further oxidized to 11-cis-retinal in the RPE. 
11-cis-retinal diffuses back into the photoreceptors 40. Therefore, it was interesting to see, if 
the concentration of retinyl esters is also altered in ADM.  
The linearity of the analysis of retinyl esters was confirmed with retinyl palmitate in a range 
between 2 nM and 2 µM (2, 20, 200 and 2000 nM). 
Chapter 5: Application of Lipidomics Method 
188 
 
Figure 5-10: Retinyl palmitate with the fragment 269.2 caused by the loss of the fatty acid with in-source 
fragmentation. 
Retinyl palmitate shows a significant in-source fragmentation losing the esterified fatty acid 
during ionization. The full mass ion was around 0.5 % (5.5 e6 compared to 1.1 e9 for 2 µM 
sample) of the total retinol. The chromatogram and fragmentation pattern is shown in Figure 
5-10. Linearity was checked for the full mass [M+H]+ ion, but also for the retinol-fragment   
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[M-FA+H]+. Both showed a linear correlation between the concentration of the standard and 
the peak area. 
 
Figure 5-11: Linearity of retinyl palmitate. A: Quantification based on the full mass of retinyl palmitate on [M+H]+ 
ion. B: Quantification based [M-FA+H]+ because of ion-source fragmentation. 
Free retinol and retinyl esters were analyzed in eye tissues. Due to the massive in-source 
fragmentation, total retinyl esters were quantified using the retinyl fragment with the mass of 
269.2 Da. Because of missing internal standard, free retinol and retinyl esters were 
correlated to D7-cholesteryl ester 16:0 the internal standard. Therefore, values are reported 
as the ratio of the area of free retinol or retinyl ester to the internal standard. 
Cholesterol and cholesteryl ester were significantly elevated in all analyzed tissues of the 
ABCA1 and ABCG1 knock out mice (Figure 5-12 ). Retinyl esters (Figure 13) were 
significantly elevated in all tissues (retina, RPE and PEC) whereas free retinol was only 
elevated in RPE tissue (Figure 5-13). The most prominent change was seen in RPE tissue, 
which was expected as the knockout of ABCA1 and ABCG1 was RPE specific. The elevated 
lipid level in the retina, but also in the posterior eye-cup tissue can be explained by the 
incomplete separation of the three eye tissues during sample preparation. Therefore, the 
elevated level of cholesteryl esters in retina and posterior eye-cup might be from 
contamination of RPE tissue. There was no difference in the sphingolipid profile between 
wind type and knockout tissue (Figure 5-14). 
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There was a significant change in cholesteryl ester in all eye tissues of mice with ABCA1 and 
ABCG1 deletion in the retinal pigment epithelium. Also, retinyl esters were changed in RPE 
tissue. By contrast, sphingolipids were not altered by the knockout of ABCA1 and ABCG1. 
Cholesteryl ester accumulation probaby happens secondary to impaired cholesterol efflux 
and hence increased intracellualr levels of free cholesterol in the ABCA1 and ABCG1 
deficient cells. To prevent  ER stress and apoptosis  induced by free cholesterol cells 
actuivate the cholesterol esterifiction by ACAT.  
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Figure 5-12: Free Cholesterol and cholesteryl esters were analyzed in A: posterior eye cup samples, B: RPE and 
C: neutral retina. Statistical significance was calculated using two-tailed t-test, where ***= p<0.001, **= p<0.001, 
*= p<0.05, ns = not significant. 
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Figure 5-13: Free retinol and retinyl ester were analyzed in A: posterior eyecup samples, B: neutral retina and C: 
RPE. Statistical significance was calculated using two-tailed non-parametric t-test, where ***= p<0.001, **= 
p<0.001, *= p<0.05, ns = no significance. 
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Figure 5-14: Sphingolipid classes were analyzed in A: posterior eyecup samples, B: neutral retina and C: RPE. 
Statistical significance was calculated using two-tailed non-parametric t-test, where ***= p<0.001, **= p<0.001, *= 
p<0.05, ns = no significance. 
These results support an important role of the ABCA1/G1 lipid pathway for the function of 
RPE, which in turn supports the retina function. RPE cells lacking ABCA1 and ABCG1 may 
not be able to manage the physiological lipid load coming from the photoreceptors. Over 
time, RPE cells with lipid accumulation undergo cell death with the consequent 
photoreceptors loss. This suggest that the ABCA1/G1 pathway might contribute to impaired 
lipid handling in the RPE of AMD patients. 
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5.5 Conclusion 
Various diseases are linked to disorders in lipid metabolism. Therefore, a comprehensive 
lipid analysis is needed to determine changes in disease conditions, map pathway 
connections, evaluate treatment efficacy or search for and validate novel biomarkers. We 
were able to establish and validate a lipidomics method towards application to mammalian 
cells, tissues and plasma. Lipid profiles were identified within a broad set of samples, 
involving plasma samples of tissues and cells humans and mice. With the measured lipid 
profiles, we supported the understanding of disease mechanisms in a neuropathy caused by 
rare mutations in association with sphingosine-1-phosphate lyase and in a mouse model of 
AMD, got more insight into the regulation of sphingolipid metabolism by ORMD3, and 
unravelled novel effects of gastric bypass surgery. 
This method, therefore, offers a tool to analyse lipid profiles in a high throughput setting for 
many research questions. 
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6 Conclusion and Outlook 
In this work, we used liquid chromatography (LC) and mass spectrometry (MS) techniques to 
elucidate the structure of 1-deoxysphingosine, unravel the metabolism of 1-
deoxymethsphingolipid, evaluated the turbulent flow chromatography for online extraction of 
sphingolipids and developed an LC-MS2 method for the comprehensive analysis of the 
sphingolipidome covering regular sphingolipids (SL) but also minor and atypical sphingolipid 
species. 
We showed, that the double bond position of native 1-deoxysphingosine (1-deoxySO) is at 
(14Z) position and not at (4E) like in canonical sphingosine, indicating that the metabolism of 
1-deoxySO is distinct from the canonical sphingosine pathway. Further investigations need to 
be done to identify and characterize the responsible enzyme, which introduces the double 
bond in 1-deoxySO, but presumably also the second double bond in sphingadiene, a di-
unsaturated downstream metabolite of sphingosine, containing an (4E) and (14Z) double 
bonds 1. This provides novel insights into lipid metabolism and opens new possibilities for 
treatment for patients with HSAN1 or diabetes type 2, as the 1-deoxysphingolipid metabolism 
can possibly be targeted without affecting the canonical pathway 2-8.  
This different location of the double bond in 1-deoxySO must be considered in the study of 1-
deoxysphingolipids (1-deoxySL) in different contexts.  In any case the accurate analysis of 1-
deoxySL is mandatory, as commercially available 1-deoxySO, but also the corresponding 1-
deoxyceramides contain a (4E) double bond rather than a (14Z) double bond. These two 
backbones have different biological effects in cell culture, but also behave differently upon 
LC-MS2 analysis 9, 10.  
After finding some differences in the metabolism of L-alanine based 1-deoxySL, we also 
investigated the metabolism of glycine based 1-deoxymethylsphingolioids (1-
deoxymethylSL). This other group of atypical sphingolipids was found in human plasma and 
is also elevated in the context of HSAN1. However 1-deoxymethylSL were not studied in 
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detail so far and assumed to follow the pathway of either L-serine or atypical L-alanine based 
sphingolipids 8. 
Although the metabolism of the three different amino acid based sphingolipids starts with the 
condensation of palmitoyl-CoA with L-serine, L-alanine or glycine by the enzyme serine-
palmitoyl-transferase (SPT) 11, 12, we found several different branching points within the 
metabolic pathways for the different sphingolipids. After the formation of the initial sphingoid 
backbone, sphinganine, which can be N-acetylated to dihydroceramide 10, we found 
differences in the further desaturation to ceramide by dihydrosphingosine desaturase. For L-
serine and glycine based sphingolipids, the desaturation at (4E) or (3E) respectively over 
DES1/2 is possible, which leads to the second major sphingoid backbone sphingosine 13. For 
L-alanine based 1-deoxySL, we showed that, this desaturation does not occur, but a double 
bond is introduced at (14Z) by another different enzyme 14. This reaction also occurs for L-
serine or glycine based sphingolipids, but seems to be an alternative pathway of secondary 
desaturation for these lipids. Further, we showed, that the major downstream metabolite of 1-
deoxymethylSA is a di-hydroxylated 1-deoxymethylSA species, which was not known before, 
and therefore, never quantified in any (disease) condition. This needs further investigation, 
as the role of this lipid in HSAN1 might have been underestimated so far 2-8.  
In the second part of this doctoral work, we developed and validated a comprehensive LC-
MS2 method with automated online extraction for comprehensive and fast analysis of 
sphingolipids including the atypical ones, as well as other classes of lipids. 
We showed that a turbo flow column for online extraction of lipids from biological samples is 
of limited use, as the online extraction showed poor recovery (12.0% to 93% for different lipid 
classes compared to Bligh and Dyer). We further compared a newly published single-phase 
extraction protocol using methyl-tert-buthyl-ether / methanol / chloroform (MMC) 17, which 
showed less variance at equal recovery rates for the different sphingolipid classes, also 
covering very low abundant sphingolipids. The need for protein precipitation with an organic 
solvent prior to online extraction with turbulent flow makes the manual extraction effort more 
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time-consuming and almost comparable to those of single-phase extraction procedures like 
the MMC protocol. In conclusion, the TLX extraction for lipidomics analysis is not 
advantageous compared to other, more established protocols. Therefore, the single phase 
MMC protocol was implemented for sphingolipidomics studies in this work. 
We developed an LC-MS2 method with data dependent acquisition to detect and quantify 
different groups of sphingolipids, including free sphingoid bases, S1P, ceramides, 
hexosylceramides and sphingomyelins, but also the low abundant 1-deoxysphingolipids. 
Further, we demonstrated, that also the C30 column retains glycerophospholipids, free 
cholesterol and cholersteryl esters and that also these classes can be separated with the 
developed LC conditions. Also these lipid classes show a linear correlation between 
concentration and signal intensity. Additionally, also neutral glycerolipids and free fatty acids 
were separated by the developed method.  
For a validation the entire method was applied to various kinds of samples. Lipid profiles 
were analysed by LC-MS2, lipid species identified by the library and finally semi-automatically 
quantified in a broad range of samples, including plasma samples of patients and knockout 
mice as well as tissues and cells. The lipid profiles helped to better understand disease 
mechanisms, in a neuropathy caused by rare mutations in sphingosine-1-phosphate lyase or 
in a murine AMD model generated by knock-out of ABCA1 and ABCG1 in the retinal pigment 
epithelium, get more insights into the regulation of sphingolipid metabolism by ORMDL3, or 
gastric bypass surgery. 
For a further focus on low abundant and rather atypical lipids, the method could be extended 
with a targeted acquisition list of atypical lipid species as addition to the data dependent 
acquisition, which manly covers more abundant species. As many published 
sphingolipidomic methods mostly cover just the high abundant species, a specific focus on 
low abundant species reveals new insights in lipid metabolism. The method, therefore, offers 
a universal tool to analyse the lipid profile for high but also low abundant species in a high 
throughput setting and allows addressing many research questions.  
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